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Breast cancer is a heterogeneous disease with distinct subtypes and many different
clinical presentations. Neoadjuvant therapy of breast cancer offers a window of oppor-
tunity to study translational changes in tumours as a result of treatment alone and may
help to identify tumour response status. Pairs of samples collected from different sites
or sequentially from the same individual can potentially provide additional prognostic
information for the risk stratification of breast cancer. Here, we seek to aggregate mul-
tiple studies of valuable, multi-sampled, patient-matched cohorts for meta-analysis to
check for an enhanced ability to make new and significant findings about the underly-
ing mechanisms of tumour treatment response.
Multiple sequentially-matched datasets of pre- and on-treatment matched primary
tumour and lymph node samples were collected and examined for differentially
expressed genes and pathways indicative of pathological response. Machine learning
methods were applied to identify biomarkers of response from the on-treatment sam-
ples, and profiling comparisons were made to assess the additional value of matched
patient samples to accurately predict risk. Lastly, five sequentially sampled datasets
were aggregated for meta-analysis by combining the normalised pre- to on-treatment
expression level differences to identify commonalities in the response to therapy across
both endocrine and chemotherapy treatment strategies.
The gene, AAGAB, was identified through iterative differential analysis, and was
found to be 78% accurate in validation for the prediction of pathological complete
response in neoadjuvant chemotherapy treated breast cancer. AAGAB demonstrated
significant separation of patient survival curves (log rank p = 0.0036), and the on-
treatment samples more accurately reflected the patient risk than the pretreatment
samples. Matched lymph node tissue of primary breast cancer was more successful
at capturing the patient’s risk of recurrence than the primary biopsy, correctly iden-
tifying 83% (10/12) of the recurring patients compared to 25% (3/12) in the primary.
Underlying differential expression analysis also showed a considerable number of
high profile breast cancer genes over-represented in the lymph node. Aggregation of
multiple sequential studies resulted in low post integration concordance values with
the reference patient data (<30% profiling agreement), and is not recommended for this
type of analysis. However, combining the pairwise change values for gene expression
level data was successful, and resulted in the creation of highly accurate models for
predicting patient response (F1 accuracy score, 0.92) as well as the identification of
potential common escape pathways to breast cancer therapies.
Analysis of the matched pre- and on-treatment samples revealed the intrinsic
value of multiple on-treatment biopsies. These samples offer valuable new targets for
biomarker identification that show significant increases in accuracy for the predic-
tion of response and long term outcome in neoadjuvant chemotherapy. Additional
sampling of involved metastatic lymph node also improves the prognostic capabilities
for clinicians by providing a potentially more accurate view of the per-patient risk
profile. Lastly, the pairwise expression change values show the direction of tumour
change, which can be used to create new models for the prediction and classification
of patient risk and for furthering our understanding of the mechanisms behind patient
non-response.
Lay-Abstract
Breast cancer is not one disease but many, and there is evidence that each subtype
has distinctly different characteristics. For many years, the standard of care for
breast cancer was surgery followed by radiation therapy or more targeted treatments,
if deemed appropriate. A possible alternative approach is for patients to receive
treatment prior to surgery. This method shows promise for distinguishing patients
with good outcomes from patients with poor outcomes. Pre-surgery treatment was
recently shown to be as effective as the standard care treatments, but may improve our
ability to identify new ways to detect response to treatment in patients and help future
patients.
The most common site for a tumour to move to, and the first place breast cancer
usually spreads, is to the nearby lymph nodes of the armpit. When tumour cells are
detected in the lymph node, patients are known to have worse outcomes and are more
likely to have a future reappearance of cancer. At present, when the tumour is present
in lymph nodes, this information is not used beyond a categorical risk factor for the
patient. However, the progression to the lymph nodes and the profile of that tumour
may hold important information for new treatment parameters for each individual. It
is possible that the characteristics inherent to the lymph node tumours that facilitate
the progression from the breast allow these samples to better represent the risk of the
patient as a whole.
As pre- and on-treatment matched samples and patient matched tissue samples are
both rare, analysis of these samples is often of limited value. Combining available data
for analysiswould boost the significance of all findings derived from this data. However,
integration of this data must be undertaken carefully and with enough subtlety to not
erase the underlying biological information. This proves a non-trivial task but has a
large potential payout for future analysis and biomarker testing.
These informativematchedpaired samples havehelped identify newmethods for pa-
tient risk prediction and combiningmany smaller studies has improved our understand-
ing of the differences between different types of patients and treatment strategies.

Acknowledgements
This thesis might contain all my own words, but it isn’t the product of only one
person. I need to thank my supervisor, Andy Sims, for his constant supervi-
sion, patient and helpful oversight, guidance and experience. I would not have
been able to succeed these last few years with a less capable or less kind men-
tor. Dr. Olga Oikonomidou for co-supervision and for granting access to the NEO
trial, which comprised a major portion of my thesis work and all of the patients
whose samples made all of my work possible. I would also like to acknowledge
my funding body, CRUK, for their generosity.
I would also like to thankmy family for their invaluable support. My parents are
my inspiration in life and have provided help, support and advice beyond what
I can write. During my PhD, I adopted two dogs, who were the missing limbs I
didn’t know I didn’t have. Bean and Isla have taught me responsibility in a way
I never knew before. They also helped to get me outside every once in a while.
Lastly, my best friend and themost amazing woman I know, thank youMax, this
would not have happenedwithout you. You have helpedmy growth as a student
and an academic, you are responsible for my growth as a person, and you are
my reason to keep to moving. Check it out, we did it!
In light of recent events and with the global pandemic family and community
have never been more important. It is with a heavy heart that this thesis is now
being resubmitted under the current circumstances. Like it takes a village to
raise a child it takes a tribe to produce a body of work like this.

We who cut mere stones
must always be envisioning cathedrals.








1.1 Cancer and Therapy . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Breast Cancer - Incidence and Outcomes . . . . . . . . . . . . 1
1.3 Detection, Diagnosis and Subtypes . . . . . . . . . . . . . . . 2
1.4 Treatment Options and Decision-making . . . . . . . . . . . . 6
1.5 Clinical Decision Making Tools . . . . . . . . . . . . . . . . . 8
1.6 Molecular Subtyping and Prognostic Signatures in Breast Cancer 9
1.7 Publicly Available Gene Expression Datasets . . . . . . . . . . . 10
1.8 Gene Expression Profiling Methods and Datasets . . . . . . . . 12
1.9 Predictive Biomarkers for Patient Response . . . . . . . . . . . 13
1.10 Prognostic Gene Expression Signatures for Breast Cancer . . . . 13
1.11 Sequential Sampling . . . . . . . . . . . . . . . . . . . . . . 15
1.12 Opportunities and Challenges of Patient-Matched Samples . . . . 16
1.13 Availability of Datasets . . . . . . . . . . . . . . . . . . . . . 17
1.14 Dataset Integration . . . . . . . . . . . . . . . . . . . . . . . 20
1.15 Dataset Integration Improves Statistical Significance . . . . . . . 21
1.16 Using On-Treatment Information May Enhance Prediction of Re-
sponse or Prognosis . . . . . . . . . . . . . . . . . . . . . . . 22
1.17 Thesis Hypothesis, Aims and Outcomes . . . . . . . . . . . . . 23
Contents
2 On-treatment Biomarkers can Improve Prediction of Response to
Neoadjuvant Chemotherapy in Breast Cancer 25
2.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
2.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
2.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . 28
2.3.1 Patients, Response Criteria, and Samples . . . . . . . . . 28
2.3.2 Gene Expression Profiling . . . . . . . . . . . . . . . . 30
2.3.3 Statistical Analysis Methods . . . . . . . . . . . . . . . 30
2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.4.1 Gene Expression Differences Between Responding and
Non-responding Breast Cancer Tumours Treated with
Chemotherapy are Subtle and Time Dependent . . . . . . 33
2.4.2 Responding and Non-Responding Tumours are More Differ-
ent Upon Exposure to Chemotherapy . . . . . . . . . . . 37
2.4.3 AAGAB is a Promising Potential Novel On-Treatment
Biomarker of Response to Chemotherapy . . . . . . . . . 39
2.4.4 Comparison of Pre- and On-treatment Predictions of
Response and Outcome . . . . . . . . . . . . . . . . . . 42
2.4.5 Pathway Enrichment as an Indicator of Divergent Expression 45
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
2.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
3 Informing New Prognostic Decisions Through Patient Matched
Tissue Gene Expression Analysis 49
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
3.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . 52
3.3.1 Ethics Statement . . . . . . . . . . . . . . . . . . . . . 52
3.3.2 Patients and Datasets . . . . . . . . . . . . . . . . . . . 53
3.3.3 Statistical Analysis . . . . . . . . . . . . . . . . . . . . 54
3.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
3.4.1 Inter-Patient Gene Expression Exceeds Matched Patient Tis-
sue Samples . . . . . . . . . . . . . . . . . . . . . . . 55
3.4.2 Discordance in Molecular Subtype and Prognostic Signatures 61
3.4.3 Validation of Pretreatment Expression Differences in Non-
Local Cohort . . . . . . . . . . . . . . . . . . . . . . . 63
3.4.4 On-treatment Gene Expression Differences Between Pri-
mary Tumours and Paired Lymph Node Metastases are
Primarily Maintained . . . . . . . . . . . . . . . . . . 65
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
Contents
3.6 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
4 Evaluation of Approaches to Integrate Sequential Pre- and On-
treatment Patient-Matched Breast Cancer Datasets 71
4.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.2.1 Integration Methods for Transcriptomic Data . . . . . . . 77
4.3 Materials and Methods . . . . . . . . . . . . . . . . . . . . . 77
4.3.1 Data Selection and Acquisition . . . . . . . . . . . . . . 80
4.3.2 Preprocessing, Normalisation, and Analysis of Expression
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.3.3 The Origins of Technical and Biological Variance . . . . . 81
4.3.4 Pre-Treatment only Integration as Reference Performance
Data . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
4.3.5 Uncorrected Integration Methods . . . . . . . . . . . . . 83
4.3.6 Reproducible ComBatWorkflows and Integration Testing . 86
4.3.7 Patient Matched Concordance and Correlations as Integra-
tion Metrics . . . . . . . . . . . . . . . . . . . . . . . 87
4.4 Results | Unintegrated Data Meta-analysis . . . . . . . . . . . . 88
4.4.1 Subtype Composition of Unintegrated Datasets . . . . . . 88
4.4.2 Continuous and Categorical Risk Classification Across Mul-
tiple Independent Datasets . . . . . . . . . . . . . . . . 90
4.4.3 Pre-integration PCA Visualisation Data . . . . . . . . . . 92
4.4.4 Principal Components Analysis of Independent Uninte-
grated Data . . . . . . . . . . . . . . . . . . . . . . . 94
4.4.5 Analysis of underlying Data Structure Through Similarity
Scores . . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.5 Results | Correlation Analysis . . . . . . . . . . . . . . . . . . 95
4.5.1 Pretreatment Samples Corrected with Platform ComBat
Batch Correction . . . . . . . . . . . . . . . . . . . . . 95
4.5.2 Uncorrected Combination of Sequentially Sampled Pre- and
On-treatment Datasets . . . . . . . . . . . . . . . . . . 98
4.5.3 ComBat Integration of Sequential Samples withMultiple Co-
variates . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.6 Results | PCA Analysis . . . . . . . . . . . . . . . . . . . . . 100
4.6.1 Pretreatment Samples with Platform ComBat Batch Correc-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
4.6.2 Uncorrected Combination of Sequentially Sampled Datasets 103
4.6.3 ComBat Integration of Sequential Samples withMultiple Co-
variates . . . . . . . . . . . . . . . . . . . . . . . . . 105
Contents
4.7 Results | Heatmap Visualisations . . . . . . . . . . . . . . . . 107
4.7.1 ComBat Integration of Sequential Samples withMultiple Co-
variates . . . . . . . . . . . . . . . . . . . . . . . . . 107
4.8 Results | Molecular Subtyping and Prognostic Scores . . . . . . 109
4.8.1 Pretreatment Samples with Platform ComBat Batch Correc-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
4.8.2 Uncorrected Combination of Sequentially Sampled Datasets 111
4.8.3 ComBat Integration of Sequential Samples withMultiple Co-
variates . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.9 Results | Differential Expression Analysis . . . . . . . . . . . . 117
4.9.1 Uncorrected Combination of Sequentially Sampled Datasets 117
4.9.2 ComBat Integration of Sequential Samples withMultiple Co-
variates . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.10 Results | Random Forest Classification . . . . . . . . . . . . . 118
4.10.1 Pretreatment Samples with Platform ComBat Batch Correc-
tion . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
4.10.2 Uncorrected Combination of Sequentially Sampled Datasets 118
4.10.3 ComBat Integration of Sequential Samples withMultiple Co-
variates . . . . . . . . . . . . . . . . . . . . . . . . . 119
4.11 Results | Proliferation Changes . . . . . . . . . . . . . . . . . 119
4.12 Results | Post-ComBat Distributions . . . . . . . . . . . . . . . 122
4.13 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 123
4.14 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
5 Meta-Analysis of Multiple On-treatment Datasets Reveals Com-
mon Transcriptional Differences In Non-responsive Tumours 129
5.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . 129
5.2 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
5.3 Methods and Materials . . . . . . . . . . . . . . . . . . . . . 132
5.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 134
5.4.1 General Changes in Gene Expression are Conserved
Between Treatments . . . . . . . . . . . . . . . . . . . 134
5.4.2 Non-Response Vectors of Chemotherapy and Endocrine
Show Concordance On-treatment . . . . . . . . . . . . . 139
5.4.3 Pathway Analysis Highlights Conserved Genes Indicative of
Non-response Pan-treatment . . . . . . . . . . . . . . . 142
5.4.4 Identification of Non-responsive Patients from Pairwise
Delta Expression Values . . . . . . . . . . . . . . . . . 145
5.4.5 Breast Cancer Transformation and Classification . . . . . 146
5.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 147
Contents
5.6 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
6 Perspectives, Discussion, and Conclusion 149
6.1 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
6.2 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . 156




AAGAB Alpha And Gamma Adaptin Binding-Protein
AI Aromatase Inhibitor
API Application Programming Interface




CDK C D K
CMF C M F
cfDNA cell-free DNA
ctDNA circulating tumour DNA
DGEA Differential Gene Expression Analysis
DNA Deoxyribo Nucleic Acid
EB Excision Biopsy
EGFR Epidermal Growth Factor Receptor
ER Estrogen Receptor
FF Fresh Frozen
FFPE Formalin Fixed Parafin Embedded
GSEA Geneset Enrichment Analysis
HER2 Human Epidermal-Growth-Factor Receptor
HR Hormone Receptor
IGF Insulin-like Growth Factor
IHC Immunohistochemistry Chemical
JSON JavaScript Object Notation
LumA Luminal A
LumB Luminal B
LFDA Local Fisher Discriminant Analysis
MAPK Mitogen Activated Protein Kinase
METABRIC Molecular Taxonomy Of Breast Cancer International Consortium
MDS Multi Dimensional Scaling
NAC Neoadjuvant Chemotherapy
Contents
NCBIGEO National Centre for Biotechnology Information Gene Expression Omnibus
NIT No Intervening Treatment
NKI National Kaker Instituut
NPI Nottingham Prognostic Index
OR Odds Ratio
PCA Principal Component Analysis
PCNA Proliferating Chain Nuclear Antigen
PCR Pathological Complete Response
POETIC Peri Operative Endocrine Therapy for Individualising Care
PR Progesterone Receptor
RNA Ribonucleic Acid
ROR Risk Of Recurrence
SAM Significance Analysis of Microarrays
T2 Time 2nd
TM TimeMid-chemo
TNBC Triple Negative Breast Cancer
TP Time Pre-treatment
TS Time Surgical
tSNE t distributed Stochastic Neighbour Embedding
USS Ultra Sound Sonography
1 | Introduction
1.1 Cancer and Therapy
Cancer represents a state of fundamental dysregulation of the biological and
cellular processes that underpin survival and fitness in healthy cells. Com-
mon hallmarks of cancer include growth signalling pathways, apoptosis, and
replication;1 all of which represent control over the cell cycle. In this way,
cancer is a corruption of otherwise normal, healthy cells generating malignant
cells which form clusters called tumours. Therefore, cancer therapies treat the
tumour to the detriment of the body, and must seek to target characteristics
inherent to the process of tumourigenesis, such as the significantly higher rates
of proliferation and damaged DNA repair mechanisms.2 Anti-mitotic agents
that target DNA replication mechanisms are effective at targeting tumour cells,
but are systemic and non-specific, placing a significant burden on the patient.3
Thus, reducing over-treatment and identifying patients who will have good
responses to therapy is an important area of research with real clinical impacti
and the potential to improve patient care.
1.2 Breast Cancer - Incidence and Outcomes
Breast cancer (BC) is themost prevalent new cancerii amongwomen and the sec-
ond most deadly.4–6 Globally, it is the most common cancer in women, with 1.7
million new cases reported each year and over 500,000 deaths in the year 2012.7
Alone, it accounts for a quarter of all cancer cases and 15% of cancer deaths in
women.7 Breast cancer represents a significant number of the total new cases
of cancer every year in the UK, with 54,724 new cases in 2017 (or 15% of all new
cancer cases) and a total mortality of 11,433.8 Thanks to advances in the treat-
ment of BC in the last several decades, the total mortality rate has dropped 32%
iDue tomy unique position between clinical oncology and dry lab research, I only mean
to emphasise the clear target of producing said results.
iiSpecifically malignant cancer, ductal carcinoma in situ is present in an overwhelming
number of women according to necropsy results, but is largely asymptomatic.
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since the 1970’s and 17% in the last decade.8 Early detection of BC can help to in-
crease the survival rates in patients by significantmargins, asmuch as 20% after
5 years.9 Currently, breast cancer has an 89.7% 5 year-survival rate10 and a 78%
10-year survival rate in the UK (female cancers only).8 Improvements in screen-
ing, treatment and diagnosis have produced a positive trend in the survival rate
of BC and are continued fields of research.11
In 2012, there were 1.7 million newly diagnosed cases and 500,000 deaths
from BC globally, representing almost a quarter of all newly diagnosed cancers
and 15% of cancer related deaths in women.12 These numbers represent a het-
erogeneous disease of different clinical, histological and intrinsic factors.13 In
supervised analysis of patients with known clinical and prognostic outcomes,
and despite tumour cellular heterogeneity, inter-patient variation often exceeds
the variance between groups of patients with regard to biological or clinical
status.14 This means identifying trends that significantly differentiate transla-
tional changes between responsive and non-responsive BC can be very diffi-
cult.
1.3 Detection, Diagnosis and Subtypes
In theUK, allwomenbetween the ages of 50 and 70 are invited for a breast screen
every 3 years. This results in approximately 2millionwomen a year undergoing
breas screening in the UK.15 These screenings are responsible for reducing mor-
tality in the UK by asmany as 1,300women per year. Additionally, breastmasses
can be detected by a physician, usually following a clinical breast examination
as a result of patient reported symptoms.15,16 A lump can be ratified by mammo-
gram, MRI and ultrasound, but a definitive diagnosis can only be given through
biopsy. Biopsies are performed as either a fine needle aspiration biopsy, a core
needle biopsy or as a surgical biopsy, and the sample is examined by a pathol-
ogist to determine the malignant or benign nature of the mass. The pathology
report contains key information that along with clinical information will facili-
tate treatment decision making and will also offer important information about
the patient’s prognosis.17,18
Breast cancer is broadly defined as a malignancy originating in breast tis-
sue of men or women,19 and is frequently described by the structure where it
originates, either ductal or lobular or as one of a few rarer sub-categories of
BC, including Paget’s, Phyllodes or inflammatory BC.20 BC is then more specifi-
cally defined as either in situ (in its original place) or invasive, and both are fur-
2
ther dichotomised into more refined subtypes, usually ductal or lobular,18see
Figure 1.3.1 on Page 3. Ductal carcinoma in situ (DCIS) is the most common in
situ subtype of BC, and is further described as either comedo or non-comedo,
where the latter are further classified as cribiform, micropapillary, papillary,
and solid.18,21
Invasive carcinomas are those that have infiltrated past their point of origin
and are subdivided into different groups based on their histological features, the
most common being Invasive Ductal Carcinoma (IDC) of no special type, which
accounts for between 70 and 80% of all invasive BC tumours.22
Breast cancer tumours are typically divided into three grades as a function of
its differentiation; grade 1 (well differentiated), grade 2 (moderately), and grade
3 (poorly).22 Other common categories of invasive carcinoma include lobular,
ductal/lobular, mucinous, medullary, papillary and tubular.18 See Figure 1.3.1
















Figure 1.3.1: Histological Subtypes of Breast Cancer. An illustration of
the broad categories of histological BC subtypes.
HER2-enriched tumours are those with amplification/over-expression of
HER2 (Human Epithelial growth factor Receptor 2) and, which under IHC
(Immunohistochemical) classification, appear as ER-(Oestrogen Receptor)/PR-
(Progesterone Receptor)/HER2+.23 HER2-enriched tumours frequently overex-
press related genes to HER2, namely GRB7 (Growth Factor Receptor Bound
Protein 7) and PGAP3 (Post-GPI Attachment To Proteins Phospholipase 3) and are
most likely grade 3.24 Additionally, these tumours often have poor prognoses,25
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but have good rates of pathological clinical response due to the availability of
targeted agents and susceptibility to standard chemotherapies.26
Basal tumours, or triple negative tumours, are characterised under IHC as
ER-/PR-/HER2- and have expression profiles similar to the basal epithelial cells
of breast tissue,27 but are not necessarily identical. A summary of the character-
istics of the molecular subtypes is included in Figure 1.3.2 on Page 5. Due to the
lack of receptor targets, the only standard of care is chemotherapy, which, in con-
junction with the generally aggressive nature of these tumours, leads to basal-
like tumours having the worst clinical prognosis of the molecular subtypes.24,28
The poor prognosis is also partly explained by the lack of treatment options
available and recurrence rather than a lack of treatment efficacy.26 On the other
end of the response spectrum are ER+ tumours, the most common and of least
severe general prognosis, are defined by their positive oestrogen receptor sta-
tus. While oestrogen receptor negative tumours tend to be of higher grade and
have a worse prognosis than ER+ counterparts, a small subset of triple negative
BCs have better clinical outcomes and respond well to neoadjuvant chemother-
apy, showing much better overall survival.29,30 Further analysis has shown that
TNBC (Triple Negative Breast Cancer) is a heterogeneous disease with between
four and six potential subtypes, each characterised by distinct patterns of gene
expression that have different treatment and survival characteristics.29–31 This
subsetting of TNBC may be important for future drug discovery and biomarker
generation for these difficult to treat tumours.31 BRCA (BReast CAncer gene) sta-
tus is another important consideration for prognosis and treatment. BRCA gene
mutations are highly associated with increased likelihood of developing specific
epithelial cancers, most notably breast and ovarian.32
4
Figure 1.3.2: Breast Cancer Molecular Subtypes, Prognosis, Receptor
Status and Treatment Options. This diagram shows the molecular sub-
types of BC and how their receptor status relates to their relative prognosis.
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1.4 Treatment Options and Decision-making
The most common and conventional means of treating BC are radiotherapy,
chemotherapy, hormone therapy and targeted therapies.33 Conservation of
breast tissue in the treatment of localised disease, rather than mastectomy,
is now the most common surgical approach to BC,34,35 additionally it is the
preferred surgical approach by both patients and clinicians. When surgery is
preceded by treatment (neoadjuvant setting), it may shrink the tumor volume
and reduce the amount of breast tissue resected.36 Further treatment is usually
given after surgery (adjuvant setting) to reduce the risk of recurrence or
metastasis and improve patient outcomes.33,36 Choosing a therapeutic pathway
should be made with consideration of available information on the tumour,
patient characteristics, pathological features, and histological information,
such as the patients risk of recurrence and metastasis as well as the patient’s
wishes.37 Additionally, the inclusion of intrinsic phenotypes such as ER/PR
(Oestrogen/Progesterone Receptor), HER2 (Human Epithelial growth factor
Receptor 2) and KI-67 (a gene marker of proliferation) should be considered
in the treatment decision making process where possible at these factors have
been shown to add prognostic value to clinicians.38
Non-specific treatments for BC are radiation therapy and chemotherapy.
These treatment options do not discriminate between cell types but are designed
to take advantage of cancer’s proliferative nature. Radiation therapy is the
direct exposure of the cancer cells to radiation, and is frequently given in combi-
nation with chemotherapy, as it can be used in early local cancer to reduce the
chance of recurrence.39 Chemotherapy is usually given to patients presenting as
ER-, especially triple negative tumours (negative ER/PR/HER2 status), however it
is also prescribed to HER2+ patients as well as Luminal tumours (ER+) at higher
risk.37 There are a few options in the treatment of cancer using chemotherapy.
Historically CMF (cyclophosphamide, methotrexate, fluorouracil) was used in
practice more than 15 years ago, but more recently taxanes and anthracyclines
have been prescribed. Taxanes and anthracyclines may be given independently
or in combination, and have been shown to have improved performance over
treatment with CMF.40 The combination therapy of taxanes and anthracyclines
was shown to reduce mortality rates by one third, regardless of patient age or
tumour characteristics.41 However, these compounds are not generally well
tolerated and can have adverse toxic effects, especially to those with preexisting
co-morbidities and heart problems.42
Hormone, or endocrine, therapy (ET) is a targeted treatment option for
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BC. The purpose of endocrine (hormone, ET) therapy is to block the activity
of hormones and is recommended to all patients with significant endocrine
receptor expression (defined as >1% of the cells).33 ET can be used in addition
to chemotherapy, radiation and targeted therapies, as long as the patients are
ER+.33 The choice of treatment, however, is dictated by the patient’s menopausal
status and individual risk.33 For pre-menopausal patients, treatment with an
ER antagonist is standard (e.g., tamoxifen, 5-10 years) and can be combined
with ovarian ablation (surgically or chemically), but comes with associated
risks of fertility and endometrial hyperplasia and cancer.43 When combined
with ovarian ablation, ET is at least as effective as treatment with CMF44 and
the combination of an AI (Aromatase Inhibitor) with surgical ovarian ablation
or administration of a gonadotropin releasing hormone (GnRH) agonist is a
tolerable substitute for tamoxifen.45 In post-menopausal women, the ovaries
are no longer producing oestrogen, therefore surgical ablation or chemical with
GnRH-agonists are no longer necessary and the standard treatment for this
cohort then becomes 5-10 years of adjuvant tamoxifen.46
Another prominent targeted therapy is trastuzumab which, in combina-
tion with chemotherapy, has been shown to reduce recurrence of HER2+ BC
by half when compared to chemotherapy alone.47 Further, improved treat-
ment response was observed when trastuzumab was used in combination
with chemotherapy alongside another HER2+ agent like Pertuzumab.47,48
Trastuzumab has been approved for use in patients with positive nodal involve-
ment or larger tumours (greater than 2 cm diameter) as well as any patient
who will derive benefit from combined treatment and for concurrent use
with taxanes, however, concurrent administration with anthracyclines is ill
advised due to both therapies having notable cardiotoxicity.49–51 Additional
targets for targeted therapies include PI3K (Phosphoinositide 3-kinase)/mTOR
(Mammalian Target of Rapamycin) and CDK (Cyclin-dependant kinase), as
these are frequently dysregulated in BC.52,53 Everolimus (an mTOR inhibitor)
and CDK4/6 inhibitors (Palbociclib, Abemaciclib, Ribociclib) are FDA (Food
and Drug Administration) approved drugs with improved treatment response
in combination with existing chemotherapy agents in a variety of BC types.
Common UK breast cancer treatment strategies are summarised in Figure 1.4.1
on Page 8, according to the European Society of Medical Oncology (ESMO).54
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Figure 1.4.1: Generalised Treatment Strategies for Early BC. A basic
overview of the treatment options for different clinically relevant subtypes
of BC are shown in this diagram to illustrate the heterogeneous nature of
BC treatment, sourced from ESMO.
1.5 Clinical Decision Making Tools
There are applied decision making tools currently in use in the UK that com-
bine multiple clinical factors of the patient and tumour to help make informed
treatment choices and prognosis. The Nottingham Prognostic Index (NPI) com-
bines factors including the number of involved lymph nodes, tumour size, and
tumour grade to calculate a score that is descriptive of prognosis in an attempt
to identify high risk, poor prognosis patients.55 The NPI has proven to be more
informative than lymph node status alone as a means for predicting prognosis
and has been validated in other British datasets and treatment centres.55,56 Adju-
vant! Online is another clinical tool that attempts to predict and quantify patient
response to either endocrine or chemotherapy treatment in terms of predicted
overall survival rates (patient survival from all causes of mortality) and recur-
rence free survival (survival based on no recurrence of the tumour).57 These es-
timates are derived from patient age, menopausal status, tumour staging, num-
ber of involved nodes and ER status.57 PREDICT NHS is another prognostic tool
and the first that also encompasses mode of detection when calculating patient
outcomes, and has been proven to be an effective and discriminatory means of
prognostication.56 In this regard, PREDICT NHS performs well across different
prognostic groups and age ranges, and builds on work such as Adjuvant! Online
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to create new and contemporary prognostic tools.56
1.6 Molecular Subtyping and Prognostic Signatures in
Breast Cancer
In addition to histological subtypes, BC tumours can be described by receptor
status and, more recently, by HER2 and TNBC (Triple Negative Breast Cancer)
labels. Further subtyping, based on gene expression, has been popularised by
Perou and Sorlie.58 Though it should be noted that this molecular subtyping
method is experimental. Molecular subtypes may be of use for predicting re-
sponse to specific therapies18 and, at least in the case of invasive carcinomas, it
can be recommended to calculate the relevant sub-typing information for prog-
nostic consideration.59 These intrinsic subtypes of BC include Luminal A (High
ER, low HER2) and Luminal B (Low ER, Low HER2 and High Proliferation), Her2
(HER2 positive, ER negative), Basal (ER negative, HER2 negative, PR negative)
and normal-like.58,60,61
The generation of these subtypes may one day have widespread clinical ap-
plications for patient and clinician decision making because they have signifi-
cantly different survival characteristics, for example, Basal like tumours having
the poorest prognosis.61 However, due to prohibitive costs, these methods have
not seen broad clinical uptake, but the creation of targeted gene panels, like the
FDA approved PAM50 (PredictionAnalysis ofMicroarray 50), havemade the gen-
eration of molecular subtypes possible on a small scale and have been shown
to be comparable to full microarray analysis.62 Methods like PAM50 have also
been shown to out perform clinical information in predicting recurrence of BC.
Importantly, utilising both targeted gene panels and clinical information such
as T (Tumour size), N (Number of involved nodes), M (Metastatic status) and
grade show improved predictive power, providing a potential future avenue for
research.62
Seminal gene expression profiling studies by Sorlie and Perou described
the five so-called “intrinsic” molecular subtypes of BC that correlate with
distinct clinical applications in terms of treatment and prognosis.25,27 Luminal
tumours, A and B, have positive hormonal receptor status and have expression
profiles similar to normal luminal epithelial cells of breast tissue, but differ
more than “normal-type” tumours.27 Immunohistochemically, they appear as
ER+/PR+/HER2- (Luminal A) and ER+/PR+/HER2+/- (Luminal B),23 but Luminal A
have lower levels of expression for proliferation and are usually a lower grade
9
1 Introduction
than Luminal B.24,25 Luminal subtypes of breast cancer are the most common,24
but have distinctly different prognoses; Luminal A usually exhibits a much
better treatment outcome than Luminal B.63 ER- tumours, of which there are
two, make up half of the four distinct intrinsic molecular subtypes: Luminal A,
Luminal B, HER2-enriched and basal-like.27 The fifth subtype, normal-like, is
now believed to be caused by contamination of normal mammary cells in the
tumour biopsy.64 Separating patients into these subtypes has important clinical
ramifications, as they have variable treatment options and different prognoses.
For example, patients with Luminal or HER2 subtypes have options for targeted
and hormonal therapies, while patients with basal subtyped tumours gain no
advantage from these treatments and only have chemotherapeutic options.64
Prognostic signatures, like PAM50 and OncotypeDX, have been developed to
give patients and clinicians improved treatment options.64
1.7 Publicly Available Gene Expression Datasets
Newer and larger sources of publicly available transcriptomic data have enabled
breakthroughs in “PrecisionMedicine” andwill be crucial to the future improve-
ments of the treatment and prevention of BC.65 The predominant sources of
these datasets are, by large, initiatives andnational projects including the Cancer
Genome Atlas (TCGA) and the International Cancer Genome Consortium (ICGC).
Large scale efforts to collect and make available databases will facilitate new
waves of in silico hypothesis testing for researchers without the ability to de-
velop their own large-scale cohorts. This data is fundamental to improving the
scientific process of individual and personalisedmedicine, as well as powerfully
proving or disproving currently held assumptions.65
There have been several recent seminal database publicationswith far reach-
ing impact and utility. The Molecular Taxonomy of Breast Cancer International
Consortium (METABRIC) is one such effort that sequenced 173 genes in 2433 pa-
tients, along with expression data, copy number aberrations (CNA), and long-
term followup.66 This study identified 40 drivermutation genes and correlations
between the measured genomic information and survival to assess the impor-
tance of genome-based analysis and stratification of breast cancer subtypes for
therapeutic purposes.66 The dataset was made publicly available in 2012, with
sequencing data added later, and led to the development of the IntClust (IC10)
novel sub-grouping classifier, which was based on upstream driver genes iden-
tified by the integration of genomic and transcriptomic data.67
10
The Cancer Genome Atlas collected DNA copy number, methylation
information, array and sequence based mRNA expression, micro RNA and pro-
tein/phosphoprotein expression information for 825 primary BC patients.65,68
They identified specific and significant mutations in TP53 (Tumour Protein
53), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit
alpha) and GATA3 (GATA Binding Protein 3) across all BCs and found evidence
for four primary BC subtypes, each distinct and with significant molecular
heterogeneity.68 Comparisons were also drawn between basal-like BC and high
serous grade ovarian cancers with regard to molecular commonalities and they
hypothesised the opportunity for shared therapeutic options.68 Additionally,
they concluded that clinically observed heterogeneity in BC was mostly within
and not between distinct BC subtypes.68
Outside of major studies, online repositories exist to host individual datasets
from researchers and clinicians including the National Center for Biotechnol-
ogy (NCBI), the European Bioinformatics Institute and, at a smaller scale, The
Swiss Institute of Bioinformatics. These accept deposited data and host datasets
of genomic information, and allow for improved access to the available public
data. Large scale changes and additions to these repositories can be found in the
Nucleic Acids Research (NAR) annual database overview. These additions show
the rate of growth of available genomic information and highlight the increase
in availability of such data. Figure 1.7.1, Page 12 shows the rate of additions and
updates to the NAR over a four year period.69–72 While these represent different
types of datasets (proteomic, transcriptomic, and genomic), the rate at which
new datasets are accepted shows the trend in the availability of data. The avail-
able amount of information for bioinformatic analysis is growing yearly and
is opening new pathways to treatment and therapy. Other large scale dataset
projects have taken the open source approach, creating useful, open access tools
for generating cancer signatures in BC and in other tumours.73,74
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Figure 1.7.1: NAR Year on Year Growth. The 2017 publication of the NAR
database issue saw the addition of 54 new databases and 98 updates to
existing databases. It saw a steady increase from 2016 (62 new databases
and 95 updates) and 2015/2014 (56 and 115, and 58 and 123 new
databases and updates, respectively).
1.8 Gene Expression Profiling Methods and Datasets
Gene expression profiling gives a snapshot of a tumour’s cellular activity as
a function of the level of activity of all measured genes at a specific point in
time. This has enabled the detection of differences in gene expression levels
among different types of BC and helped to create subtype specific profiles.75
This technology has helped to better understand the heterogeneity of BC and
is offering new clinical tools for the prognosis and treatment of BC.76 Some
profiling techniques, such as OncotypeDX (Genomic Health Inc, Redwood
City, CA), MammaPrint (Agendia, Amsterdam, The Netherlands) and PAM50
(Prosigna), are commercially available and showing validated utility in this
area, as well as being refined through ongoing clinical trials.76 This progress is
aided by the development of newer and more efficient means of sequencing
large scale genomic information.
Microarray platforms for generating the necessary expression level data, like
Affymetrix, use thousands of nucleic acid probes to hybridise complementary
nucleic acid sequences in solution and measure their relative concentrations to
calculate gene expression levels estimated indirectly by observing the hybridis-
ation events.77 Beadchip sequencing techniques, like Illumina, use thousands of
3 micron silicon beads dispersed in random wells on a testing substrate. These
wells are covered in hundreds of thousands of oligonucleotide primers and the
12
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concentration of binding at each bead ismeasuredwith fluorescence to estimate
the amount of the gene bound.78 Lastly, RNAseq utilises deep-sequencing to iso-
late sample RNA, generate complementary cDNA and sequence the fragments,
before aligning the reads to map the sample transcriptome. RNAseq has single
base resolution and is sensitive enough to distinguish isoforms, but is the most
costly of these technologies.79
These techniques have all helped to resolve detail in expression level data
from patient samples and have made the available predictive and prognostic
tools possible.
1.9 Predictive Biomarkers for Patient Response
Biomarkers for cancer fall into three categories; predictive, prognostic or
diagnostic.80 Predictive biomarkers are utilised to predict response to specific
therapies like trastuzumab, where the activation of HER2 pathways in BC is
indicative of response.80 Prognostic biomarkers are not treatment specific;
instead, they attempt to quantify the risk of future relapse or recurrence of
cancer to a patient and help clinicians make informed treatment decisions.80
Lastly, diagnostic biomarkers are used to ascertain if a patient has a specific
form of a disease.80 As has been touched on, most biomarkers and prognostic
tools are developed using single time point patient and tumour information
and do not take into account any on-treatment information. The addition of
on-treatment information may be advantageous for the development of robust
new biomarkers to aid clinicians.
1.10 Prognostic Gene Expression Signatures for Breast
Cancer
The most established gene expression based prognostic tools for BC are Onco-
type DX and MammaPrint. Oncotype DX is a genomic assay (Genomic Health,
Inc., Redwood City, CA, USA) used to predict the likelihood of BC recurrence and
aids in the treatment selection process for patients with ER+ disease.81 Oncotype
DX works by comparing the expression of 16 key genes to the expression of five
reference genes and algorithmically generates a recurrence score based on these
measurements.82 The effectiveness of Oncotype DX has been independently val-
idated in node-negative patients to accurately predict risk of recurrence regard-
less of patient age or tumour size.82 Additionally, the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B-20 trial showed that the calculated recur-
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rence scores could be used to identify the patients to whom adjuvant chemother-
apy conveyed the most advantages over endocrine therapy alone. It found that
patients with high risk of relapse gained the most added benefit from adjuvant
chemo (RS (relapse score) greater than or equal to 30%).83 MammaPrint is a
microarray-based, recurrence risk test reliant on the expression of 70 genes that
make up its specific signature.84 This test functions as a means of identifying
patients with a low or high risk of distant metastasis in order to aid physician
treatment selection and minimise unnecessary treatment, as patients labelled
as low risk can omit chemotherapy without a reduction in disease-free survival
(subsequent fatalities were not caused by a recurrence of the cancer).85 This re-
sult was ratified in the RASTER trial which showed that in the 5-year, distant
recurrence-free interval (DRFI), the use of MammaPrint correctly identified low
risk patients and the omission of additional chemotherapy did not compromise
their outcomes.86
While both MammaPrint and OncotypeDX methods suggest patient progno-
sis and help to identify patients who did not need additional chemotherapy,
there are a few key differences between the techniques. Both can now be ap-
plied to FFPE (Formalin Fixed Paraffin Embedded) samples, though, initially,
MammaPrint was more limited in application, as it could only be performed
on fresh frozen samples.87 Fresh frozen samples are usually “higher quality”
samples as they experience less degradation from environmental exposure post-
resection, which usually leads to better coverage during subsequent analysis.
Additionally, while both are primarily for ER+ tumours, MammaPrint was de-
veloped with a younger cohort, and is most appropriately applied to patients
under 61 years of age.87 Finally, trials for both methods are underway to iden-
tify if either is appropriate for ER- tumours, which would substantially differ-
entiate between these methods and increase their utility in the future. Other
techniques for gene expression profiling that are less well adopted include the
Genomic Grade Index and PAM50 (Prosigna).
PAM50 (Prosigna; Nanostring Technologies, Seattle, WA, USA) is another re-
currence scoring test for ER+ patients designed from 50 key genes and is appro-
priate for postmenopausal women undergoing endocrine therapy.87 PAM50 can
report the intrinsic subtype of the tumour88 and has the added advantage of be-
ing performable locally,87 whereas MammaPrint and Oncotype DX must be per-
formed at specified testing centres. The Genomic Grade Index (MapQuant Dx, Ip-
sogen, France) represents an entirely different strategy, which is currently used
to better define histological grade assessments.89 Instead of assigning grades to
tumours, it defines low and high molecular grade risk groups based on a 97
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gene signature (or abbreviated 6 genes RT-PCR signature) in order to separate
tumours into more distinct prognosis groups.87,89
EndoPredict is a validated assay tool used in the prediction of metastasis for
patients with ER+, HER2- BC.90 EndoPredict incorporates both clinical and ge-
nomic information to calculate the risk of metastasis on a per patient basis.90
This information can be used to inform treatment options and has already been
used to advise treatment progression on patients in the study cohort, resulting
in additional chemotherapy for some high risk patients or endocrine-only treat-
ment plans for lower risk individuals.90 Another predictive tool is the Breast
Cancer Index (BCI) which is a gene expression based signature for predicting
the early and late lifetime disease recurrence of BC in ER+ patients.91 This test
was shown to perform well from the time of diagnosis for the prediction of high
and low risk disease recurrence.91 This information can be used to help inform
treatment decisions as well as the suitability of long term adjuvant endocrine
therapy.91 Newer tests are being developed for specific treatment cohorts that
have refined applicability and improved resolution of patient prognosis, which
can potentially provide significant improvements in the treatment decisionmak-
ing process. One such test is the OncoMasTR, which used network delineation to
identify the underpinning genes that are the upstream drivers of BC in a cohort
of ER+ LN- patients.92 The seven genes derived from this transcriptional regres-
sion were shown to be more sensitive when predicting the need for additional
chemotherapy for women with no lymph node involvement.92 OncoMasTR can
be used in the future to assist in treatment decision making for similar patients
in an effort to avoid unnecessary chemotherapy.92
1.11 Sequential Sampling
Sequential sampling, taking several samples over time to monitor the change in
tumour biology, is offering new insights into the effects of treatment on BC, see
Figure 1.11.1 on Page 16 for an illustration of the approach. Initially uncommon,
the collection of multiple biopsies from the same patient has become more rou-
tine with the rise in neoadjuvant therapies.93 Studies of neoadjuvant therapies
and pre-surgical treatments allow for unique in vivo analysis of tumour treat-
ment response,94 as well as the possibility of predicting the response to treat-
ment earlier in the treatment cycle.95
Neoadjuvant studies of sequential samples take place after diagnosis but be-
fore surgery, providing a “window of opportunity” that offers the possibility
15
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of observing translational changes that are solely the response of the tumour
to treatment.96 Measuring these changes can potentially indicate if a tumour is
likely to respond to treatment or generate resistance andboth outcomes canhelp
inform patients and clinicians on how to proceed with treatment.97–99 Though
the exact structure of sequential studies will differ, diagnostic biopsy samples as
well as one or more on-treatment (neoadjuvant samples taken after the initial
treatment and before total resection) samples and the surgical/resection sample
are usually collected. Acquisition of these samples can prove difficult for patient
retention in trials, especially in the CT (chemotherapy) setting, where treatment
side effects are much more pronounced and additional patient stress is a con-
tributing factor.
Figure 1.11.1: Window of Opportunity Schematic for Neoadjuvant Ther-
apy. The general structure of neoadjuvant trials and treatment strategies
are illustrated here, with a pretreatment opportunity to sample the tumour
positive tissue and measure the effects of therapeutics prior to surgery.
1.12 Opportunities and Challenges of Patient-Matched
Samples
Sequential samples offer increased resolution for the change in tumour biol-
ogy with treatment. Most studies focus solely on the presentation of the tu-
mour at diagnosis.95 However, by looking at the on-treatment changes, impor-
tant expression pathways that are linked to different clinical outcomes can be
observed.100 Additionally, these sequential samples can offer insight into the
molecular changes that drive tumour evolution in patients. Specifically, Gut-
tierez et al. 101 recently reported significant HER2 and MAPK signalling in pa-
tients with acquired resistance to tamoxifen in matched pairs of breast sam-
ples.
Sequential sampling offers a unique opportunity to study drug efficacy,
predict response and provides an increased rate of predictive biomarker
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generation.96 The latter was demonstrated in BC by researchers at The Univer-
sity of Edinburgh through the addition of on-treatment expression information
to enhance predictive power.102 This resulted in a four-gene biomarker that is
91% accurate in validation and also significantly improved prediction of both
recurrence and breast cancer-specific survival rates.102 Further studies within
this field are required to establish if this only holds true for ER+ cohorts or if
this is more generally applicable. Challenges involved in collecting sequential
samples are varied; additional sampling is inherently more expensive and
patients are subjected to additional stress. Early on-treatment biomarkers for
response would reduce the incidence of inappropriate treatment selection and
remove the burden of multiple biopsies. Furthermore, Turnbull et al. have
shown that a two-protein signature can be highly effective for predicting
response in patients at early time points in BC therapy.103
1.13 Availability of Datasets
Studies of sequential time points like those discussed previously are rare com-
pared to single time point studies. Table 1.1 on Page 19 highlights some of the
available datasets of sequentially sampled patient studies.96,102,104–112 It is worth
noting the discrepancy between endocrine and chemotherapy in terms of pa-
tient cohort size. Endocrine studies have a higher success rate for sequential
biopsies because of the reduced levels of stress experienced by patients com-
pared to chemotherapy. Endocrine therapy patients are also at a reduced risk of
post biopsy complications and secondary immunosuppression. Practically, this
means more chemotherapy based trials of sequential samples must be aggre-
gated in order to reach similar levels of significance for any subsequent results,
assuming a significant effect size. Not all datasets are annotated well; some lack
phenotypic data for each patient and others defined response status (if available)
in different ways, e.g. radiological vs pathological complete response. Therefore,
validation across these disparate datasets becomesmore challenging as common
end points need to be defined to draw direct comparisons. Samples are also
processed across different platforms, leading to the inclusion of batch effects
that need to be considered and removed113 in order to adjust for technical vari-
ance while retaining the underlying biological information.114 Lastly, while se-
quential studies all follow general paradigm of pre-to-on-treatment, time points
can differ between studies due to different study designs and sampling require-
ments. All studies have a pretreatment biopsy sample but the first on-treatment
sample is not always uniform nor are subsequent time points. Furthermore,
datasets may contain a variety of different on-treatment time point samples due
17
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to different trial and study requirements. Finding a lowest common denomina-
tor of treatment samples is necessary for direct comparisons, but will inevitably






























































































































































































































































































































































































































































































































































































































































































































A significant problem for sequentially sampled dataset analysis is the size and
availability of data. There are multiple obstacles that prevent a simple integra-
tion of data to improve sample size; primarily, batch effects and the influence of
different processing platforms or methods. However, when discussing the im-
pact on time-dependent data, on-treatment effects become a problem. Contem-
porary work ongoing at the University of Edinburgh is showing that integration
of compositionally diverse datasets can skew subtyping results.115 Additionally,
integrating treated and untreated data together can reduce distinctions between
the sample populations. All of these factors will have to be combated, but with
successful integration of sequential datasets, the ability to gauge the effect of
treatment and leverage the pairwise patient response for risk stratification is
improved.
Dataset integration is an attractive target for furthering bioinformatics, as it
is desirable to create larger, higher value datasets. These datasets can improve
the statistical significance of results and enhance detection of low frequency
anomalies from heterogeneous data. However, integration can also introduce
bias and statistical artifacts due to the nature of batch correction methodolo-
gies seeking to normalise parametric distributions. To better illustrate this point;
a two dimensional representation of multiple expression sets would appear as
multiple distinct clusters of points. Differential analysis on this unintegrated
data would find the differences between the clusters, not the differences be-
tween labelled samples across all of the datasets. Additionally, there can be large
cell-type heterogeneity and sampling impurities, which, when not considered,
can introduce additional noise as these samples are essentially “mislabelled”.
Such samples are clearly identified through visualisations of the data and the ef-
fects of integration through techniques like principal component analysis. Small
and disparate datasets are a significant bottleneck to generating novel biomark-
ers and prognostic signatures.116 As no standard for processing platforms ex-
ists, the need for a robust integration method becomes more evident as more
high quality genomic data is made available.117 As expression data can vary
greatly between platforms in terms of scale and structure, integrating, compar-
ing and validating results across independent studies remains challenging.117
Batch effects can confound the integration of disparate datasets and removing
systematic differences between datasets is necessary for the robust integration
of data. As demonstrated by Sims et al., removing batch effects and reconcil-
ing systematic biases between expression sets allows for the direct integration
of raw expression data with improved statistical significance for downstream
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analysis.95 Examples of these batch creating effects include platform or institute
of the data origin, sampling errors, multiple biopsy variation, cell type hetero-
geneity/composition. These can all have profound effects of the resultant gene
expression levels, and especially in comparative analysis.
1.15 Dataset Integration Improves Statistical Signifi-
cance
Dataset integration allows for the creation of larger andmore representative co-
horts for statistical analysis and would eliminate the effects of overfitting on
a resultant biomarker, due to the wide nature of gene expression data. The
small size and specificity of many modern datasets give rise to incomplete clin-
ical tools that are difficult to validate in exogenous data.118,119 Currently, sev-
eral prognostic and profiling signatures have been shown to have some level of
concordance in independent datasets.118 However, it has been established that
much larger sample sets are necessary to make true consensus biomarkers.120
Additionally, many prognostic markers and profiling signatures do not validate
in other datasets, even when the differences between the sets are minimised.121
This is frequently due to overtraining of prognostic markers on small datasets
that inhibit their general utility in disparate/dissimilar datasets.121
There are a number of technical difficulties that plague genomic data integra-
tion. Due to differences in pre-processing pipelines and gene- and probe-level
annotation, feature size of integrated data is often diminished in order to retain
complete feature coverage.122 Several groups have reported that integration of
expressionmicroarray data has positive effects on statistical power, the ability to
identify differentially expressed genes of interest andmore robust, reproducible
results.122–124 While there is no standard for the method of integration, it has
been shown that, as long as the integration methodology is rational and care-
fully executed, the improvements to downstream analysis are significant.122
There are few existing examples for the integration of sequential samples.
Primarily, this may be due to the relative scarcity of sequential datasets and
the added confounding factor of patient and treatment response heterogeneity.
Integration must be carefully considered, as it has been shown previously that
dataset composition can affect the accuracy of expression derived subtypes in
BC.125 As ongoing treatment changes the predicted intrinsic subtype, integration
of different timepointsmust be handled carefully to avoid normalisations across
treatments that could potentially distort gene expression measurements and in-
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troduce, rather than remove, bias.125
1.16 Using On-Treatment Information May Enhance Pre-
diction of Response or Prognosis
There is a substantial precedent for the clinical use of gene expression profiling.
This is primarily based upon correlated relationships between pretreatment pa-
tient samples, post treatment patient samples, and long-term survival analysis.
While this methodology has proven suitable in the generation of successful ex-
pression signatures for prognostic prediction (Onxotype DX, MammaPrint etc.),
the scarcity of on-treatment information has made the generation of signatures
from sequentially sampled data significantly more rare. Developing early on-
treatment profiling signatures for response in both neoadjuvantly administered
chemotherapy and endocrine therapy could improve patient care and reduce
over prescription. As BC is a multifaceted disease, a single biomarker is un-
likely to be successful at predicting response in a molecularly diverse setting.
Fortunately, there is now access to sequentially sampled data for both treat-
ments types, which facilitates the generation of niche markers for both treat-
ment paradigms.
A new landmark study in this field, the POETIC trial, is a phase III, multi-
centre, randomised trial of ER/PR+ BC measuring the effect of a perioperative
aromatase inhibitor with on-treatment changes to KI-67.126–128 This study builds
on the established results of the IMPACT trial, which suggests that on-treatment
changes in KI-67 at twoweeks are strongly suggestive of patient outcome.129 Ellis
et al. have also demonstrated that on-treatment information can be informative
for the accurate prediction of response to endocrine therapy.130 In a 2017 study,
they examined the expression levels of KI-67 in patients at two and four weeks
and found that patients with elevated KI-67 levels (higher than 10%) were ex-
hibiting endocrine resistance andwere triaged to neoadjuvant chemotherapy.130
The triaged cohort experienced lower rates of pCR (5.7%, 2/35 patients).130 Indi-
vidually, these studies support the use of on-treatment gene expressionmonitor-
ing for improved patient stratification.
Studies of integrated pre- and on-treatment information are still in their
infancy. However, Turnbull et al. revealed that on-treatment proliferation
markers could be combined with patient-matched pretreatment markers
to accurately predict the clinical response and recurrence-free survival of
patients.102 In this study, the tests utilising on-treatment information outper-
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formed pretreatment-only diagnostic tools, in both accuracy and specificity.102
The on-treatment signature developed was found to be 96% accurate, while the
pretreatment-only signature was 93% accurate in a local dataset.102 However,
in validation, their four-gene, pre- and on- treatment signature outperformed
a similar pretreatment only signature by 14%.102 Continuing work by Sims et
al. has combined NPI prognostic groups with their two-protein signature to
further refine the predictive capabilities of these on-treatment signatures.103
Figure 1.16.1 on Page 23 highlights the overall structure of this study and how
to follow the results that are presented.
Figure 1.16.1: Flow Diagram of the Overall Structure of Thesis. This the-
sis contains four results chapters which correspond to Chapters 2-5. Chap-
ter 2 feeds directly into chapter 4, which subsequently feeds into chapter
5. Results chapter 3 is independent in regards to the data analysed, but
has similar themes of comparing the value of matched non-primary tissue
samples for prognostic purposes.
1.17 Thesis Hypothesis, Aims and Outcomes
This thesis aims to assess the value of additional on-treatment sampling of
neoadjuvantly-treated BC patients for the purpose of biomarker identification
and risk stratification to prove the following thesis:
If patient-matched on-treatment or lymph node positive samples are in-
formative for the classification and characterization of breast cancer,
then they should facilitate improved differential and statistical analy-
sis of breast cancer.
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Sequential sampling of neoadjuvantly treated breast cancer should capture
more informative transcriptional changes, which will be more indicative of
tumour response to therapy. This will enable improved identification of patient
response and enhance clinical decision making options, furthering the goal of
personalised medicine. This project aims to enumerate the value of multiple
sampling in matched primary and lymph node biopsies to provide additional
prognostic risk information. Lastly, in an attempt to improve future analysis of
BC, this thesis aims to exhaustively study the possibility of integrative analysis
and/or comparative meta-analysis to improve the resolution of treatment
specific changes and more accurately model and predict risk to patients.
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Neoadjuvant chemotherapy is increasingly given preoperatively to shrink
breast tumours prior to surgery. This approach also provides the opportu-
nity to study the molecular changes associated with treatment and evaluate
whether on-treatment sequential samples can improve response and outcome
predictions over diagnostic or excision samples alone.
Methods
This study included a total of 97 samples from a cohort of 50 women (aged
29–76, with 46% ER+ and 20% HER2+ tumours) with primary operable breast
cancer who had been treated with neoadjuvant chemotherapy. Biopsies were
taken at diagnosis, at 2 weeks on-treatment, mid-chemotherapy, and at resection.
Fresh frozen samples were sequenced with Ion AmpliSeq Transcriptome yield-
ing expression values for 12,635 genes. Differential expression analysis was per-
formed across 16 patients with a complete pathological response (pCR) and 34
non-pCR patients, and over treatment time to identify significantly differentially
expressed genes, pathways, and markers indicative of response status. Predic-
tion accuracywas comparedwith estimations of established gene signatures, for
this dataset and validated using data from the I-SPY 1 trial.
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Results
Although changes upon treatment are largely similar between the two co-
horts, very few genes were found to be consistently different between respon-
ders and non-responders, making the prediction of response difficult. AAGAB
was identified as a novel potential on-treatment biomarker for pathological com-
plete response, with an accuracy of 100% in the NEO training dataset and 78%
accuracy in the I-SPY 1 testing dataset. AAGAB levels on-treatment were also sig-
nificantly predictive of outcome (p = 0.048, p = 0.0036) in both cohorts. This single
gene on-treatment biomarker had greater predictive accuracy than established
prognostic tests, Mammaprint and PAM50 risk of recurrence score, although in-
terestingly, both of these latter tests performed better in the on-treatment rather
than the accepted pre-treatment setting.
Conclusion
Changes in gene expression measured in sequential samples from breast
cancer patients receiving neoadjuvant chemotherapy resulted in the iden-
tification of a potentially novel on-treatment biomarker and suggest that
established prognostic tests may have greater prediction accuracy on than be-
fore treatment. These results support the potential use and further evaluation
of on-treatment testing in breast cancer to improve the accuracy of tumour
response prediction.
Overview
A generalised diagram of for this work, especially with regards to the gener-
ation of the most vital outcomes is presented in Fig. 2.1.1, on Page 27. This high
level over view shows the flow of the paired samples from patient fold change
values through to candidate gene lists for response and lastly validation testing
in new testing data.
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Figure 2.1.1: Overall Study Design and Workflow. This workflow diagram
illustrates a high level overview of the analysis of the NEO trial data. Start-
ing on the left, there are the matched patient samples across time, Pretreat-
ment (TP), Early On-Treatment (T-On), Mid-Treatment (TM) or the surgically
resected sample (TS), then differential gene expression analysis of the time
point pairs, followed by candidate gene discovery and risk modelling on
the output gene lists. Lastly, these results are validated in a contemporary
study, the I-SPY trial.
2.2 Background
Chemotherapy is among the most common effective treatments for breast can-
cer, alongside radiotherapy, hormone therapy, and targeted treatments. Neoad-
juvant chemotherapy (NACT) is given prior to surgery to reduce the tumour
burden and provide early information on treatment response.131 Studies have
shown that patients with tumours that have a pathological complete response
(pCR) following neoadjuvant chemotherapy are much less likely to recur than
those inwomenwith residual disease.132Neoadjuvant chemotherapy is now con-
sidered as the standard of care in breast cancer and has seen a rise in recent
years with data from powered studies suggesting that the pathological complete
response achieved following neoadjuvant chemotherapymight be a surrogate of
good prognosis.133 Recent meta-analysis has shown significant tumour response
and an increase in the rate of breast-conserving surgery following NACT with
good rates of long-term local recurrence (5.5% vs. 15.9% adjuvant chemother-
apy), but an increase in the rate of short-term local relapses (1.35 RR 0–4 years,
1.53 RR 5–9 years).134
Neoadjuvant treatment provides a “window of opportunity” (Fig. 2.4.1, A, on
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Page 35), where sequential sampling of a tumour enables observation of the
changes that occur in response to treatment to be measured and considered
in the context of response and outcome.135 Neoadjuvant therapy studies and
pre-surgical treatments allow for a unique in vivo analysis of tumour treatment
response,136 aswell as the possibility of predicting the response to treatment ear-
lier in the treatment.135 It has been suggested that on-treatment biomarkersmay
be superior to thosemeasured before exposure to treatment.133,137 On-treatment
information has already been shown to be informative for the accurate predic-
tion of response to endocrine therapy.138 Here, it was found that patients with
elevated KI-67 levels (higher than 10%) at two or fourweeks exhibited resistance
to endocrine therapy and were triaged to neoadjuvant chemotherapy.138 It has
also been demonstrated that there is potential of on-treatment biomarkers by
developing a four-gene signaturewhich combined pre-treatment expression lev-
els or two biomarkers (IL6ST, Interleukin 6 Signal Transducer, and NGFRAP1,
Nerve Growth Factor Receptor Associated Protein 1) with patient-matched 2-
week on-treatment expression levels of two proliferation markers (ASPM, ab-
normal spindle microtubule assembly, MCM4, Minichromosome Maintenance
Complex Component 4) to accurately predict the response to endocrine therapy
in a blinded independent validation set.137
To date, gene expression-based studies of neoadjuvant chemotherapy treat-
ment have largely been limited to studying the association of pre-treatment
samples with pathological response.139,140 Patient-matched sequential sampling
gene expression studies have been previously attempted; however, they have
not evaluated the predictive capacity or proposed new on-treatment predictive
biomarkers.141–143
In this study, we present the largest sequentially sampled patient-matched
analysis of neoadjuvant chemotherapy-treated breast cancer tumours to evalu-
ate whether on-treatment biomarkers can improve the accuracy of predicting
response before resection. Numbers of patients with sequential breast tumour
samples are limited, but we compare and validate our results with the data from
the I-SPY 1 trial.
2.3 Materials and Methods
2.3.1 Patients, Response Criteria, and Samples
The NEO study consists of 50 breast cancer patients with sequentially sampled
biopsies at four time points, pre-treatment (TP, 34 samples), 2 weeks on treat-
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ment (T-On, 12 samples), mid-chemo (TM, 23 samples), and at surgical resection
(TS, 24 samples). There were three clinically defined response statuses: com-
plete responders (pCR by resection), good responders (tumour volume reduc-
tion, but lack of pCR), and non-responders (progressive disease or small tumour
volume changes on treatment, these included patients with stable non respond-
ing disease). There were 11 TP-T-On, 23 TP-TM and 36 TP-TS pairs. Patients
were of mixed histological grade and HER2 status; ages ranged from 29 to 76.
Patients were primarily treated with 3 cycles of FEC 100 (5 Fluorouracil, Epiru-
bicin, Cyclophosamide) and docetaxel 100 with Herceptin, where appropriate.
Three patients received paclitaxel, one patient received additional carboplatin,
one patient received Epi-cyclophosphamide and paclitaxel, and one patient re-
ceived docetaxel and cyclophosphamide. Eligible patients werewomenwith his-
tologically confirmed invasive breast tumours and with no evidence of distant
metastatic disease, no prior history of malignancy, and fit enough to receive
chemotherapy in the opinion of the responsible clinician irrespective of age.
All cases were discussed at the breast Multi-Disciplinary-Meeting in Edinburgh
Breast Unit at the Western General Hospital, and consensus from this meeting
was to be treated with neoadjuvant chemotherapy. Dr Oikonomidou is responsi-
ble for the conceptualization and the set up of the NEO study aswell as obtaining
relevant approvals for the study R&D and Ethics. Dr Oikonomidou and her team
identified eligible patients. These patients were consented to the study prior to
any sample collection taking place. All samples were collected and processed by
Dr Oikonomidou’s group. The wet lab experiments were performed by Dr. Car-
los Martinez-Perez and Dr. Arran Turnbull. Analysis was performed by Richard
Bownes.
Core needle (16-gauge) biopsies were taken from the primary breast tumours
before treatment (TP) and between 10 and 14 days after the first dose (T-On) of
chemotherapy. A third sample was taken at the mid-chemotherapy point day
20–21 (TM), and finally, a core biopsy was taken from the excision specimen (TS)
after it has been removed prior to submission to pathology. Fixed and frozen
samples of normal and tumour tissue were collected from all specimens and
fresh frozen samples were used for subsequent analysis.
The I-SPY 1 trial is composed of patients with invasive breast cancer > 3 cm,
or at least one tumour-positive axillary lymph node.141 Patients were treated
with an anthracycline-based chemotherapy followed by taxanes.141 Samples
were normalised and corrected for background red/green signal; Bioconductor
R packages marray and Limma144 were used for this analysis. From the original
221 patients, only 36 had matching pre- and on-treatment samples, and 39
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had matching biopsy and excision samples; pathological complete response
was used for response criteria. Pairwise gene expression was handled with
SAM (Siggenes) and follow-up analysis with Ingenuity Pathway Analysis from
QIAGEN Bioinformatics. I-SPY 1 trial data is hosted at NCBI GEO under accession
GSE32603.141
2.3.2 Gene Expression Profiling
RNA extraction was performed via Ribo0-RNAseq, and whole transcriptome se-
quencing was performed with Life Sciences Ion AmpliSeq™ Transcriptome Hu-
man Gene Expression Kit. This generated greater than 8 M reads per sample
with an average of more than 90% valid reads for 12,365 targeted genes. Most
analyses were performed in R145 using packages available through CRAN and
Bioconductor.146 Outside of the R environment, the stand-alone applicationMul-
tiple Experiment Viewer147 was utilised for pairwise ranked product feature se-
lection, and DAVID148 was used for pathway identification and Gene Set Enrich-
ment Analysis (GSEA). Additionally, the python package scikit-learn149 was used
for unsupervised clustering analysis. Ninety-seven samples were analysed over
13 AmpliSeq chips, but no systematic batch effects were evident and no batch
correction was performed within the training data. Gene expression data for
the NEO study has been made publicly available at the NCBI GEO data reposi-
tory under accession GSE122630.
2.3.3 Statistical Analysis Methods
Principal component analysis (PCA) was performed on unfiltered gene lists to
reduce dimensionality and visualise differences in response at all times and to
identify present differences between patient treatment statuses. Local Fisher
discriminant analysis (LFDA)150 was used at each time point to determine if
the response groups could be distinguished with treatment time with a semi-
supervised clustering approach, concurrently with class advised K-means clus-
tering. LFDA is a form of supervised dimensionality reduction that maximises
between-class scattering andminimises within class scatter, and is a refined ver-
sion of normal Fisher discriminant analysis;150 this exploratory analysis was
used in order to visualise comparative differences in treatment time, not as a
means of feature selection. Pairwise significance analysis of microarrays151 us-
ing the siggenes package in R was used to consider the consistency of differen-
tially expressed genes due to treatment in the sequential patient-matched sam-
ples.
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The primary method of reporting significance between two groups, or mea-
suring the significance of the difference present between two effect populations
in this study, is through a combination of parametric and non-parametric tests.
When measuring the effect between groups of unpaired samples, standard T-
tests were performed. The five basic assumptions were always tested: The val-
ues are on a continuous scale (expression values), the samples are to the best
of my knowledge representative of the population as a whole as the only con-
straint on the sampling process was agreeing to be part of the study and no filter
was made for age or ethnicity. Graphically the data conforms to a normal bell
shapeddistribution after processing, but is slightly long tailed prior to normalisa-
tion. The fourth criteria of a reasonably large sample size is satisfied as the other
assumptions hold and there are sufficient samples to calculate the test statistic.
Lastly, standard deviations on both side of the mean are approximately even
suggesting homogeneity of variance. Non-parametrically, a Wilcoxon T-test was
used when measuring the differences in expression of paired samples. Assump-
tions here were easier to satisfy as every sample is inherently paired and come
from the same population, additionally, the comparisons are from within pair
differences.
Rank Product analysis through MEV was used to identify differentially ex-
pressed genes between response classes at each time point. MEV was chosen in
this instance over comparable analysis using siggenes due to the level of consis-
tency it provided over contemporary methods with regards to ease of use and
granularity to select appropriate comparisons from the data annotation. For
the remainder of this work the lists obtained from the MEV-derived rank prod-
ucts implementation will be used for analysis. Successive levels of standard p
value (0.05, 0.01, 0.001), without correction for multiple testing, were used in or-
der to determine the number of differentially expressed genes, and at lower p
values which time points had the most strongly differentiating genes. Later vali-
dation with multiple corrections identified no false positives and thus no results
were eliminated. Significance analysis of microarrays was also performed using
varying false discovery rates (1%, 5%, 10%) to identify common differentially ex-
pressed genes between responders and non-responders across both datasets at
each time point in order to perform a “sanity check” on the gene lists derived
from a more reproducible source. However, these lists were not included in
future analysis. Gene score enrichment analysis was used to validate the time
point selection by looking for the highest number of enriched pathways. The
gene list from themost differential time point (TM) using theNEOdatasetwas ex-
tracted and used in a random forestmodel (10,000 trees, m-try as the square root
of the feature number) using pCR status as the class label (clinician-identified
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pCR and non-pCR). The most deterministic genes for class prediction were fed
into a classification and regression tree in order to produce amaximally reduced
and repeatablemodel; thismethodology is further describedbyTurnbull et al.137
Themethod employed in Turnbull and co-workers study identified differentially
expressed genes between different time point patient sample pairs as ameans of
dimensionality reduction then used the reduced feature space as the input to a
random forest classificationmodel trained on response. The ranked variable im-
portance of each feature is ordered and all genes with a calculated importance
to classification over 5% is then fed into a CART (Classification and Regression
Tree) model to create a decision tree with maximal pruning for risk stratifica-
tion on minimal genes.137 The CART decision tree method was applied to the
NEO dataset for training and tested in the independent I-SPY 1 dataset using the
same cut-points determined by mean-centring the datasets, this was done make
the range of values comparable. This protocol was repeated using the gene list
from the pre-treatment-only samples, using the same p values and tree configu-
rations for selection. Survival analysis was performed at different time points
using the log-rank test which tests the null hypothesis that the probability of an
event is equal in both populations. The log-rank score is calculated as:
𝑋2(𝑙𝑜𝑔𝑟𝑎𝑛𝑘) = (𝑂1−𝐸1)2𝐸1 +
(𝑂2−𝐸2)2
𝐸2
In the above equation E represents the expected number of events, and O the
observed. Log-rank was selected as this was a standard comparison between
two classes,152 accuracy is presented as balanced F1 scores.
Risk of relapse scores, where specific gene markers are used to estimate the
risk of a patient experiencing a relapse, such as MammaPrint, and intrinsic
subtypes, such as PAM50, were estimated from the gene expression data using
the geneFu R package.153 Subtypes and risk scores for IC10,154–156 Pam50,156
scmod1157 and scmod2,158 ssp2003154 and ssp2006,155 and the continual and
categorical risk values for MammaPrint159 and rorS156 were calculated with
geneFu. These operate by assigning centroid mappings for each subtype or
risk group, transforming the numerical expression matrix data into a reduced
space and mapping onto the centroid map. The least distant subtype is then
assigned to the tested sample. These methods take matrices of gene expression
data as the input and output output sample subtype or profile assignments per
column. This information was used for concordance comparisons as well as
Sankey diagrams to show the change over time.
IC10 is an integrative clustering algorithm which identifies ten subtypes of
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breast cancer marked by their upstream gene driver signatures which have
shown distinct clinical outcomes and was originally derived from examining
both genomic and transcriptomic data. Pam50 is a tumour profiling test
specifically designed for use on ER+ and HER- breast tissue, but which can be
used to profile tumours into five different subtypes with differentiating clinical
prognoses, or can be employed as the ROR (Prosigna) risk of relapse score
which attempts to calculate the likelihood of tumour metastasis. SCMOD1/2
are Subtype Clustering Models based on a series of parameters described by
Desmedt, 2008,157 andWirapati, 2008,158 which separate tumours into groups of
ER-/HER2-, HER2+ and ER+/HER2- subtypes for prognostic purposed. SSP2003/6
are classifiers that have shown good concordance with clinically defined
histologically derived molecular subtypes, identifying tumours as Her2, Basal,
LumA and LumB. These were first described by Sorlie, 2003154 and Hu, 2006155
respectively. Lastly, Mammaprint is a genomic test which uses a panel of genes
to estimate the risk of tumour recurrence and classifies patients according to
their estimated risk.
2.4 Results
2.4.1 Gene Expression Differences Between Responding and Non-
responding Breast Cancer Tumours Treated with Chemother-
apy are Subtle and Time Dependent
Unsupervised principal component analysis was first used to assess whether se-
quential patient-matched samples from patients receiving chemotherapy (Fig.
2.4.1, B, on Page 35)would cluster by time point or response status. Therewas no
significant grouping of patients according to sampling time: pre, early, or later
after chemotherapy in either the NEO or I-SPY 1 studies (Fig. 2.4.1, B, on Page
35). There were no significant differences between the two cohorts in terms of
age, grade hormone receptor, and HER2 status, and the subset of patients with
mid-chemo samples was not significantly different from the whole NEO cohort
(Table. 2.1, on Page 36). Patient-matched samples enable the pairwise analysis
to look for consistent changes in the gene expression during treatment. Pair-
wise significance analysis of microarray analysis using a 10% false discovery
rate (FDR) identified a relatively small proportion of overlapping upregulated
(5%) and downregulated (4%) genes between the two studies. However, genes
that were increased or decreased in response to treatment in one study were
also clearly and consistently increased or decreased in the other study, further
suggesting it would be difficult to discriminate responders fromnon-responders.
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Indeed, there was no clustering by response status before or during treatment.
These results likely reflect the considerable inter-patient differences being sub-
stantially larger and more significant than the subtler commonalities in gene
expression of a particular time point or response class of each tumour. More en-
couragingly, semi-supervised LFDA of each time point revealed significant sepa-
ration on-treatment that was not apparent in pre-treatment samples, indicating
that there aremeaningful differences between the classes as early as 2weeks on-
treatment (Fig. 2.4.2, A, on Page 38). Complete responders and non-responsive
patients were more clearly separated than partially responding patients. These
results suggest that there is a potentially greater predictive value looking at on-
treatment than pre-treatment biomarkers.
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Figure 2.4.1: On-Treatment Study Design and Unsupervised Analysis. A)
Neoadjuvant studies all follow similar design scheme, with a pre-treatment
sample, potential on-treatment matched samples and a surgical biopsy
sample, and with matched patient phenotypic data, where possible. B)
Unsupervised clustering by PCA shows no significant trends in response or
treatment time.
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2.4.2 Responding and Non-Responding Tumours are More Different
Upon Exposure to Chemotherapy
In an attempt to quantify the molecular differences between the response
groups at each time point, rank product analysis was performed at different
standard p values (0.05, 0.01, and 0.001). This approach was hampered by
different numbers of samples at each time point (with T-On having very few
samples); however, the number of genes differentially expressed at all p values
tended to be greater during rather than before treatment (Fig. 2.4.2, B, on
Page 38). Similar results were also seen using 1%, 5%, and 10% FDR (Fig. 2.4.2,
B, on Page 38). The biggest differences between the response classes were at
TM (mid-chemo), which agrees with the LDFA results, which showed the least
amount of overlap of the response classes at TM. Gene set enrichment analysis
across the response classes at each time point also demonstrated more enriched
pathways after 2 weeks of treatment (29), mid-chemo (30), and resection
(29), compared to pre-treatment (18). Next, we sought to examine common
differentially expressed genes between responders and non-responders across
the two datasets. More genes were significantly differentially expressed (FDR
= 10%) between the responders and non-responders on-treatment compared
to pre-treatment in the NEO and I-SPY 1 datasets. In accordance with the
LFDA results, more significantly differentially expressed genes (1814) were
observed between on-treatment samples, with 6% (197), but only one was
common between NEO and I-SPY pre-treatment. Examination of the 468 most
significantly differentially expressed genes (p < 0.001) between responders and
non-responders in the NEO dataset at mid-chemo did not clearly distinguish
between response groups or time points, further demonstrating that identifying
biomarkers of response to chemotherapy is very difficult.
Evaluation of the alteration of the intrinsic subtype assigned to tumours
would alter upon treatment. Analysis of the NEO and I-SPY data sets together, it
was found that basal tumorswere relatively stablewith only 2/19 (11%) tumours
changing. More tumours were classified as LumA or normal-like on-treatment,
which likely reflects a reduction in the expression of proliferation genes during
chemotherapy (Fig. 2.4.2, C, on Page 38).
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*  P = 0.05 **  p = 0.01 *** p =  0.001 Normal LumA LumB HER2+ Basal
Figure 2.4.2: Initial Evidence of On-Treatment Expression Level Changes.
A) LFDA analysis revealed that supervised separation algorithms could sig-
nificantly identify response specific clusters. B) Differential expression on-
treatment was increased for over and under expressed genes compared to
pre-treatment. C) This Sankey diagram shows that there is evidence of pro-




2.4.3 AAGAB is a Promising Potential Novel On-Treatment
Biomarker of Response to Chemotherapy
The mid-chemo gene list from the NEO dataset (1102 genes, p value = 0.01, FDR
= 5%) was fed to a random forest model for further feature selection and classi-
fication and regression tree (CART) model, which reported AAGAB (Alpha And
Gamma Adaptin Binding protein) as the most predictive gene for response pre-
diction in the NEO training dataset with 100% accuracy (Balance F1-Score) for
pCR prediction on the mid-chemo samples (Fig. 2.4.3, A, on Page 41). Other
methods of classification would have likely been successful, including logistic
regression, but the importance of the RF model was in the ability to report eas-
ily interpretable importance scores with an intrinsic comparable scale for cut
point selection. Validation was conducted independently on publicly available
sequentially sampled chemotherapy data from the I-SPY 1 trial,140 and reported
76% accuracy using AAGAB at the same expression level on the scaled and cen-
tred expression data at the on-treatment time point prior to resection (T-On). For
comparison, the pre-treatment only sample gene listswere put through the same
protocol in order to consider whether highly predictive models could be gener-
ated before chemotherapy. IGF1Rwas themost predictive pre-treatmentmarker
with an accuracy of 74% and 63% in the NEO and I-SPY datasets, respectively
(Table 2.2). AAGAB was the sixth most accurate predictor (65%, 57%); receiver
operator curves show the relative specificity and sensitivity of this marker pre-
and on-treatment (Fig. 2.4.3, A, on Page 41). Gene expression levels of AAGAB
were lower in responders across all time points in the NEO cohort but weremost
significantly different at mid-chemo. In the I-SPY dataset, AAGAB was signifi-
cantly lower before treatment and at excision (Fig. 2.4.3, C, on Page 41). We
wondered whether AAGABwas lower in responders due to a reduction in prolif-
eration, but Pearson correlation analysis with common proliferation-associated
genes (TOP2A, BUB1, MKI67, MCM2, FOXM1, and PCNA) demonstrated no signif-
icant correlation to any of these genes (Fig. 2.4.3, D, on Page 41), suggesting that
AAGAB is independent of proliferation. Survival analysis demonstrated that re-
sponse status predicted by AAGAB level, at mid chemo in the NEO study and
at 2 weeks in the I-SPY 1, was significantly associated with the outcome (NEO
p = 0.048, I-SPY 1 p = 0.0036) (Fig. 2.4.3, D, on Page 41). Interestingly, the level of
AAGAB before treatment was not associated with the outcome in either cohort
(p = 0.71 and p = 0.2, Fig. 2.4.3, D). None of the other top ten pre- or on-treatment
markers were significantly associated with the outcome in both datasets (Table
2.2); only one gene (ARF5) was associated with the outcome in the NEO dataset
(p = 0.004). Taken together, the single gene on-treatment biomarker AAGAB ap-
pears to outperform novel pre-treatment markers and established prognostic
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tests in predicting pCR and long-term outcome to chemotherapy.
Response Accuracy Response AUC Outcome (Log-Rank)
NEO I-SPY NEO I-SPY NEO I-SPY
Pre-Treatment
AAGAB 64.70% 56.90% 0.65 0.58 0.71 0.2
IGF1R 73.50% 62.60% 0.76 0.69 0.36 0.11
CTNNB1 70.60% 49.30% 0.73 0.46 0.6 0.4
SLC20A2 70.60% 55.50% 0.72 0.57 0.063 0.56
HMGCL 67.60% 46.70% 0.67 0.45 0.1 0.97
ST6GALNAC5 67.60% 51.70% 0.69 0.53 0.6 0.28
C1orf51 61.80% NA 0.61 NA 0.12 NA
KRTCAP3 61.80% 54% 0.63 0.57 0.78 0.78
SETDB2 50% 49% 0.48 0.51 0.29 0.15
FADS2 29.40% 47.80% 0.27 0.5 0.14 0.73
On-Treatment
AAGAB 100% 78% 1 0.63 0.048 0.0036
ZNF165 87.50% 53.50% 0.91 0.57 0.26 0.7
KRTCAP3 79.20% 52.30% 0.85 0.56 0.81 0.49
RFC2 79.20% 40.10% 0.85 0.35 0.51 0.44
C20orf151 70.10% NA 0.75 NA 0.36 NA
ARF5 70.10% 43.20% 0.75 0.36 0.0038 0.2
BSPRY 70.10% 47.70% 0.75 0.49 0.47 0.19
NGRN 58.30% NA 0.66 Na 0.53 Na
CHST7 29.20% 45.50% 0.21 0.52 0.65 0.4
SLC18B1 25% Na 0.18 NA 0.55 NA
Table 2.2: Relative Performance of AAGAB Pre- and On-Treatment Com-
pared with Other Markers Derived from the Same Methodology. Com-
petitive gene markers for response using the same methods were gathered




















   
   
   









   







   
   
   
   
   
   
   






















Figure 2.4.3: AAGAB Expression, Response and Outcome Predictive Val-
ues. A) AAGAB perfectly separated response categories using the on-
treatment expression values as shown in the confusion matrix. Subplot A
shows the AUC curves of different separation values. B) The box plots show
that there was significant down regulation of the expression of AAGAB in
both cohorts in the responding patients on-treatment. C) This heatmap
shows that expression of AAGAB is not correlated with known proliferation
markers, suggesting its activity is independent of proliferation. D) Kaplan-
Meier diagrams show AAGAB also significantly separated (log rank values)
KM survival curves using the on-treatment expression values.
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2.4.4 Comparison of Pre- andOn-treatment Predictions of Response
and Outcome
Wewere also keen to assess whether estimations of established prognostic signa-
turesmight be different upon treatment and if on-treatmentmight bemore accu-
rate. Almost all responding patients were predicted to have poor outcomes with
the estimated Mammaprint,160 PAM50,62 or rorS161 signatures in pre-treatment
samples of theNEO cohort, whereas around half of the responding patientswere
predicted as good outcome using on-treatment data (Fig. 2.4.4, A, on Page 44).
Overall accuracy improved by 2–8% using on- rather than pre-treatment data;
however, improvement in the ability of these tests was not uniform between
response classes. In this diagram red indicated the sample was classified as non-
responsive, blue indicates that the sample was predicted a good outcome. Good
outcome predictions for responders to neoadjuvant chemotherapy sawan aggre-
gate increase in predictive capabilities from 11 to 44.4%, whilst poor outcome
predictions for non-responders saw a moderate decrease in accuracy, 75 to 63%.
These values are drawn from comparisons of the categorical classification and
response status of the patients. Survival insteadwas considered as the end point
of the study, but due to the limited number of patients and available follow up,
response was considered to be a more robust and appropriate metric. Where
possible, prognosis was compared to response and, in regards to the patient co-
hort presented, 82% of patients with good response also experienced RFS until
the most recent date of available follow up. This study will not speculate how
this data may extrapolate past this point but the trends suggest a positive cor-
relation. The log rank test significantly differentiated the survival curves of the
neoadjuvant responders compared to the non-responders (p-value 0.032) with
a median RFS of 1045 days for the responders and 842 for the non responders.
The responders only saw three patients lost to metastasis compared to ten in the
non-responders.
Where clinico-pathological variables (NPI, Grade, Her2 status)were available,
the hazard ratio of each feature was calculated in the pre-treatment setting at
diagnosis. The hazard ratios were then compared to the calculated risks gen-
erated through the different subtyping methods and in comparison to the per-
formance of AAGAB in the pre-treatment and on-treatment setting. None of the
gene expression signatures either pre- or on-treatment or established prognos-
tic markers from diagnostic samples (NPI, Grade, Her2 status) were significantly
associated with the outcome in contrast to the remarkable performance of on-
treatment measurement of AAGAB (Fig. 2.4.4, B, on Page 44) when comparing
the confidence intervals of the hazard ratios. The values for this diagram are
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tabulated in Table 2.3, Page 43 for all 59 paired samples from both datasets.
Pre-Treatment
HR 95% CI p
NPI 2.3 -0.26-5.38 0.72
Grade 1.1 -1.98-7.40 0.81
Her2 -28.3 -53.1-27.8 0.96
Node Status 1.49 -1.18-6.11 0.74
ER Status 0.57 -1.72-3.98 0.51
Pam50 1.52 -0.22-7.14 0.63
rorS 0.09 -2.20-2.42 0.30
MammaPrint 0.06 -1.38-1.51 0.23
AAGAB -0.1 -0.99-0.78 0.17
On-Treatment
Pam50 0.62 -1.12-2.71 0.26
rorS 0.57 -1.82-3.0 0.29
MammaPrint 0.53 -1.07-2.11 0.24
AAGAB -1.72 -3.02-(-0.43) 0.0021
Table 2.3: Tabulated Hazard Ratio Information This table contains the
Hazard Ratio, confidence intervals and p values for each feature, for both
the pre- and on-treatment tests.
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Figure 2.4.4: On-Treatment Predictive Value and Hazard Ratios. Sam-
ples are colored by predicted response, Red for non-responsive, Blue for
responsive. A) On-treatment samples were more predictive of prognos-
tic risk using existing classifiers (MammaPrint/rorS), suggesting that on-
treatment expression more fully captures patient risk. This study acknowl-
edges that Mammaprint was designed for diagnostic sample testing and
seeks to compare the efficacy in a new treatment space. B) On-treatment
AAGAB expression levels were the most important indicator of risk, even
when comparing clinical features such as receptor or nodal status.
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2.4.5 Pathway Enrichment as an Indicator of Divergent Expression
Parallel to differential gene expression between the responsive and non-
responsive patient samples, GSEA analysis using common cancer adjacent
hallmark pathways was performed. Figure 2.4.5, B, on Page 46 shows the results
of this analysis. In concordance with the results of the LFDA and differential
gene expression count, the amount of enrichment increased on-treatment.
There was divergence of the pathway enrichment between the two response
classes in excess of the pre-treatment samples. This strongly indicates further
support for the on-treatment expression profiles being significantly different to
the pre-treatment scores.
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Figure 2.4.5: Further Clustering and Pathway Analysis. A) On-treatment
differences have shown to be significant, but are still too subtle for fully
unsupervised analysis. B) Increased enrichment of cancer hallmark path-





Determiningmolecular differences between tumours to select themost effective
treatment is the defining feature of precision oncology. Accurately predicting
which patients will respond to treatment before exposure relies on a highly
specific target. In breast cancer, ER status is a good indicator of response to
endocrine treatment, but resistance, both primary and acquired, is common.
Chemotherapy is an unselective treatment, relying on cancer cells growing
faster than normal cells. The results presented here, along with others,137,138
suggest on-treatment biomarkers have improved value in predicting whether
tumours respond to treatment and are associated with the outcome. Changes in
gene expression in sequential patient-matched samples were fairly consistent
in response to chemotherapy across two independent datasets, regardless of
the response status. Identifying molecular markers between responding and
non-responding tumours was much more challenging. We previously demon-
strated that lobular and ductal breast cancers respond to endocrine treatment
in the same way, despite clear histological and molecular distinctions that are
apparent and maintained on-treatment,162 demonstrating that pre-treatment
variations do not necessarily lead to differences in response. The results of this
study are somewhat exploratory, rather than definitive, but further illustrate
the considerable potential value of on-treatment sampling.
There are no universally agreed-upon markers predictive of response to
chemotherapy, and the few that have been investigated in the neoadjuvant
setting typically centre around established markers including ER, P53 HER2,
and Ki-67;163 thus, the introduction of novel biomarkers can expand the cur-
rently available clinical options for physicians. A study published over a decade
ago stated that the differences in gene expression between responders and
non-responders to neoadjuvant chemotherapy must be rather subtle.142 The
results presented here confirm this statement; however, our results suggest that
on-treatment biomarkers may provide important information for predicting
response.
As cancer is inherently a proliferative disease, measuring the change in
markers of proliferation on-treatment is logical and genes like KI-67 have
been demonstrated previously to be potentially a new clinical tool for disease
prognosis and prediction.97,164 It is, therefore, all the more interesting that
the potentially novel biomarker identified in this study, AAGAB, is not tightly
correlated with known markers of proliferation. AAGAB has primarily been
studied for its role in punctate palmoplantar keratoderma165 and the role of
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adaptin in the clathrin-independent endocytosis of epidermal growth factors.
The level of AAGAB was found to be prognostic of response (p < 0.001) in renal
cancers (favourably) and in thyroid cancers (unfavourably) and expression is
elevated in breast cancer, relative to the normal breast (p < 0.001) according
to the Human Protein Atlas.166,167 However, the exact role of AAGAB in breast
cancer is currently unclear and potentially warrants further investigation.
Clearly, further validation of the role of AAGAB in breast cancer is warranted
and will be performed as new neoadjuvant chemotherapy datasets become
available. This study supports the use and identification of genes or markers
from on-treatment biopsies as a tool for improving patient response classi-
fication. We propose that the use of on-treatment samples offers valuable
insight into the dynamic changes correlated with response, and submit our
findings as support for continued neoadjuvant sampling, and novel biomarker
generation.
2.6 Conclusion
We have identified AAGAB as a novel on-treatment biomarker for accurate pre-
diction of pCR and outcome in patients treated with neoadjuvant chemother-
apy. A semi-supervised analysis and evaluation of estimations of established
molecular signatures also highlight the potential value of on-treatment biomark-
ers. Combining on-treatment biomarkers with known clinical prognostic fac-
tors could further improve the accuracy of response predictions and deserve
further study. On-treatment expression changes in the neoadjuvant setting may
offer greater possibilities for the identification and creation ofmore future novel
biomarkers.
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Prediction of prognosis and response to treatment for breast cancer is heav-
ily focused on primary tumour characteristics, even for patients with disease
that has already spread to the axillary lymph nodes. Despite the presence of
cancer cells in one or more lymph node being an establishedmarker for predict-
ing patient outcome, relatively little attention has been paid to the molecular
characteristics of tumour positive lymph nodes.
Methods
Three transcriptomic datasets of primary breast cancer and patient-matched
tumour content confirmed lymph nodes were generated and analysed totalling
214 samples from 98 patients to assess the relative variation between site of
biopsy, different patients and the effects of treatment.
Results
Unsupervised analysis failed to differentiate tissues types, indicating strong
similarity in overall expression profiles between primary tumours and patient-
matched lymph node metastases. Pairwise analysis revealed 168 differentially
expressed genes, with lymph node samples enriched for pathways associated
with MAPK signalling, WNT deregulation tumour progression and metastasis.
Lymph node samples also had significantly worse predicted outcomes with
higher estimated PAM50 (p=0.0001) and Mammaprint (p=0.004) risk-of-relapse
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scores. There was a 150% enrichment for basal and 172% enrichment for
luminal B intrinsic subtypes in nodes compared to matched primary samples.
These results are confirmed in newly available and contemporary cohorts,
with 65 matched patient primary and node pairs and 18 additional technical
replicate nodal pairs. On-treatment sampling showed that primary disease sam-
ples and matched nodal samples change in similar ways during neoadjuvant
treatment, with uniform drops in risk of relapse scores and were distinct from
the pretreatment samples after exposure to therapy.
Conclusion
This study is the largest transcriptomic analysis of patient-matched primary
breast cancers and lymph node metastasis samples to-date. Lymph node sam-
ples were found to have a higher estimated risk of relapse and are assigned to
worse prognosis intrinsic subtypes, but are still more tightly correlated within
patients than unmatched tissues. Overall, treatment appears to affect nodes in a
similar manner to primary tumours. These results illustrate the potential value
of considering the molecular characteristics of lymph node samples for captur-
ing risk beyond the primary alone.
Overview
A generalised diagram of this work, especially with regards to the generation
of the most vital outcomes is presented in Fig. 3.1.1, on Page 51. This high level
overview shows the flow of the paired samples from patient fold change values






























Matched Tissues Validation in 
Lawler 
Dataset
Figure 3.1.1: Overall Study Design and Workflow. This workflow dia-
gram illustrates a high level overview of the analysis of the primary and
node matched sample datasets. Starting on the left, there are the matched
patient samples across time and tissue resection type, then differential gene
expression analysis of the time point and tissue pairs, as well as subtype
and risk prediction scores for comparative analysis. These results were
then expanded and validated in a contemporary study, the Lawler trial.
3.2 Background
Lymph nodes are the most common site of breast cancer metastasis, and the
spread of disease from the sentinel to subsequent nodes is an established path-
way of disease progression.168 Understanding how lymph nodes are involved
in breast cancer is fundamental to predicting patient outcome, as node status is
still one of themost accurate predictors of overall survival.169 The extent of node
metastasis is also crucial to proper staging of the primary tumour by defining the
Tumour size,Number of involved nodes andMetastatic status (TNM), as the pres-
ence and number of affected nodes is part of the initial staging calculation.170
This information is often gained through lymph node resection of some or all
of the axillary lymph nodes, and by sentinel lymph node biopsy which seeks to
identify the earliest involved lymph node to spare unnecessary resection to un-
affected nodes, where possible.171 Nodal involvement is important for treatment
considerations and clinical decision making.172
A number of studies have documented the discordance between established
immunohistochemistry (IHC) markers inmatched primary and tumour-positive
lymph node samples. ER, PR, HER2 and KI-67 have all been shown to have signif-
icant discrepancies in the expression of these biomarkers in as many as 36-54%
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of patients.173–176 Switching molecular subtypes between matched primary and
brain metastasis has been observed for 45% of patients (9/20) in one study177
and 47% (8/17) in another.178 Discordance in classification has potentially dras-
tic implications for clinical decision making, as treatment selection is currently
made based on the known characteristics of only the primary tumour when it
is almost always the relapsed tumour that is fatal. A number of gene expres-
sion studies have been performed to predict metastasis in lymph node negative
patients179–181 or compare transcriptional signatures between lymph node posi-
tive and lymph node negative tumours.182,183
Three studies have profiled matched primary and lymph node metastasis
samples.184–186 However, these are relatively small with patient numbers in
the tens, and there is little consensus for how the differences between samples
relate to established prognostic signatures used for clinical decision making or
how they are affected by treatment. Recent and exhaustivemeta-analysis of this
space (366 studies, including 14 with genome-wide expression) have concluded
that there are different expression patterns in the metastatic setting compared
to primary tumour, but recognised this is still an avenue for further research,
and that additional work is needed to inform new clinical interventions.187
High resolution aCGH studies have concluded with similarly inconclusive
results, indicating through cluster analysis that lymph nodes clustered closest
to their matched primary, and that copy number aberrations were not notably
different.188 This suggests a high clonal relationship between primary tumour
and metastatic tumour.188 To better understand the prognostic value of these
samples, further work is needed to examine consistent molecular differences
between primary breast cancer and matched metastatic tissue. This study aims
to expand on the body of work describing the gene expression differences
between tumour biopsies by comparing the differences in relative expression
and calculated prognostic risk, and using clinical follow up to ascertain the
additional value to patients and clinicians.
3.3 Materials and Methods
3.3.1 Ethics Statement
Patients from the three cohorts gave informed consent to be included in the stud-
ies and were approved by the local regional ethics committees. For some sam-
ples, automatic consent was given at time of collection and other samples were
consented into the trials post-collection.
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3.3.2 Patients and Datasets
Dataset 1 (DS1) included 76 pretreatment samples, 24 primary samples and 52
nodal samples (of which, 22 patients had matched primary and nodes, and a
further 10 patients had matched nodal samples). These samples were collected
from patients of the Edinburgh Breast Unit. RNA extraction was performed via
Ribo0-RNAseq, and whole transcriptome sequencing was performed with Life
Sciences Ion AmpliSeq Transcriptome Human Gene Expression Kit as described
previously.189 This generated greater than 8 M reads per samplewith an average
of more than 90% valid reads for 14,781 targeted genes. The available annota-
tion for each dataset is contained in Table 3.1 on Page 54. These samples were
consented, collected and transported by Dr. Beatrix Elsberger, sample process-
ing was performed by Dr. Arran Turnbull and Dr. Carlos Martinez-Perez.
Dataset 2 (DS2) included a total of 87 samples (of which, 25 had matched pri-
mary and nodes, and an additional five had matched nodes). RNA extraction
was from the aqueous phase by column-based purification (RNeasy mini kit, Qi-
agen) and then labelled and hybridised (HumanHT-12 v4 Illumina BeadChip)
according to the manufacturer’s protocol (NuGEN) as previously described.190
These samples were collected in the Edinburgh Breast Unit, the samples were
processed by Dr. Laura McArthur.
Dataset 3 (DS3) represents a unique series of pre- and on-treatment matched
primary and lymph node metastasis samples from HER2-positive breast cancer
patients treated with trastuzumab plus chemotherapy at Ninewells Hospital in
Dundee. RNAwas extracted from 2x20µm FFPE tissue sections using the RNeasy
FFPE kit and then analysed by Lexogen QuantSeq using single read (1x75bp) se-
quencing with the NextSeq 500/550 High-Output v2 (75 cycle) Kit on the NextSeq
550 platform. Data was generated from a total of 53 samples, 15 matched pri-
mary and node pretreatment samples, 13matched primary samples across treat-
ment, 4 matched nodal samples across treatment and 5 matched resected pri-
mary tumour and nodal samples. This dataset was originally collected and pro-
cessed by Dr. Arran Turnbull and Dr. Cigdem Celli.
To differentiate between the different groups of patients according to the
types of samples collected and for clarity, the following sample nomenclature
will be used throughout this chapter: P1N1, relating to the patientswithmatched
pretreatment primary and nodal samples; N1N1, meaning matched pretreat-
ment nodal samples; P1P2, meaning to pre- and post-treatment primary tumor
samples; N1N2, meaning matched pre- and post-treatment nodal samples and
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P2N2, meaning matched post-treatment nodal samples.
Characteristic Dataset1 Dataset2 Dataset3
Platform Ampliseq Illumina HT12v4 Lexogen QuantSeq
Gene Count 14781 17296 11425
Patients 32 49 21
Tumour Samples 24 31 33
Lymph Samples 52 56 20
Matched P1N1 22 25 15
Matched N1N1 10 5 0
Matched P1P2 X X 13
Matched P2N2 X X 5
Matched N1N2 X X 4
Tumour Grade
1 2 1 0
2 13 18 1
3 17 12 20
Oestrogen Receptor Status
Positive 30 6 14
Negative 2 22 7
NA X 3 0
HER2 Status
Positive 1 17 21
Negative 1 2 0
NA 30 12 0
Number of Recurrences 16 10 7
Median Follow up (Years) 7.39 6.58 6.15
Table 3.1: Characteristics for Tumours and Patients in Datasets 1-3. Sum-
mary of all available data for Datasets 1-3, including clinical annotation
and recurrence status. X indicates a feature with no information for that
dataset. P1N1 relates to the patients with matched pretreatment primary
and nodal samples, N1N1 matched pretreatment nodal samples, P1P2
matched pre- and post-treatment primary tumour samples, N1N2matched
pre- and post-treatment nodal samples and P2N2 matched post treatment
nodal samples. HER2 status was assigned through tissue pathology stain-
ing.
3.3.3 Statistical Analysis
All statistical analysis was performed in R,191 using packages freely available
from Bioconductor192 and CRAN, including differential expression and pathway
enrichment analysis. Raw read counts were pre-processed using Limma144
and edgeR to provide cleaned, voom-normalised expression levels for analysis.
Limma and the inbuilt Bayesian methods of differential expression analysis
were used to identify significantly differentially expressed genes between the
tissue types, and between the treatment times where applicable.193 Resultant
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gene lists were used to identify enriched gene pathways with GO,194 and
Camera.195 Heatmaps andmultidimensional scaling plots were used to visualise
the findings. The GeneFu R package153 was used to generate estimated intrinsic
subtypes and PAM50 or Mammaprint risk of relapse scores (rorS). These tests
use normalised expression matrices as the input, and output a per sample
assignment. Kolmogorov-Smirnov tests were used for comparing distributions,
and T-tests and Wilcoxon tests were used for comparing group means, in order
to quantify the significance of the between class differences. All data been
submitted to NCBI GEO196 and is awaiting acceptance to be made publicly
available.
The primary method of reporting significance between two groups, or mea-
suring the significance of the difference present between two effect populations
in this study is through a combination of parametric and non-parametric tests.
Standard T-tests were performed when measuring the effect between groups of
unpaired samples. The five basic assumptions were always tested. First, the
values are on a continuous scale (expression values). Second, the samples are
(to the best of my knowledge) representative of the population as a whole, as the
only constraint on the sampling process was agreeing to be part of the study and
no filter wasmade for age or ethnicity. Third, graphically the data conforms to a
normal bell-shaped distribution after processing, but is slightly long-tailed prior
to normalisation. The fourth criteria is to have a reasonably large sample size is
satisfied. This is satisfied as the other assumptions hold and there are sufficient
samples to calculate the test statistic. Lastly, standard deviations on both sides
of the mean are approximately even, suggesting homogeneity of variance. Non-
parametrically, a Wilcoxon T-test was used when measuring the differences in
expression of paired samples. Assumptions here were even easier to satisfy, as
every sample is inherently paired and they all come from the same population,
and, we are looking at within pair differences.
3.4 Results
3.4.1 Inter-Patient Gene Expression Exceeds Matched Patient Tissue
Samples
The pairwise nature of the samples analysed in this study enabled assessment of
the relative differences in gene expression between tumours from different pa-
tients and pairs of matched primary and lymph node metastases from the same
patient, both before and on-treatment (Figure 3.4.1, A, Page 59). Comparing the
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gene expression profiles of matched primary and lymph node metastasis sam-
ples revealed the expectedfinding that intra-patient variation is lower than inter-
patient, regardless of the tissue of origin.197 Matched primary and nodal sam-
ples taken before treatment were more highly correlated than unmatched pri-
mary or nodal samples (Figure 3.4.1, B, Page 59). This indicated that the patient,
not tissue was more important for determining the overall expression profile of
the sample. Additionally, this was corroborated by the data, showing that there
was no significant difference between the matched primary/node and matched
node/node samples. This pattern of correlation has been previously observed in
untreated data, suggesting that in all cases intra-patient similarities aremore sig-
nificant than between.198 Unsupervised analysis of the patient cohorts through
principal component analysis or hierarchical clustering (Figure 3.4.2, Page 60)
showed nomajor grouping of patients by tissue type. These clusters were gener-
ated using complete linkages and Euclidean distances. Identifying differentially
expressed genes consistent between patient-matched pairs of primary and node
metastasis samples was hampered by having three relatively small datasets to
consider.
It should be noted that the numerical comparisons between datasets were
drawn from scaled expression level differences, but the categorical summary
differences were generated by functions of the expression level data. Improv-
ing the number of samples is important for statistical power, but the addition
of new and potentially confounding heterogeneous data must be balanced with
the additional significance available to the results. No direct integration of the
expression level values was attempted for these cohorts, as this adds an unnec-
essary amount of uncertainty and removes underlying biological variance, as
will be demonstrated in the next chapter of this thesis.
Limma was used to rank genes in order of differential expression, then lin-
ear models were fitted and an empirical Bayes method used to shrink the probe-
wise sample variances and identify significantly differentially expressed genes
between groups. This was performed by representing the pairwise differences
between gene expression tissues as lists of contrasts to allow identification of the
genes with the largest changes between categories. Following this initial step,
a naive Bayes model calculates the probability of the genes belonging to either
group and a decision treemodel identifies the geneswhich pass a predetermined
significance threshold (FDR > 0.05). This analysis of the relative gene expression
values indicated that there were 168 genes differentially expressed between the
nodes and primaries (adjusted p<0.05). Gene ontology and pathway enrichment
(FDR=0.05) revealed 54 significantly differentiated pathways including cell cycle,
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MAPK (Mitogen-activated Protein Kinase), WNT (Wingless-type MMTV integra-
tion family of genes) and IL-17 (Interleukin 17).
Despite the differential expression across the three study datasets, the expres-
sion of these genes does not appear to be consistent between the different trials.
This suggests that the cut off for gene selection was too lax and that these genes
were overlapping more due to their presence in each dataset, and the large bio-
logical role they play, rather than uniformity in differential pathway analysis as
a result of common treatment response. These findings are reexamined later in
a validation dataset.
Differentially, node metastasis samples have higher expression of a number
of significant cancer-related genes including HER family members (EGFR
(Epidermal Growth Factor Receptor), ERBB2 (Erb-B2 Receptor Tyrosine Kinase
2) and ERBB3 (Erb-B2 Receptor Tyrosine Kinase 3)) and MAPK members
(MAPK1 (Mitogen-Activated Protein Kinase 1), MAP2K1 (Dual Specificity
Mitogen-Activated Protein Kinase 1) and MAP2K2 (Dual Specificity Mitogen-
Activated Protein Kinase 2)) and known proliferation markers like MYC (MYC
Proto-Oncogene), IGF2 (Insulin Like Growth Factor 2) and PCNA (Proliferating
Cell Nuclear Antigen). There was consistently lower expression of angiogenesis
genes VEGFA (Vascular Endothelial Growth Factor A) and VEGFB (Vascular
Endothelial Growth Factor B) in the nodes compared to primary samples as well
as higher levels of TNF (Tumour Necrosis Factor) in nodes. Additionally, other
inflammation-related genes, including IL6 (Interleukin 6), IL17B (Interleukin
17B), CXCL1 (Chemokine Ligand 1) and CCL17 (Chemokine Ligand 17), had gen-
erally lower levels of expression in the node compared to the primary. There
are some studies examining the resultant gene lists of pairwise differential
expression,186 which concluded that metastatic lymph node tumours are trans-
lationally very similar to the parent tumour. Suzuki et al. note that small groups
of genes are significantly expressed in the lymph node over the primary breast,
and the differences aremechanistically important tometastasis; however, there
was no overlap in the gene lists prepared in this study compared to that body
of work. The findings presented here more closely align with Hao et al. who
found differential invasion and proliferation markers in tumour positive lymph
(IGFBP-5 (Insulin like Growth Factor Binding Protein 5), CD1 (Cluster of Differ-
entiation 1) and MMP2 (Matrix Metallopeptidase 2)) through microarray data
and tissue array validation.199 Additionally Ellsworth et al. report a metastatic
signature for lymph node metastasis that contains WNT2 (Wingless-type MMTV
integration member 2) differential expression.200 The aforementiond groups
and the results presented in this chapter contradict other existing bodies of
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P1N1      N1N1      uP1-N1      uN1        uP1
Figure 3.4.1: Study Design Diagram, Patient Correlation and Differen-
tial Expression. A) The samples in this study expand on the normal neoad-
juvant design with parallel matched primary tissue and matched tumour
positive lymph samples pre- and on-treatment. P1 indicates pretreatment
primary tumour sample, N1 pretreatment nodal resection. P2 represents
post treatment primary tumour sample, N2 post treatment nodal sample.
B) The paired samples of node-node and primary-node samples pairs were
significantly more correlated than samples from different patients (unpaired
represented by the u prefix). c) Matched primary and node samples with
their corresponding Pam50 assignments to visualise the concordance of
molecular subtypes.
59




Figure 3.4.2: Unsupervised Principal Component Analysis and Heatmap
Visualisation of Datasets 1-3. There is very little separation by either PCA
or hierarchical clustering on unfiltered gene lists by tissue type in these
three data sets A) Dataset 1, B) Dataset 2, C) Dataset 3. Suggests that the
differences between tissues are subtle. Complete linkages and Euclidean
distances were used to generate these clusters. Cluster robustness was
not measured as this was a cursory investigation to identify the presence
or absence of clear separation. Perceived groupings were checked for
homogeneity of clinical features and were absent.
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3.4.2 Discordance in Molecular Subtype and Prognostic Signa-
tures
Assessment of PAM50 intrinsic subtyping58 indicated that matched pretreat-
ment primary and node metastasis samples (P1N1) share the same intrinsic
subtype in a little over half (29/56) of patients (Figure 3.4.1, C, Page 59). However,
multiple patient-matched samples of lymph node metastases prior to treatment
(N1N1) were concordant in 80% (21/26) of samples, suggesting there is greater
consistency in gene expression between positive lymph nodes than between
matched primary and lymph node metastasis samples. Analysis of estimations
of the PAM50 and MammaPrint risk of relapse scores illustrated a systematic
shift between matched primary tumour and lymph node metastasis samples.
The PAM50 (rorS), and MammaPrint scores were consistently higher in the
node than the matched primary for 79% and 64% of patients in those tests
respectively. A two-sided Kilmongorov-Smirnov test confirmed a significant
difference in risk predictions between primary and nodal samples (rorS p-value
= 0.0001, MammaPrint p-value = 0.004). Perhaps not surprisingly, the increases
in rorS were greatest in those tumours which had relatively low scores in the
primary. The rorS in the lymph node metastasis was not much higher for
those patients who already had a high score in the primary tumour. Ninety
five percent confidence intervals on the Loess regression support this finding
(Figure 3.4.3, A, Page 62). A cumulative distribution function comparing the
two distributions establish proof of a bimodal distribution (Figure 3.4.3, B, Page
62). Follow-up data for the samples is up-to-date, and there are 12 patients with
a known clinical recurrence. However, for patients known to have suffered a
subsequent distant metastasis, the estimated rorS scores were higher in 83%
(10/12) of patients considering the lymph node score rather than the primary.
Substantially increased rorS scores classified six additional patients as at high
risk of recurrence based on lymph node samples but only intermediate risk
based on the primary samples. Currently, there are no other studies examining
the efficacy of existing diagnostic-sample-based, molecularly-derived risk
profile assessment methods, like PAM50/rorS, on non-diagnostic samples (with
the exception of as of yet unpublished work conducted in-institute). However,
as was seen in Chapter 2 of this thesis, the techniques employed in this study
appear to have improved sensitivity in the on-treatment environment, which
was the impetus to test this method on locally advanced lymph tumour tissue.
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PAM50 rorS                                      Mammaprint
p=0.0002 p=0.009
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Figure 3.4.3: Statistical Comparisons of Primary BC and Matched Lymph.
A) Pairwise dot plot with Loess regression line showing the relative increase
in the estimated prognostic risk of the lymph sample relative to the primary
tissue. B) Results of the Kilmongorov-Smirnov tests to establish significance
of the distance between the distributions represented by the estimated risk
of the tissue pairs. C) Change from high to lower risk in primary tumour
samples relative to the matched lymph tissue is shown here to illustrate risk




3.4.3 Validation of Pretreatment Expression Differences in Non-Local
Cohort
Examination of the concurrency of the results presented in Section 3.4.2 in ex-
ogenous data was performed using data from a publicly available 2017 study of
primary breast tumor with metastatic tissue.205 To do this, the same tests used
in Section 3.4.1/2 were used to compare the fraction of samples in the 2017 study
with matched metastatic lymph node tissue. Sixteen matched pairs were also
found in another dataset, GSE44408.206 As can be seen from the bottom of Fig-
ure 3.4.4, Page 64 and Panel C of Figure 3.4.1, Page 59, there is a strong similar-
ity in the representation of PAM50 subtypes in the local data and in validation,
with the exception of the increased primary “Normal” samples in our own data.
The forks represent the matched multiple node biopsy samples, which in the
Lawler study, the 2017 study, represent technical replicate samples, hence the
tight similarity between the samples. In both datasets, it is evident that when
there is a change in subtype, the subsequent prognostic profile associated with
the change is worse in the lymph than in the primary. It should be noted that
there is a discrepancy in the overall agreement of the nodal and primary sam-
ples with 53.63% (37/69 samples) presenting differently, compared with 19.3%
(17/88) differential samples in the Lawler data.
The gene lists that were extracted previously in this study were examined as
pairwise differences in this cohort as well. Excluding MAP2K2 (Dual Specificity
Mitogen-Activated Protein Kinase 1) and SERPINF1 (Serpin Family F Member
1) all of the genes were present and express a similar trend in relative expres-
sion, suggesting that the differential profiles of lymphmay be consistently differ-
ent. EGFR (Epidermal Growth Factor Receptor) and MAPK3 (Mitogen-Activated
Protein Kinase 3) were consistently the most strongly differentially expressed,
while some growth and proliferation markers also showed strong congruency
between the studies, primarily MYC (MYC Proto-Oncogene), PCNA (Proliferating
Cell Nuclear Antigen), IGF2 (Insulin like Growth Factor 2), WNT2 (Wingless-type
MMTV integration member 2), CDK6 (Cell Division Protein Kinase 6) and IL6 (In-
terleukin 6). However, the statistical evidence is not supported by the visuali-
sation of the underlying data as in Figure 3.4.4, Page 64. The fact that the ex-
pression levels are not more visually conforming between the studies suggests
that the cut off for gene selection was too lax and that these genes were over-
lapping more due to their presence in each dataset, and the large biological role
they play, rather than uniformity in differential pathway analysis as a result of
common treatment response.
63







































Figure 3.4.4: Pairwise Differences of Local Cohort Genes of Interest. The
genes that were extracted from the iterative differential expression and path-
way analysis were examined here as in the original data. Similar patterns of
expression can be seen, particularly in MYC, PCNA, IGF2, WNT2, CDK6
and IL6. As in previous analysis, blue represents those genes which see
lower expression in the node; red indicates higher expression in the above
heatmap. The bar chart along the bottom represents the molecular sub-
type according to PAM50 assignment of the primary (top row) and the node
(bottom row) for each sample pair, and the hair loops shows paired node




Lastly, the actual prognostic differences between the matched samples
within the Lawler study show a strong parallel to our own results, see Figure
3.4.5, Page 65. The continuous rorS and MammaPrint scores indicate a sys-
tematic shift of the associated risk of the lymph when compared to the node
(rorS p<0.005, MammaPrint p=0.092 (Pairwise T-Test)), and is especially true of
the lower risk samples. This is in strong agreement with the results from our
locally derived data, especially for the lower risk primary samples which show
a greater percentage gain in predicted risk. MammaPrint reported statistically
insignificant differences with p>0.05. It should also be noted the technical
replicates are visibly overlapping in Figure 3.4.5 and the predicted risks are
very closely matched.
Figure 3.4.5: Pairwise Differential Risk Prediction of Primary vs. Nodal
Tissue. The results of the pairwise comparison, in the Lawler dataset, be-
tween the predicted risk in the node and the associated primary tissue
follows much the same pattern as in our local dataset, with significant dif-
ferences correlating to the tissue of origin. Purple represents the samples
with a higher rorS or MammaPrint score in the node; the orange samples
conversely represent the samples with a higher risk presentation in the pri-
mary tumour.
3.4.4 On-treatment Gene Expression Differences Between Primary
Tumours and Paired Lymph Node Metastases are Primarily
Maintained
Unsupervised principal component analysis of Dataset 3 clearly delineated sam-
ples by time, suggesting that gene expression is more affected by treatment than
the site fromwhich the tissue originated (Figure 3.4.6, A, Page 67). Cluster analy-
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sis of thefivehundredmost variable genes supports this finding, with the highest
branching of the dendrogram enriched for on-treatment samples, with a signif-
icantly different pattern of expression to the other samples. Additionally, there
were no notable groups of patient or tissue clusters visible on a heatmap of total
linkage and euclidean distance (Figure 3.4.6, B, Page 67). In addition, the correla-
tion of samples ismarkedly changed on-treatment. Thematchedpatient samples
of pre-treatment to on-treatment primaries and nodes showed lowered average
correlation compared to the pretreatment pairings suggesting a strong profile ex-
pression change with treatment (Figure 3.4.6, C, Page 67). Clustering of the pair-
wise change values frompretreatment to on-treatment for the primary pairs and
nodal pairs revealed that only seven of the differentially enriched genes were
retained on-treatment and there was no clustering of patient by tissue (Figure
3.4.6, D, Page 67).
Assigning molecular subtypes to the samples from the small number of pa-
tients with primary tumour and lymph node metastasis before and after treat-
ment revealed that subtype was largely concordant (75%, 6/8) between primary
and lymph node at the same time point (consistent with the clustering and differ-
ential expression analysis), but was often discordant following treatment (63%,
5/8, Figure 3.4.6, E, Page 67). As can also be seen from Figure 3.4.6 all four sam-
ples from one patient were classified as HER2-enriched, whilst the other three
patients switched from HER2-enriched or luminal B to luminal A or normal-
like during treatment. Two of the patients would have been classified as HER2-
enriched based upon the lymph node sample, but normal-like and luminal B
basedupon the primary tumour prior to treatment. The estimated risk of relapse
scores were significantly (Wilcoxon p-value, 0.0189) lower post-treatment than
pretreatment. Three of the four patients withmatched primary and lymph node
samples before treatment had reductions post-treatment in the scores of both tis-
sues (Figure 3.4.6, F, Page 67). This result is not surprising, as down-regulation of
genes involved with proliferation is expected during treatment and is a promi-
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Figure 3.4.6: Expression Profile Progression with Treatment in Matched
Primary/Lymph Samples. A) PCA diagram illustrating clear separation
of the pre- from on-treatment samples. B) Heatmap with total linkage
and euclidean distance of the 500 most variably expressed genes on- to
pretreatment with clear isolation on the basis of biopsy time. C) Correla-
tion box plot of matched patient samples drops on-treatment, suggesting
diverging expression profiles with therapy. P1 indicates pretreatment pri-
mary, P2 post treatment, N1 pretreatment node, N2 post treatment. D)
The heatmap as in A shows that there are far fewer differentially expressed
genes between nodes/primary tissue pairs on-treatment. E) This tile plot
shows that subtype concordance is more similar across tissue than treat-
ment time in matched samples. F) This line plot shows the reduction in
estimated prognostic risk is uniform between the tissue types on treatment.
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3.5 Discussion
The presence of cancer in lymph nodes has long been established as an adverse
prognostic indicator, and previous studies have observed discordance in indi-
vidual receptor levels between primary breast tumours and lymph node metas-
tasis. However, to date, this is the largest study to take an unbiased data-driven
gene expression comparison between primary breast tumours and lymph node
metastasis. The results presented here demonstrate that gene expression pro-
files of patient-matched primary breast cancers and lymph nodemetastasis sam-
ples are much more similar than tumours and lymph node samples from un-
related individuals. Previous studies have made similar statements on the ex-
pression profiles ofmatched patient samples,202–204 but did not examine changes
on-treatment. However, there are consistent gene expression differences be-
tween primary tumours and lymph node metastases. The difference in general
expression level profiles between the tissue types is a logical result given that
lymph tumour tissue should display increased pro-metastatic and infiltrative
characteristics, an effect observed in other studies186 with varying degrees of
overlap to this work.199,200 This change in expression profile, and the tumour’s
ability to adapt to and leave the local site of the primary tumour, go hand-in-
hand.
These results demonstrate that transcriptomic analysis of pairwise primary
tumours and lymph node metastasis samples can contain important new infor-
mation about disease progression. This leads to a potential improvement in the
ability to accurately capture the prognostic risk presented by primary breast
cancer and associated lymph metastases on a per patient level through new or
existingmethods like PAM50.207 Changes in the calculated risk ormolecular sub-
type may have implications for treatment response. Additionally, this risk can
equally be captured by any tumour positive lymph tissue sample, as the differ-
ences between matched primary and node were larger than between matched
nodes of the same patient. This indicated that, while the lymph may present at
a higher risk than the primary, the expression profile and the risk of associated
nodes is more uniform.
The response to therapy was largely consistent in the two tissue types.
On-treatment, gene expression differences due to treatment were much more
prominent than differences between tissue types, which were maintained. It
is encouraging that lymph node metastasis samples respond to treatment in
a similar way to the matched primary. There are parallels with our previous
study, which demonstrated highly similar transcriptional response to endocrine
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treatment in ductal and lobular carcinomas despite clear histological andmolec-
ular differences between the subtype pre- and post-treatment.162 While there is
an apparent scarcity of these samples, we hope that the results demonstrate the
value of further work into these matched tissue samples, as this could facilitate
a more in-depth and powered study into the differences between tissue types of
patients who do and do not respond to treatment.
The same relative increase of differential risk associatedwith the lymphnode
samples were seen in the non-local data validating the observations made on
our own local cohorts. The lymph tissue biopsies show strong similarity for risk
stratification in terms of comparative subtype-associated risk, differential gene
expression and the significant difference in the continuous prognostic risk com-
pared to the primary breast tissue. This cohort almost doubles the number of
available samples, and is strong supporting evidence, barring the missing fol-
low up data for the study, that the patterns of change which were observed are
statistically significant and not a random occurrence.
3.6 Conclusions
Through the combination of correlation and differential expression analysis,
along with classification and prognostic signature evaluation, it has been deter-
mined that matched lymph nodemetastasis samples havemore aggressive gene
expression profiles and higher predicted risk of relapse than patient-matched
primary breast cancers. This increased predicted risk can potentially be trans-
lated to an improved ability to predict recurrences in patients over the primary
tumour biopsy results. Tumour expression profiles were markedly different
post-treatment, and changes due to therapy weremuch greater than differences
between tissue site. This study suggests that, where applicable, matched node
biopsies may be of additional value to clinicians and patients as an additional
tool for risk stratification and treatment decisions.
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Neoadjuvant therapy represents a unique opportunity to monitor tumour
expression level changes and response to treatment in a similar time frame
to tumour evolution. Changes in the transcriptomic landscape of cancer on-
treatment have already been shown to correlate with response and outcome in
labelled patient data frommodestly sized studies. Can more significant findings
be reached by combining several contemporary datasets, and will this allow us
to further the goal of personalised medicine?
Methods
Five transcriptomic datasets of primary breast cancer were collected and
combined using ComBat to create a unified expression dataset with matched an-
notation data. Results of each ComBat integration method were compared with
unintegrated and separately analysed data to establish discordance, and were
also compared to parallel methods to evaluate performance.
Results
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Integration of patient-matched sequential sample datasets proved remark-
ably complex. Attempts with existing techniques exposed new challenges to
large scale integration. Biological and systematic covariates were evaluated to
improve batch correctionmethodologies; however, integration of these datasets
failed to return concordant values for expression, intrinsic subtype or calculated
risk scores (agreement scores for calculated subtype ranged from 19-30%). Addi-
tionally, matched patient correlations were low (median 0.62), and differential
expression between the altered and unaltered data was non-overlapping (mean
30.2% shared pathways), suggesting systematic changes to the expression pro-
files post-integration.
Conclusion
This study evaluated methodologies for the integration of multiple sequen-
tially sampled datasets to create the largest uniformly annotated transcriptional
dataset of sequentially sampled neo-adjuvant primary breast cancer. However,
unifying transcriptional data across multiple studies proved an insurmountable
task to accomplish, while still maintaining the underlying biological variation.
Alternatively, considering only the pairwise differences within each dataset
allowed for cross-study comparisons and improved analysis. This resulted in
an expression list object of similarly normalised data, with unified annotation
data for analysis and is presented to provide opportunities for on-treatment
biomarker identification and validation. This solution provides improved statis-
tical power for the identification of pan-treatment trends in breast cancer and
a pragmatic and workable solution for comparing and combining datasets.
Overview
A generalised diagram of this work, especially with regards to the generation
of the most vital outcomes is presented in Fig. 4.1.1, on Page 73. This highlights
the flow of data from the individual datasets, throughmultiple different integra-
tionmethodologies whilemeasuring the changes to the original data, and finally
through different subtype and risk assessment test agreement levels.
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Figure 4.1.1: Overall Study Design and Workflow. This diagram shows
the paths the data has been put through to compare the efficacy of each
integration method. The individual datasets are combined using different
integration methods, then the resultant integrated datasets are subtyped
and scored for prognostic risk. The starting datasets are retrieved from the
composite dataframes and compared to the starting data to evaluate the
performance of each integration method.
4.2 Background
There is an abundance of pretreatment only breast cancer gene expression
data sets like with 50-300 patients like the NKI,159 with a few larger exceptions
like METABRIC208 (n=2,506) the breast cancer specific section of the TCGA209
(n=987). Recently, tools and packages have been made available for accessing
this type of data from curated repositories (MetaGXData, specifically Breast,73
and curateTCGA210). Additionally, there are tools leveraging the vast amounts of
well annotated data on NCBI GEO to allow for the bespoke creation and testing
of meta-datasets like ImaGEO,211 which facilitate the acquisition and probing of
specific, relevant GEO accessions for analysis. While it is broadly understood
that more samples and a more representative cohort improves the significance
of results, these are examples of meta-analysis, but do not demonstrate true
data integration. These meta-datasets increase sample size and representa-
tiveness of the data, but, fundamentally, only test a hypothesis or assertion
in several datasets independently, pool the results and report the aggregate.
Integration of -omic data would assist in a new and improved understanding of
the underlying biological processes and mechanisms of disease, like cancer,212
but is a non-trivial undertaking. This has also never truly been undertaken for
sequential or neoadjuvant studies, even though large datasets of well annotated
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pretreatment only data have resulted in several novel approaches for breast
cancer subtyping and risk assesment (70 gene signature, IC10, respectively),
including FDA approval and expansive clinical trials.213 This 70 gene signature
is more commonly known as MammaPrint, and is a prognostic test designed
for use in diagnostic samples to help make treatment decisions for BC patients.
IC10 is a molecular subtyping algorithmwhich classifies breast cancer based on
the activation or suppression of upstream cancer drivers and denotes classes
with distinct prognostic risks. As of yet there are no large scale datasets for
matched patient samples or window studies.
Neoadjuvant therapy for primary breast cancer is showing significant
results for patient care and outcome, including higher rates of breast conserv-
ing surgery without an increase in long term distant recurrence.214 We have
already shown that there are distinct transcriptional differences on treatment
that can be used to differentiate responsive and non-responsive primary
breast cancer in neoadjuvant chemotherapy215 in two modestly-sized cohorts.
Additionally, this work strongly suggests these samples being of increased
value to existing prognostic tests, however, this required a larger sample size
to validate. Additionally, Turnbull et al. previously showed that, in a similar
fashion, samples from neoadjuvantly treated endocrine therapy patients could
be used to create novel biomarkers for the prediction of response to aromatase
inhibitors.216 These findings suggest that the fold changes seen on-treatment
in the neoadjuvant setting for sequentially sampled breast cancer may be of
inherent value for the treatment and management of breast cancer. Turnbull
et al. also performed the first and only successful integration of multiple
on-treatment datasets.217 That 2012 study examined the integration of two
different platforms with very similar cohorts and had the significant advantage
of replicate patient samples across the platforms to validate that integration did
not distort the expression values.217
Neoadjuvant trials are, however, comparatively scarce, and there are addi-
tional factors to consider for these samples, including the increased cost formul-
tiple biopsies and the associated increased patient stress. There is potential for
justifying these risks with significantly improved insights into risk stratification
and prognosis, but integration is required for a sufficiently large cohort. Inte-
grative analysis makes the basic assumption that effect size is constant between
neoadjuvant matched patient trials and standard diagnostic examinations. It
may be the case that neoadjuvant longitudinal studies have greater signal-to-
noise ratio, this effect is a presupposition of this study. Here, we propose the trial
of integration techniques for patient-matched sequential samples of primary
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breast cancer to ascertain the viability of cross-study combination. These meth-
ods will attempt to retain the composition and biological variation of the pre-
and post-treatment samples, while also leaving thematched pre- to on-treatment
gene expression level changes intact. Figure 4.2.1, Page 75, shows the concept of
an “independent” analysis of multiple datasets and the integrative approach.
DS1 DS4DS2 DS5DS3 DS1 DS4DS2 DS5DS3
Independent Analysis Integrative Analysis
Comparison of Independent and Integrative Analysis 
Figure 4.2.1: Schematic Diagram Illustrating Independent vs. Integra-
tive Analysis. Independent, or meta-analysis, seeks to test one dataset
and make inferences with data from another, or, in this case, by testing
multiple datasets simultaneously and comparing the results. Integrative
analysis attempts to first unify the data, before probing it. This method of
aggregation can lead to differences in the presentation of the data. This
diagram is intended to illustrate the different approaches to integration of
data, either through the meta-analysis of individual examinations (left) or
by the aggregate interrogation of combined studies (right).
Figure 4.2.2, on Page 76 shows the mean-centred gene expression distribu-
tions for every dataset (A); the sub distributions of treatment-by-time point as
box plots (B); and the kernel densities (C) of the five datasets to be explored in
this chapter. This diagram should help to show that, even in a relatively small
number of datasets, there can be large differences in the expression levels of
genes between datasets. It should be noted that even within a single data set
there can be clear subdistributions of the data, which may stem from technical
or clinical factors. This diagram highlights the complexity and depth of the anal-
ysis required to integrate these different datasets efficiently. To disturb the un-
derlying distribution would alter relative gene expression values, which in turn
would make subsequent analysis invalid, as changes in gene expression would
no longer be linked to biological differences but to integration methodologies
instead.
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Figure 4.2.2: Pre-Integration Expression Distributions and Subdistribu-
tions. A) There are clear differences in the overall expression profiles of
the five different cohorts. B) When accounting for the study of origin as
well as the time points, significant splits in the expression profiles appear
at each on-treatment interval. This suggests that treatment is having a pro-
found effect on the overall expression of the samples, and that each time
point represents a new unique distribution. C) This effect can be observed
in the kernel densities and highlights the non-uniformity of the data and
the number of distinct distributions that must be shifted by ComBat.
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4.2.1 Integration Methods for Transcriptomic Data
Methods for the integration of continuous microarray expression data include
Surrogate Variable Analysis,218 Bayesian Factor Regression Models,219 Factor
Analysis220 and Array Generation-based gene Centering.221 These methods all
seek to shift the distributions of expression towards one another to achieve
integration. ComBat222 has been established as themost widely usedmethod for
batch correction and integration of microarray data,223–225 and will be utilised
in this study as the primary tool for integration. Recently, Cross Platform
Normalisation (XPN) has been shown to be a reliable method of microarray
integration for the purposes of machine learning on microarray and RNAseq
data,226 but this is a new result and XPN is designed for only two “batches”
at a time. ComBat uses an empirical Bayesian method with a combination of
additive and multiplicative terms to calculate and remove the batch effect from
the gene expression data. Due to the over-representation of ComBat in the
literature of microarray and transcriptomic data integration, it is the logical
starting place for attempting to correct the effects of batch introduced by the
high number of technical and biological confounding factors in this data. This
technology does, however, rely on the assumption that the expression data is
in some way effected by these factors,222 this constraint will be examined for
its effect on the resultant integration. We will discuss the steps required to
integrate the disparate datasets and the decisions made to analyse the effects of
the most important covariates, including dataset, biopsy time, treatment type
and calculated intrinsic subtype.
4.3 Materials and Methods
This study is comprised of five datasets of either neoadjuvantly chemotherapy
treated patients with matched pretreatment, on-treatment and surgical biopsy
samples, or aromatase inhibitor treated patients with similarly matching
samples. The datasets are all publicly available; details of the total study size,
treatment architecture, biopsy schedule and platform are contained in Table
4.1 Page 79, as well as accession numbers for reference studies. These studies
include: Miller et al., 2012 (data accessible at NCBI GEO database, accession
GSE20181), Arthur et al., 2014 (data accessible at NCBI GEO database, acces-
sion GSE55374), Turnbull et al., 2015 (data accessible at NCBI GEO database,
accession GSE59515), Magbanua et al., 2015 (data accessible at NCBI GEO
database, accession GSE32603), Bownes et al., 2019 (data accessible at NCBI
GEO database, accession GSE122630) and Ellis et al., 2017 (data accessible
at NCBI GEO database, accession GSE87411). There is an imbalance of the
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study composition between the five cohorts, which is reflected in the number
of matched paired samples and the number of possible matches, Table 4.1,
Page 79. Cross study comparisons of time points are only made where direct
comparisons exist in both cohorts. Additionally, the numbers of matched pairs
for each study are tabulated in Table 4.1, Page 79. This repository includes
the full annotation for the combined cohorts (representing 28 features in its
entirety), including sample and patient ID, ER, PR and HER2 status, clinical
response, nodal status, tumour grade, T,N,M classifications, RFS, treatment
type and schedule, processing platform and dataset of origin, a new study ID
variable, molecular classifications (such as scmod1/2, PAM50, ssp2003/6, IC10),
rorS risk and score andMammaPrint risk and score. These features describe the
patient in their clinical and prognostic presentation, as well as many derived
features, like the molecular subtyping values that allow for granular analysis
of the data. These studies were chosen because they are amongst the largest
and most well annotated publicly available patient-matched sequential biopsy
studies. Special notice should be paid to Dataset E2, which contains duplicated
samples from Dataset E1. However, they have been separately processed, and
on different platforms (Affymetrix), which means the overall patient number
is reduced. These samples will still be analysed to identify the changes that
occur as part of integration. This knowledge was not known at the start of the
analysis, however, after considerable discussion on the overall impact of these
samples on the analysis of this data, the decision was made to continue with
the work uninterrupted. Furthermore, figures 4.2.2, Page 76 and 4.4.2, Page 93
support this decision by showing that the overlapping samples do not appear to
group together or have similar expression profiles. This is primarily due to the
fact that the changes that are most important to this analysis are all calculated
on a per sample basis and, as these samples appear superficially different, the
changes can be considered individually.
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4 Comparison of Integration Methods
4.3.1 Data Selection and Acquisition
Collection of the data was primarily performed with GEOquery227 from inside R.
GEOquery collected the expression data, annotation, and GPL (GEO Platform) in-
formation for all datasets except Dataset E1 which was not hosted on NCBI GEO.
E1 is hosted locally and is comprised of three datasets, two partially overlap-
ping studies of Illumina and Affymetrix data, a description of this dataset is de-
tailed in Turnbull et al.228 Preprocessing and normalisation of the data was han-
dled in R,145 with the standard library and Bioconductor229 packages Limma230
and edgeR.231,232 Subtyping and risk assessment were performed by the geneFu
package.233 Unsupervised cluster analysis was performed with base R prcomp,
and all visualisations were handled by ggplot2.234 Data manipulation and clean-
ing was performed primarily within tidyverse,235 data packaging and function
wrapping was done using base R145 and Biobase,229 as well as XDE236 for custom
S4 data types, and oxygen2237 for documentation.
4.3.2 Preprocessing, Normalisation, and Analysis of Expression
Data
Each dataset was initially cleaned of low coverage and missing probes and pre-
processed individually. Read counts for each probe were converted to counts
per million and filtered for genes with expression in at least half of the samples.
This was done to avoid inclusion of geneswith no recorded expression level data
(NAs), and was performed entirely in R by Limma230 and edgeR.231,232 Library
counts were summed for each sample to ensure that each passed a per-dataset
threshold and was not significantly larger or smaller than its contemporaries.
The datasets were all voom normalised on the same features, Law et al. describe
this process in great detail and establish voom as a viable method for heteroge-
neous data processing.238 E1, E2, E3, C1 and C2 started with 11212 15311, 21089,
13099 and 14112 genes, respectively, and ended with 7072, 12513, 15513, 12633
and 13411 genes, respectively. Initial subtypes and risk scores for IC10,154–156
PAM50,156 scmod1157 and scmod2,158 ssp2003154 and ssp2006,155MammaPrint159
and rorS156 continuous and categorical risk values were calculated with geneFu.
MammaPrint, rorS, PAM50 and IC10 have been described previously, however
ssp2003/6 and scmod1/2 have not. The ssp2003/6 tests aremethods of calculating
BC subtypes first proposed in 2003 then updated in 2006, and have good accor-
dance to clinical assignmentsmadebyER IHC,HER2 IHC/FISH. Scmod1/2 are also
gene centroid mapping utilities based off lists of 726 and 663 genes correlated
to ESR1, HER2 and AURKA that predict HER2+ ER+/-/HER2-/High/Low subtypes.
These tests were all designed for samples in the diagnostic/prognostic setting
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and are thus exploratory for measuring these values in the post treatment set-
ting. However, preliminary results such as those in chapter two of this thesis
show that there may be added functionality when applied to calculating risk as-
sessment by leveraging the on-treatment changes.
Changes in the subtype composition results of these geneFu tests were made
using the compareDF239 package in R and tabulated. GeneFu is a centroid map-
ping distance based subtyping algorithm. The program will read in flat tabu-
lated data annotated with samples per column and genes, usually Entrez Gene
Id’s, as the rows. It will transform the data into a n-dimensional coordinate and
then find the distance between the point plotted for each sample and the subtype
centroids. The subtype with the least distance to the sample is chosen as the as-
signment for that sample. These changes represent categorical state changes in
the presentation of the samples as a result of integration. Limma was also used
for differential expression analysis, and lists of differentially expressed genes
were compared pre and post integration for each dataset to identify changes in
the driving genes per cohort. Models were trained to try and predict datasets
of origin from the integrated data as an additional method of identifying data
structure perturbance. Accuracy scores may be reported as balanced F1 scores,
this has been calculated as:
𝐹1 = Precision×RecallPrecision+Recall
This is a balancedmetric between Precision and Recall and is a sensitive met-
ric to imbalanced class sizes as are present in parts of this analysis.
4.3.3 The Origins of Technical and Biological Variance
There are numerous confounding factors to consider for cross-platform com-
parisons, each of which must be accounted for and minimised during the
integration process, see Figure 4.3.1, Page 82. These factors, including platform
and treatment type, may occlude common biological similarities between
datasets and must be corrected for. The correction process itself may also incur
additional noise from the new transformations, another consideration for this
process. The impact of these factors will be analysed post-integration in three
key ways; with single time point pretreatment only sample integration, non-
informed uncorrected joining methods, and ComBat correction with additional
covariate information for each of these artefacts.
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Platform DS1 DS2 DS3 DS4 DS5
Identification of Technical and Biological Variance
Targets for ComBat correction
ResponseTreatment Time
Figure 4.3.1: Concept Map of the Various Biological and Technical Fac-
tors to Consider for Integration. This diagram highlights some of the con-
sidered factors for covariates of ComBat analysis due to their intrinsic ability
to convolute cross study comparisons. In this example, Platform, Therapy
and Treatment Time are considered batch effects and response and sub-
type are biological covariates. Not highlighted here is the importance of
cell-type heterogeneity, which is not further explored.
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4.3.4 Pre-Treatment only Integration as Reference Performance
Data
Integration of microarray data of pretreatment only data in the adjuvant ther-
apy setting is an established practicewith early investigations identifying and ac-
counting for the multiplicative distortions introduced in the routine processing
of microarray data.240 Subsequent work by Turnbull et al. showed, for example,
the cross platform normalisation of Affy and Illumina data using XPN and Com-
Bat,216 or Greene et al. for a further instance of XPN’s application to the simul-
taneous evaluation of microarray and RNAseq data.226 Removing batch effects
with techniques like ComBat have been shown to facilitate cross platform ex-
pression comparison.241 The pretreatment samples were integrated using quan-
tile normalisation to standardise expression levels and ComBat with platform
as the “Batch” effect to be corrected. Performance of ComBat in this setting will
be quantified to provide a reference for the amount of distortion added by the
inclusion of the on-treatment samples.
4.3.5 Uncorrected Integration Methods
Uncorrected approaches to dataset integration were performed with subset (re-
taining only the expression features common to all datasets) and complete (re-
taining all features across all datasets) joins of data. Missing genes post join
were filled with added interpolation of missing features to preserve dimension-
ality (i.e. keep full gene annotation) across datasets, this was performed with K-
Nearest-Neighbor imputation, Figure 4.3.2 highlights how these values are calcu-
lated, where theKnearest neighbors are located and themissing values are filled
in with the mean value from the N neighbors. Quantile normalisation223 was
used to retain the ranking of gene expression on a per dataset basis, while con-
verging the expression distributions. Multiple tests were then used to score the
performance of these methods and used as a second reference of performance
for the ComBat assisted pre- and on-treatment sample integration.
As previously stated, complete observational and subset joins will result in
dramatically different dimensions for the product dataframe. While the number
of patients will not differ between the twomethods, the feature list (rows) of the
integrated data will reflect the difference in the mechanics of each join. In the
case of this translational data, the features are genes. The resulting size of the
gene lists are plotted below as venn diagrams. The final dimensions for each
join are: Full outer join, 1122 samples with 21075 gene annotations, inner join
1122 samples with 4786 gene annotations.
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Samples with NAs Imputed Values
Sample 1 Sample 2 Sample 3 Sample 1 Sample 2 Sample 3
Gene 1 8.52 NA 11.23 8.52 11.23 9.88
Gene 2 9.12 7.47 8.44 9.12 7.47 8.44
Gene 3 7.98 NA 9.20 7.98 9.20 8.59
Figure 4.3.2: Example Imputed Values fromContinuous Gene Expression
Data. KNN imputation works by finding the K nearest neighbours, aver-
aging the values from those neighbors and supplying them as the missing
values. In this example Gene 1 and Gene 3 are missing values for Sample
2, indicated by the blue arrow. KNN in this example is looking for the
2 nearest neighbours, Samples 1/3 indicated by the green arrows. It will
then average the values of the missing genes in these samples to impute
the missing values for Sample 2. The blue dots represent other samples
which are more distant than Sample 1/3 and are not nearest neighbors in
this case.
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4.3.6 Reproducible ComBat Workflows and Integration Testing
Integration of the pre- and on-treatment data was performed using the pre-
selected covariates of analysis; Platform (P), Therapy (TT), Time (TS), and
Subtype (ST). These covariates were chosen as they were the most uniformly
represented across the datasets. Every sample had at least onematched on treat-
ment or surgical biopsy sample (TS) and the hypothesis that the on-treatment
samples are markedly different to pretreatment had been previously examined
and determined to be true in chapter 2 which details the NEO study, and
chapter 3, which details the primary and node trials. Every sample came from a
distinct platform (P) and cross platform normalisations are a normal method of
integrating numerical expression data. Therapy was equally well annotated as
every sample either came from a Chemotherapy or Endocrine dataset and the
difference between treatment types was believed to be evident in the resultant
expression level changes. Lastly subtype can be derived for every sample
is an important metric for monitoring stability of the integration efficacy as
large changes would be indicative of large changes to the underlying relative
expression levels. Clinical/pathological variables were immediately excluded
because they were sparsely included in the sample annotation files and would
have detrimentally reduced the sample size. Purrr242 was used to functionalise
the testing process and perform the integration on all possible combinations
of integration covariates. Purrr is an R library for applying functions, or lists
of functions to lists of objects and helped to keep the analysis uniform across
the datasets as they could be analysed completely in parallel. Combination of
the covariates was not included in this analysis as the ballooning effect of the
composite covariates would have quicklymade this a functionally different task.
The effect of the above covariates was not know either and the combination
was a logical extension if certain levels of performance of integration were
met.
As in previous results chapters, the primarymethod of reporting significance
between two groups, or measuring the significance of the difference present be-
tween to effect populations in this study is through a combination of parametric
and non-parametric tests. When measuring the effect between groups of un-
paired samples standard T-tests were performed. The five basic assumptions
were always tested: The values are on a continuous scale (expression values),
the samples are to the best of my knowledge representative of the population as
a whole as with the increased sample size a greater representative cross section
of the general population is represented than would exist in any one data set
in isolation. Graphically the data conforms to a normal bell shaped distribution
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after processing as can be seen in Figure 4.2.2, with the exception of the second
on-treatment samples of dataset C1. The fourth criteria of a reasonably large
sample size is satisfied as the other assumptions hold and there are sufficient
samples to calculate the test statistic. Lastly, standard deviations on both side
of the mean are approximately even suggesting homogeneity of variance. Non-
parametrically a Wilcoxon T-test was used when measuring the differences in
expression of paired samples. Assumptions here were even easier to satisfy as
every sample is inherently paired and they all come from the same population,
additionally, we are looking at looking at within pair differences.
4.3.7 Patient Matched Concordance and Correlations as Integration
Metrics
Patient-matched correlation, heatmaps with hierarchical clustering, principal
component analysis, intrinsic subtype concordance, differential gene expres-
sion, machine learning classification and pre- to on-treatment proliferation fold
change values were compared to establish discordance between the reference
data and each iterative integration attempt. Concordance and discordance will
be measured by the amount of overlap present for a specific discrete metric
after an integration step and are inversely proportional. Discordance among
subtypes for instance would indicate that the predicted subtype for a sample
has changed post integration, and concordance would indicate that it has stayed
the same. Heatmaps were generated for every ComBat integration attempt us-
ing the R package pheatmap243 with hierarchical sample clustering and per pa-
tient annotation of the different biological and systematic features using Eu-
clidean distance, complete observational linkages and no robustness testing. Ini-
tial subtypes and risk scores for IC10,154–156 Pam50,156 scmod1157 and scmod2,158
ssp2003154 and ssp2006,155 MammaPrint159 and rorS156 continual and categori-
cal risk values were calculated. Machine learning methods for the classification
of cancers244 and the prediction of recurrence of breast cancer245 is well estab-
lished. In particular, random forest has been shown to be a robust algorithm for
breast cancer risk prediction.245 This is true of both RF classification and regres-
sion models that return categorical risk or continuous risk respectively. There
are othermethods that are established for this regression/classification problem
from linear regression models to neural networks. It is the findings of previous
work in this thesis that RF generalises well to data of this scale and noise and
due to the inherently democratic method of RF avoids some of the over-fitting of
simpler regressionmodels, but can be reliably trained unlikemore sophisticated
deep learning methods. Follow up analysis of cosine similarity was performed
using scikit-learn149 to compare the inter-patient similarity pre- and post inte-
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gration.
4.4 Results | Unintegrated Data Meta-analysis
In order to understand how each attempt at integration affected the underlying
biology of the patient samples baseline measurements were required as a ref-
erence. The following sections highlight the important diagnostic results from
these baseline tests to help make future comparisons.
4.4.1 Subtype Composition of Unintegrated Datasets
The composition of the unintegrated data is presented in Figure 4.4.1, Page 89
as pairwise risk score comparisons, annotated by the color of the initial intrin-
sic subtype calculation. Four important pieces of information are contained in
this diagram. First, there are relatively more treatment matched patient sam-
ples for the aromatase inhibitor treated datasets. Second, there is a trend in
the data for a reduction in the calculated risk of the samples on treatment com-
pared to pre, this is evidenced by the position of the sample lower on the Y axis
(On-Treatment) relative to their corresponding X axis (Pre-Treatment). Third,
there is an over representation of Basal subtypes in the chemotherapy cohorts
compared to the aromatase inhibitor treated cohorts and lastly, the most signif-
icant reductions in risk are those of the on-treatment Luminal B samples in the
aromatase inhibitor datasets (wilcoxon p < 0.05 for mean reduction). Compar-
isons of all 8 classifiers (pam50, ic10, ssp2003|6, smcgene, mammaprint, rorS,
scmod1/2) will be made, with results presented as concordance between the pre
and post integration values on a per patient basis.
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4.4 Results | Unintegrated Data Meta-analysis
A
B
Figure 4.4.1: Independent Analysis of the Subtype Composition Across
Multiple Datasets. This figure illustrates the pre integration patterns of
predicted risk change with treatment. The X and Y coordinates are the
TP (Pre-Treatment) rorS risk and T-On (2 weeks on treatment) rorS risk,
respectively. Each sample is coloured by their Pam50 assignment at TP to
illustrate subtype specification changes. A) shows the samples coloured by
the Pam50 subtype, B) shows the samples coloured by treatement received
and given a shape based on the dataset of origin.
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4.4.2 Continuous and Categorical Risk Classification Across Multi-
ple Independent Datasets
The relative risk and relapse scores for each of the five datasets were examined
using MammaPrint and PAM50 rorS. These scores were calculated to identify
differences in the presentation of the datasets and to act as a reference for the
changes in the apparent risk associated with each dataset after each method of
integration. The median risk score and the tally of categorical risks classifica-
tions for each dataset according to both rorS and MammaPrint is presented in
the following Table 4.3, Page 91. The input for this geneFu method are expres-
sion matrices like with the classification tests. No specific method of normalisa-
tion is required for any of the features estimated here. The output for these tests
are two fold, first a continuous risk score from -1 (lowest risk) to 1 (highest risk)
for MammaPrint and between 0 (lowest risk) and 1 (highest risk for rorS, second
a categorical binning of patients into classes of 0 (low risk) or 1 (high risk) for
MammaPrint, and Low, Medium and High for rorS. Continuous risk scores are
presented as means with 95% confidence intervals. Clinically it is interesting to
see that the chemotherapy prescribed cohorts are of higher average risk across
both tests, with a greater proportion of categorical high risk samples. The two
chemotherapy cohorts were comprised of patients with a worse general progno-
sis and average higher histological grade. Deviation from these values, continu-
ous or categorical will inform us on the affects of integration to the prognostic
appearance of the patient samples. E2 is aberrant here for an endocrine dataset
and appears much higher risk than the other. This is, at this point, difficult to
explain as the data has been normalised and tests with the same parameters.
The composition of the cohort was known to be of lower clinical risk as well,
suggesting some instability, possibly, with this method.
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4 Comparison of Integration Methods
4.4.3 Pre-integration PCA Visualisation Data
PCA of the unintegrated data is presented Figure 4.4.2, Page 93. The principal
components are the eigenvectors that describe the variance in the data, i.e., the
X and Y displacement of each point on a 2D axis. These eigenvectors aremade up
of the contribution ofmany features, thus the position in space of one sample rel-
ative to another indicates the similarity of those two samples. Samples from the
same cohort or the same patient would be expected to cluster near each other,
for example. The effect of a platform batch effect is clearly visible in the PCA rep-
resentation. As expected with highly dimensional data the amount of explained
variance is low, at 17.2% and 12.1% in PC1/2 respectively.
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4.4 Results | Unintegrated Data Meta-analysis
PCA of Pre-integration Independent Datasets
Figure 4.4.2: PCA Diagram of the Unintegrated Data Illustrates the
Strong Presence of Platform Associated Batch. This PCA visualisation rep-
resents the five datasets, colored by the cohort of origin. It is clear from
this initial analysis that there is distinct seperation of the data on the basis
of batch.
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4.4.4 Principal Components Analysis of Independent Unintegrated
Data
Some of the genes that comprise PC1 and PC2 for each data set pre-integration
are presented in Table 4.4, Page 94. These gene lists will be use for later compar-
ison of Principal Component outputs to enumerate the degree of change caused
by each integration attempt.
Dataset Genes in PC 1 Genes in PC 2
E1 HSPB6, MYH11, PLIN1, RBP4, EGR1 AGR3, AGR2, MUCL1, SCGB2A2, TFF3
E2 TTK, DUS1L, DHX33, CDCA8, C10orf54 TFF3, KRT19, KIAA1324, FOXA1, RARRES3
E3 LYPLA1, ARMT1, TMEM106B, CAPZA2, VPS4B DPT, FABP4, FOS, ACKR1, C1S
C1 RPL41, RP5, RPS23, EEF1A1, RPL13A COX6C, CPB1, PIP, CARTPT, SLC39A6
C2 RGS1, MNDA, EHF, SPARCL1, MYSM1 NKAIN1, SYT13, DSCR6, PDZK1, GRIK3
Table 4.4: Contents of PC1 and PC2 for Future Comparison. Top five
contributors of the first and second principal components for each dataset
are listed above, these are primarily a resource for comparing the change
in the variance as a product of integration. The biological relevance of
these gene lists has not been examined as the method for identifying them
is not to elucidate biological processes or pathways but as a comparative
metric.
4.4.5 Analysis of underlying Data Structure Through Similarity
Scores
Additional analysis of the PC results have expanded this study to include the dif-
ferences between different patient pairs pretreatment and post-treatment, the
results of this test can be found in Table 4.5, Page 95. The purpose of this analy-
sis was to determine if the structure of the data is fundamentally different pre
and post integration and to measure this cosine similarity was used between
all samples and all other samples and then averaged to create a single point for
comparison. This metric is calculated as the inner product between two nor-
malized vectors, which is approximate to the cosine of the angle between them.
This was used in this instance as an alternate metric to correlation as it can cal-
culate the distance between two vectors, samples, taking into account the sam-
ple in n-dimensional space. This means we are in effect calculating the move-
ment away from the starting position post integration for every sample relative
to every other sample. It is a supplementary method to the correlation calcu-
lations. These results suggest that the integration process even at this level of
complexity has a systematic difference not only on the presentation of the indi-
vidual samples but on the data as awhole. Comparison of key biological genes or
housekeeping genes is being omitted as it is clear from the overwhelming differ-
ences in average similarity between the integration steps that any comparison
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4.5 Results | Correlation Analysis
between these genes would yield similar differences.
Inter-Patient Avg. Similarity (Pre-Integration) Inter-Patient Avg. Similarity (Post-Integration)
C1 0.43(0.389 to 0.471) 0.67(0.619 to 0.721)
C2 0.55(0.491 to 0.609) 0.71(0.636 to 0.784)
E1 0.51(0.454 to 0.566) 0.66(0.59 to 0.73)
E2 0.84(0.78 to 0.9) 0.82(0.719 to 0.921)
E3 0.61(0.56 to 0.66) 0.73(0.668 to 0.792)
Table 4.5: Table of the Average Cosine Similarity for Each Dataset This
table shows the average cosine similarity between all samples for each
dataset pre- and post-integration. The pre-integration scores are all lower
indicating less similarity before treatment, this is possibly representative of
greater variation in the relative gene expression that appears to be some
what homogenised post-integration. While speculation on the rationale
behind the value change is ultimately moot, the salient point is that the
underlying data structure has fundamentally been altered. It is worth noting
that as usual dataset E2 appears as some what of an outlier in this analysis.
4.5 Results | Correlation Analysis
Pearson correlation of matched patient samples was calculated using the base
R cor function to establish high level similarity between samples pre and post
integration. This was used as a metric to gauge the similarity or dissimilarity of
the full transcriptomic profile of each patient sample.
4.5.1 Pretreatment Samples Corrected with Platform ComBat Batch
Correction
Correlation of individual samples is presented in Figure 4.5.1, Page 96 showing
how patients with differing similarity appear for reference post integration.
Matched patient correlation on a per-dataset level is presented in Figure 4.5.2,
Page 97 to visualise the correlation of pretreatment samples pre and post-
integration. Correlation values vary between the datasets, but are consistently
high (75% > ). It is difficult to establish a firm reference metric for acceptable
correlation values, but this level of correlation is strongly indicative of a
trend.
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Figure 4.5.1: Example Correlation Diagrams of Purely Synthetic Data The
data displayed in these correlation diagrams are purely artifical and are not
representative of specific patients, samples or studies. These are illustrative
only. A) Shows a hypotehtical correlation of 1, indicating no change in the
pre and post integration samples. B) A correlation of 0.88, indicating a
low level of distortion between the pre- and post-integration sample. C)
and D) are samples with a correlation of 0.22 and 0.24 respectively, which
would be a very low correlation suggesting a large amount of integration
distortion.
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Figure 4.5.2: Correlation of Pretreatment only Samples Using Combat
with Platform as a Covariate Correlation values on a per sample level per
dataset are shown in these box plots and show the changes that are caused
by the integration on a superficial and unsupervised level. There is a high
correlation of the data pre to post integration when considering only the
pretreatment samples, with a range of mean from 0.72-0.87 (represented
by the middle line of the boxplot) and 95% confidence intervals are the
terminal ends of the boxplot ”Whiskers”) and presented in the figure.
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4.5.2 Uncorrected Combination of Sequentially Sampled Pre- and
On-treatment Datasets
Figure 4.5.3 Page 98 shows the per dataset correlation for the uncorrected fea-
ture joining methods. Both methods showed similar levels of average correla-
tion to the pretreatment only. E2 is the most tightly correlated for both methods,
and with the exception of E3, there is little statistical difference in the average





























Figure 4.5.3: Matched Patient Sample Correlation for Uncorrected Fea-
ture Joining Methods. Correlation of patients to their matched samples
post combination by complete (left) and subset joins (right) show the resul-
tant per-patient correlation represent on a per-dataset level. This shows a
clear drop in correlation post combination, with the exception of E2. Mean
values are indicated by the midline, with upper and lower quartiles repre-
sented by the bounds of the box and the 95% confidence intervals as the
terminal ends of the whisker plots.
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4.5 Results | Correlation Analysis
4.5.3 ComBat Integration of Sequential Samples with Multiple Co-
variates
It is clear from Figure 4.5.4, Page 99 that there is a range of correlations. The E2
cohort is of significantly higher correlationwith its ownmatched preintegration
samples than the other cohorts (p < 0.05 Wilcoxon T-test). Summary table of all
correlation comparisons for QN|Inner/Outer-join and all four ComBat methods





















































Figure 4.5.4: Correlation Pre- and Post-Integration are Lower for All
ComBat Covariates. Correlation is stable across the four integration meth-
ods (Platform (A), Time (B), Therapy (C) and subtype (D) and comparatively
low when compared to either uncorrected methods, or the pretreatment
only sample integration.
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QN: Inner Join QN: Outer Join Platform Treatment Status Treatment Type Subtype
C1 0.62(0.59-0.64) 0.66(0.64-0.69) 0.59(0.58-0.60) 0.59(0.58-0.60) 0.6(0.59-0.61) 0.59(0.58-0.60)
C2 0.73(0.68-0.77) 0.76(0.71-0.81) 0.62(0.56-0.68) 0.62(0.56-0.68) 0.63(0.57-0.69) 0.62(0.56-0.67)
E1 0.68(0.66-0.70) 0.75(0.74-0.76) 0.58(0.48-0.69) 0.53(0.41-0.63) 0.58(0.41-0.7) 0.58(0.46-0.66)
E2 0.98(0.97-0.99) 0.96(0.95-0.97) 0.84(0.82-0.85) 0.83(0.81-0.84) 0.93(0.91-0.94) 0.83(0.82-0.84)
E3 0.66(0.63-0.74) 0.78(0.70-0.85) 0.68(0.63-0.72) 0.67(0.62-0.71) 0.66(0.61-0.7) 0.67(0.64-0.73)
Table 4.6: Mean Correlation and CI for Each Method for Each Dataset
This table contains the mean correlation values and the range for the 95%
CI for each method for each dataset.
4.6 Results | PCA Analysis
PCA analysis reveals how the variance within each dataset is affected by inte-
gration, at least to the extent of the first and second principal components. Di-
agrams of the first and second principal components were created to visualise
the change in variance and evaluate the performance of the integrationmethods.
Additionally, gene lists that describe the first and second principal components
of the dataset where compared pre and post integration to examine the similar-
ity in explained variance. This studywants to acknowledge thatwhenusing such
dimensionality reducing techniques such as PCA there are other techniques, like
UMAPor t-SNE, thatmaybe equally viable. Looking at arbitrary variance cut offs
and comparing the Principal Component contents, or the matrix differences of
reduced space would be two possible avenues. In addition not looking at the
transformed rotation values but looking at the loading values, the weights in
the model that multiply the original scores to create variance unites, you can
also compare the way in which the data is changed. This was not followed fur-
ther as the onus of evidencewas suggesting that any further analysis would only
yield concurrent results and was a duplication of effort.
4.6.1 Pretreatment Samples with Platform ComBat Batch Correc-
tion
The 2D representation of the first two principal components can be seen in Fig-
ure 4.6.1, 101. This was produced using only the multiplicative variable of Plat-
form, and making non-parametric estimation to the prior distributions. This
attempt at integration is visually conforming to the known ComBat output of
“successful” integrations of microarray and expression data.
Pretreatment only sample integration resulted in an average retention of PC1
gene lists of 53.6% and PC2 of 32.12%, Table 4.7, Page 102. This result indicates
that in the two eigenvectors explaining the variance of the data, there is at best
a similarity of about a half and a third of the same genes.
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4.6 Results | PCA Analysis
PCA of Pre-integration Independent Datasets
A
B
Figure 4.6.1: Integration of Pretreatment Only Samples Using QN and
ComBat Integration of the pretreatment only samples clearly shows normal
and expected integration using the literature established methods of inte-
gration for transcriptomic data. A) The pre-integration uncorrected PCA
results represented by Figure 4.4.2, from Page 93, B) the pretreatment only
integrated samples.
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4.6 Results | PCA Analysis
4.6.2 Uncorrected Combination of Sequentially Sampled Datasets
Principal component analysis of these twomethods is shown in Figure 4.6.2, 104.
It is clear from the separation of the groups that the batch effect is still present
and that normalisation alone has not reduced the intergroup differences at all.
The scale of the variational distance is different between the two gene lists in
PC1, this is likely due to the feature size of the data but despite this, the pattern
of clustering is comparable. The percentage of overlap of the first and second
principal components is presented in Table 4.7, Page 102. There is an average
PC1 overlap of 38.92% and an average PC2 overlap of 10.52%, comparably lower
than the pretreatment only integration values.
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4 Comparison of Integration Methods
PCA of Pre-integration Independent Datasets
A
Figure 4.6.2: Uncorrected Combination Methods Do Not Improve
Dataset Integration Changing the contents of the gene lists for the resul-
tant dataset changes the variance contributions of each principal compo-
nent. Here the variance is visually represented in a PCA diagram, and the
difference in inter-dataset distance are clearly apparent between the two
methods. A) Represents the uncorected data visualised by Figure 4.4.2,
from Page 93, B) the joined data that results from a full outer join, C) the
joined data from only an inner join all performed with QN.
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4.6.3 ComBat Integration of Sequential Samples with Multiple Co-
variates
PCA of the post integration data reveals significantly less visual overlapping of
the datasets than the pre-integration only or uncorrected methods, Figure 4.6.3,
Page 106. Additionally, with increased feature count for the additive covariate
there is increased fragmentation of the resultant PCA plot. With respect to the
pretreatment only, there is a clear loss of structure and batch, and compared
to the uncorrected joins there is an increase in the number of visible batches.
Table 4.7, Page 102 contains the overlap values of the first and second principal
component, there is a mean overlap of PC1 and PC2 of 1.04 and 0.28, 25.96 and
13.72, 19.6 and 23.72, 28.76 and 14.36 for the covariates of platform, treatment
time, treatment type and subtype respectively.
Theoretically, correlation between principal components should be low as
they are calculated from non-correlated, orthogonal eigenvectors with unique
contributions from each gene. As can be seen in Table 4.8, Page 105, this trend is
true for all datasets except for E2. The collinearity seen in E2 shows that the fea-
tures that define PC1 are related to the features in PC2, indicating that variance
in one plane effects variance in another.
Dataset Platform Time Therapy Subtype
C1 12.9% 13% 15.1% 15.0%
C2 6.7% 9.2% 13.1% 11.6%
E1 9.1% 8.7% 11.8% 11.2%
E2 87.2% 89.6% 86.8% 89.7%
E3 14.1% 12.2% 15.3% 11.1%
Table 4.8: Measurement of Collinearity Between PC1 and PC2 This table
contains the values of collinearity between the first and second principal
components for the five datasets across the four batch aware integration
methods. Principal components should in theory be orthogonal and thus
have no linearity, this would be a score of 0%, full collinearity would be
100% and suggest that the vectors that represent PC1/2 are not collinear
at all.
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PCA of Pre-integration Independent Datasets
A
Figure 4.6.3: PCA Plot Comparisons of Four Integration Methods. Com-
paring PCA plots of different integration methods Platform, Time, Therapy,
and Subtype reveal a decomposition of the original batches. A) The ref-
erence PCA plots of the pre integrated data represented by Figure 4.4.2,
from Page 93. B) Shows the Platform aware integration, C) Treatment
Time, D) The therapy used, E) The Pam50 subtype. These results show
many different structures distinct to the covariate of integration.
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4.7 Results | Heatmap Visualisations
In concert with the PCA diagrams, heatmaps can highlight groupings based on
the clinical and pathological features available for analysis. Heatmaps of the pre-
treatment only sample and uncorrected integration methods were omitted due
to the PCA diagram results. Heatmaps were generated for every ComBat integra-
tion attempt using the R package pheatmap243 with hierarchical sample cluster-
ing using euclidean distance and complete observation linkages and per patient
annotation of the different biological and systematic features. These were used
for visual inspection of the effectiveness of ComBat and to estimate the level
of integration based on the presence or absence of noticeable groupings of the
annotated features. In addition Silhouette coefficients were calculated for each
clustering analysis in order to enumerate and analyse the cluster robustness.
4.7.1 ComBat Integration of Sequential Samples with Multiple Co-
variates
Post integration heatmaps of the combined datasets were plotted to visualise the
representation of the biological and systematic annotation features among the
resultant batches. As Figure 4.7.1, Page 108 shows, there is no significant clus-
tering of any of the annotation features relevant to this analysis. There is some
mixing of C2 (Blue) and E1 (green) upon integration with covariates of Platform,
treatment type and subtype, however the datasets are not integrated with re-
spects to the treatment received, nor the patients by response or treatment time.
Fundamentally there appears to be present batch effects in the post integration
data that are not corrected by the integration methods. As a measure of the mix-
ing of the samples the two closest neighbors were calculated for each sample.
For ninety eight percent of the samples the nearest neighbor originated from
the same dataset. This suggests a low level of integration as the dataset of origin
was the most prominent feature of the post integration space. In addition, the
Silhouette Coefficient for each each data set with each integration method was
above 0.5, and with a mean value of 0.881, strongly suggesting that the cluster-
ing of each dataset is tight and distinct from the other datasets post integration
Table 4.9, Page 109.
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A B
C D
Figure 4.7.1: Heatmaps and Hierarchical Clustering of Post Integration
Datasets. Heatmaps (HM) and clustering can help to identify patterns, or
visually confirm results of analysis. Here, the patterns of non-integration
are clear from the distinct expression patterns per dataset, and the visible
lack of integration of the annotaion features. HM A shows the clustering
an expression patterns for Platform integration, B for Time, C for Therapy
and D for Subtyping integration.
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4.8 Results | Molecular Subtyping and Prognostic Scores
Silhouette Coefficient
E1 E2 E3 C1 C2
Platform 0.91 1 0.89 0.87 0.52
Time 0.95 0.97 0.88 0.87 0.67
Therapy 0.99 0.96 0.91 0.86 1
Subtype 0.92 0.94 0.90 0.81 0.80
Table 4.9: Silhouette Coefficients for Every Dataset Across All Integration
Variables. Silhouette Coefficients measure two values, the difference from
a sample to the mean of its cluster and the difference from a sample to the
mean of other clusters. Combined these values are used to calculate the
Silhouette Coefficient which describes the tightness and distinctness of a
cluster with values ranging from -1, no clustering, to 1, strong presence of
clustering. The values reported for these integration attempts all strongly
signal that the clustering of the integrated data remains robust and the
presence of batch is still felt in the expression data.
4.8 Results | Molecular Subtyping and Prognostic
Scores
4.8.1 Pretreatment Samples with Platform ComBat Batch Correc-
tion
Subtyping and concordance of the resultant molecular/intrinsic subtypes is
shown below in Figure 4.8.1, Page 112 for Pam50, rorS risk classification,
MammaPrint risk classification, iC10 subtyping and ssp2003/6. Agreement of
the calculated subtype is relatively high (concordance (subtype agreement) >
80%, Table 4.10, Page 110) for all tests except iC10 which was in agreement 72%
of the time. This result shows that the concordance post integration is sensitive
to the number of classifications possible for each test, where the greater the
number of outcomes, the lower the concordance. These values show results
in-line with patient-matched samples from different tissues or different treat-
ment time points (Chapters 2 and 3), indicating that the distortion of ComBat
is at least no greater than the effect of treatment. There are many colors on
display here, to save wasteful repetition or detracting from the diagrams, I will
outline the colors and matching typing for each test for the following diagrams.
For the Pam50 and scmod1/2 classifiers there are LumA(dark blue), LumB (light
blue), Normal (green), Her2 (pink) and Basal (red), for the SSP2003/6 tests they
output ER-/HER- (red), HER2+ (pink) ER+/HER- High (blue) and ER+/HER- Low
(green). The IC10 subtypes are depicted as: IC1 (orange), IC2 (slate blue), IC3
(dark seagreen), IC4 (deep pink), IC5 (azure), IC6 (dark orange), IC7 (khaki), IC8
(dodger blue), IC9 (goldenrod), IC10 (plum).
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4.8 Results | Molecular Subtyping and Prognostic Scores
4.8.2 Uncorrected Combination of Sequentially Sampled Datasets
For the data of the subset feature joins, no subtyping was available as
the reduced gene lists were too incomplete to conduct these profiling
tests. For the full outer joined data, comparisons were drawn for ev-
ery sample from every dataset with the geneFu results from the uninte-
grated data, Figure 4.8.2, Page 113. Full comparison tables are available at
https://gitlab.com/rjbownes/Integration_Rationale/Compare_df. A summary
of the differences is presented below in Table 4.10, Page 110. As no assumptions
were made as to the relative importance of the subtyping/classification tests, a
non-concordant subtype in any of the geneFu tests resulted in a step change
reduction in agreement. Agreement of the pre and post integration subtyping
was low at a mean value of 26.8% unchanged samples. Additional rorS and
MammaPrint continuous risk score comparisons were made, which clearly
show a systematic decrease in the presented risk post integration.
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4 Comparison of Integration Methods
4.8.3 ComBat Integration of Sequential Samples with Multiple Co-
variates
Analysis of the subtype composition changes for this integration based on the co-
variates resulted in a net decrease in concordance as compared to simple joins
and to the integrated pretreatment data, Figure 4.8.3, Page 115 illustrates this
point for the Pam50 subtyping test. The standout result is the large increase
in the number of Luminal A samples post integration in the aromatase inhibitor
treated cohorts and a small decline in the number of Basals in the Chemotherapy
treated datasets. This is suggestive of a systematic shift in the centroid mapping
algorithm of Luminal B samples relative expression of certain genes changing
enough to be reclassified as Luminal A. Similarly and possibly more destruc-
tively, the Chemotherapy Basal samples appear to change most frequently to
Her2-enriched samples. Table 4.10, Page 110 contains the number of undistorted
samples per ComBat covariate method. ComBat performed worse than the Pre-
treatment only and uncorrected integration in terms of subtype concordance at
19.6%, 14.2%, 19.1% and 18% unchanged samples for Platform, Time, Therapy
and Subtype integration respectively.
In addition to the categorical tests, continuous risk assessment of the sam-
ples were calculated post integration for each method, and compared to pre-
integration values. Figure 4.8.4 highlights this result for the rorS prognostic
test, on the integration with only the information of Batch in the pre and on-
treatment data, concurrent results were obtained for each method, were highly
concordant, and only one is being illustrated here for clarity. Full views of each
comparison were performed but added little if anything to the analysis, and
were only distracting as extra diagrams in text. As Figure 4.8.4 clearly shows
via the loess regression lines comparing the pre and post integration prognos-
tic values, there has been a significant shift in the relative risk scoring of the
patients post integration ( > 95% confidence intervals) for all datasets. E2 expe-
rienced a small drop in the perceived risk at lower rorS scores, but C1, C2, E1
and E3 all saw a statistically significant increase in risk for the better prognostic
class patients (p < 0.005 for all datasets but E2 by pairwise Wilcoxon t-test). At
high levels of estimated risk the five datasets show concurrent reductions in risk
post integration. Regardless of direction this represents a large and systematic
divergence of perceived patient prognostic characteristics.
114

























































































































































































































































































Representative Differential Risk Curves
Figure 4.8.4: Continuous Risk Comparison Pre- and Post-Integration
Comparison of the Pam50 rorS continuous risk assessment scores, here
the x axis is pre-integration and the y is post-integration shows there is a
large and systematic shift away from the pre-integration risk values. DS E3
shows a significant increase in the preceived risk of the low risk patients
(p = 0.0011 paired Wilcoxon t-test for samples in Low or Intermediate
rorS classifications pre-integration), this is consistent with the results of the
subtype concordance scoring.
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4.9 Results | Differential Expression Analysis
The inherent value of this data lies in the information contained in the pre- and
on-treatment gene expression fold changes. These have previously been shown
to help separate response classes to chemotherapy215 and identifymarkers of re-
sponse in aromatase inhibitor treated cohorts.137Maintaining these changes is of
paramount importance to the value of this work. DE gene lists were calculated
using linear Bayesian models and filtered for significance (FDR < 0.05). These
were compared pre and post integration to evaluate the overlap in retained dif-
ferentially expressed genes. This comparison is not drawn for the pretreatment
only integration as there are no pairwise differences across treatment time.
4.9.1 Uncorrected Combination of Sequentially Sampled Datasets
Table 4.11, Page 117 contains the overlap values for the shared differentially ex-
pressed genes present in the reference unintegrated data and both uncorrected
integration methods. Dataset E2 has the highest agreement with all the correc-
tion methods with the independently analysed data, however the remaining
data share comparatively little with their references, with as little as 3.4% of
the same genes being differentially expressed. In addition the complete over-
lap has ~13% more conserved similarity when compared to the subset feature
integration.
Differentially expressed gene list overlap pre- to on-treatment
Complete Join Subset Join Platform Time Therapy Subtype Mean
C1 21.2% 13.4% 22.6% 22.6% 23.4% 22.4% 20.9%
C2 32.4% 29% 27% 27% 31.8% 27% 20.9%
E1 42.4% 38.4% 48.8% 48% 39.4% 47.4% 44.7%
E2 91.6% 41% 50.4% 48.2% 87.4% 49% 61.27%
E3 3.4% 4.4% 5% 4.6% 4% 5% 4.4%
Mean 38.2% 25.5% 30.7% 30% 37% 30%
Table 4.11: Percentage of Differentially Expressed Genes Retained After
Integration. Each row contains the percentage of differentially expressed
(DE) genes retained for each method, for each data set. The summary
statistics are listed on the bottom and right most column.
4.9.2 ComBat Integration of Sequential Samples with Multiple Co-
variates
Results, Table 4.11, Page 117, are similar in magnitude to the pretreatment at-
tempts at integration but do not represent an improvement in the retention of
biological features, according to the differentially expressed genes. There is less
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average similarity across the five datasets than before and a newminimum simi-
larity (E3/4%). This strongly suggests that the important patient-matched transla-
tional changes that are a product of neoadjuvant treatment are being further lost
to ComBat. Dataset E2 has the highest average agreement regardless of method,
further identifying the outlier nature of this dataset.
4.10 Results | Random Forest Classification
Machine learning methods for the classification of cancers244 and the predic-
tion of recurrence of breast cancer245 is well established. In particular, random
forest has been shown to be a robust algorithm for pattern detection.245 In this
study, a random forest was trained on the pre integration data in order to try
and identify the original batches in each post integration method. By inverting
the results of the random forest output, we can gain a measure of the level of
integration based on the mixing after ComBat. Ideally, this results in the “fail-
ure” of the RF model to correctly identify the dataset of origin, indicating that
the descriptive features of each sample have been sufficiently shifted together
to appear as if from one distribution
4.10.1 Pretreatment Samples with Platform ComBat Batch Correc-
tion
Random forest classification was 17% accurate (F1 score) in the identification of
the original batch in the post integration data. This is below the 28% majority
classifier performance and a clear indication of the successful integration of ex-
pression data. Integration of pretreatment samples with QN and ComBat show
that features descriptive of batch have been eliminated and the distributions are
shifted together well enough to represent a single batch.
4.10.2 Uncorrected Combination of Sequentially Sampled Datasets
Naive integration methods showed poor levels of integration according to the
inverse RF metric. The random forest model classified 100% of the Complete
feature joined samples correctly with the batch of origin this indicated that the
integration was not sufficient to obscure the original batch effects. The subset
feature joined samples had visible overlap of the E1 and E2 samples and this is
represented in the RF model performance at 82% accuracy. Both of these meth-
ods failed to shift the underlying expression values sufficiently to render the
batch of origin indistinguishable.
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4.10.3 ComBat Integration of Sequential Samples with Multiple Co-
variates
Random forest mislabeled 142 samples (981/1122, 87%) for the platform inte-
grated pre and on-treatment samples, 250 (872/1122, 77%) for treatment time in-
tegrated, 400 (722/1122, 64.3%) for the treatment type covariate and 478 samples
(644/1122, 57.4%) for subtype adjusted ComBat correction. Subtype integration
had the lowest random forest accuracy, correctly identifying the lowest number
of integrated samples but still failed to reach the 28% benchmark. All ComBat
assisted integration methods, except the Platform covariate, out performed the
uncorrected method, however they all fell short of the pretreatment only inte-
gration performance.
4.11 Results | Proliferation Changes
As proliferation is an important biological marker of response to treatment, en-
suring that the expected reduction to proliferation is still present post integra-
tion is an important metric to validating the integration methods. A reduction
in proliferation markers has long been a marker for response to therapy97 and
to see a large deviation away from this would indicate a systematic disturbance
to the fold change values in the pre and post treatment samples. Figure 4.11.1,
Page 120 shows that for each dataset there is a significant reduction in prolif-
eration markers on treatment compared to pretreatment expression levels in
the data prior to integration. For all methods, the post integration on-treatment
fold change values are not statistically distinguishable from zero but also have
positive means. This indicates that universally, the starting values for the pro-
liferation markers profiled in this test (PCNA, MCM2, MKI67, AURKA, FOXM1,
BUB1 and TOP2A) have been reduced with respect to the patient-matched on-
treatment values or the post treatment samples appear to now have higher ex-
pression than before. The implication of this result however is that the changes
on-treatment no longer represent the known, normal biological trend of the pre-
integration data and are no longer representative of of these important markers.
These values are tabulated in Table 4.12 below.
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4 Comparison of Integration Methods
4.12 Results | Post-ComBat Distributions
To further investigate the possibility of the on-treatment samples causing the ad-
ditional noise, Figure 4.12.1, Page 122was drawn to highlight theComBatprocess
of distribution normalisation. This diagram shows the contributions of each ad-
ditional dataset to the complexity of thenormalisation calculations. Eachdataset
introduces new distributions that must be shifted and in turn these increase the
complexity of the integration function. It is possible to see that there are addi-
tional “shoulders” in the distributions of the pre and on-treatment data, indicat-
ing bi or multimodal distributions in the data, which are partially obscured by
larger or wider distributions.
Figure 4.12.1: Evidence of Multiple Incompatible Distributions in the Pre-
and On-Treatment Data. It is possible to discern the shoulders of addi-
tional subdistributions in each dataset for the different combinations of
datasets that are likely antinomic to the ComBat distribution shifting pro-
cess. This diagram is meant to visualise the distributions that are being
normalised and combined togther in the ComBat process. As can be seen
from the successive addition of each new batch, the columns, there is
increased topological complexity to the underlying data. The order of ad-
dition of the data sets changes the mid-step topology, but the final con-
formation is always the same. In this diagram the top row represents the
non-parametric, and the bottom the parametric, implementations of Com-
Bat. The first panel shows three datasets, E1/2/3, the middle panel adds
C1 and the final panel adds C2.
The presence of additional sub-distributionswas further explored by examin-
ing the distributions of the gene expression on a per-time point-per-dataset level.
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Figure 4.2.2, Page 76 shows the mean centered gene expression distributions for
every dataset (A), then the sub distributions of treatment-by-time point as box
plots (B), and kernel densities (C). There are clear distinctions between the time-
point-treatment distributions, as seen by the box plots and kernel densities, both
ofwhich support the idea that these additional distributions are limiting the abil-
ity of ComBat to successfully integrate the data.
4.13 Discussion
There were an enormous number of possible covariates of ComBat integration;
dataset, sequencing platform, type of treatment, time on treatment, intrinsic sub-
type, known response, histological grade, ER positivity, PR positivity and HER2
status, detection method, BRCA mutation status, node status, age, tumour size
andmenopausal status to name just a few. Of these, the factors that were trialled
were platform, treatment time, treatment type, and intrinsic subtype. These fea-
tures were chosen as covariates to improve the performance of ComBat primar-
ily as theywere themost feature complete variables for consideration andwould
retain the greatest sample number. Ideally, these factorswould account formost
of the inter-dataset variation and enable the most uncompromising integration
of the data.
Integration of these disparate cohorts has proved an enormously difficult un-
dertaking. Batch correction is a fairly standard procedure,246 but is possibly in-
sufficiently subtle to combine on-treatment neoadjuvant data and keep the im-
portant and highly sensitive patient-matched fold change values intact, despite
its use in the normal removal of these effects frommicroarray data.247,248 Kernel
density estimates of the normalised data for each integration method suggests
that integration can be performed completely as the distributions of the expres-
sion data appear as a singular, uniform, curve with normal parametric char-
acteristics. Importantly, each component distribution is fully indistinguishable
from the others. This is strongly juxtaposed by the results of the genewise clus-
tering, principal component analysis, subtyping concordance, random forest
analysis, correlation testing and analysis of the shared differentially expressed
genes which all would indicate that the integration of the data has been highly
descriptive to the underlying data and thus totally unsuccessful. ComBat has
previously been shown to improve the statistical analysis of -omic data and im-
prove the identification of differentially expressed genes,249 and concordance
with known biological pathways250 but that seems to falter with the addition of
the on-treatment samples.
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Integration of single time point cross platform data, has been previously
described216,241 and successfully performed with quantile normalisation and
ComBat. As expected, the post integration results of this method were the most
concordant. Correlations of the patient samples post integration were compar-
atively high, > 75% and PCA results of this protocol were visually conforming
to the expected integration outcome. These two tests indicate that the patients
still resemble their pre-integration expression profiles, but the datasets are no
longer distinct. Subtyping and risk scoring showed similar levels of overall
similarity with ~80% subtype agreement post integration and a non-significant
difference in the presented risk of recurrence. This is especially important as
these metrics are valuable descriptive features with implicit biological and
clinical implications that need to be maintained to ensure fair analysis post
integration. Discrepancies here would indicate that the post integration data
does not have the same biological representation as the pre-integration data.
Because the resultant subtyping and risk assessment tests are so concordant,
inferences made on the post integration data can still justifiably applied to the
pre-integration samples allowing for integrative analysis. Lastly, supervised
machine learning models were unable to distinguish the study of origin in
the pretreatment only integrated samples. Overall, this signifies that the
biological diversity of the original data was meaningfully maintained, while
simultaneously removing as much of the technical variance as possible, this is
certainly in keeping with the results from Turnbull et al. 216 and other modern
examinations of single time point integration retaining significant biological
information.249,250
Uncorrected approaches to integrationwere outperformedby the established
pretreatment only protocols. Correlations of the cross integration matched pa-
tients samples were lower as a whole with the exception of dataset E2, which
was aberrantly well correlated. Post integration the overall expression values
were not as representative of the pre-integration data, suggesting more distur-
bance to the relative gene expression values possibly as a result of the lack of
subtlety in the basic joining methods. The subsequent PCA diagrams illustrate
that, regardless of the change to the underlying relative gene expression, the
inter-dataset variance is maintained. This result indicates that no technical vari-
ance has been removed but the biological values have been altered. Subtype
agreement post integration was very low, just 26.8%. This confirms the result of
the correlation analysis that the relative gene expression values have been de-
structively shifted. The post integration subtyping and risk assessment values
are now no longer representative of the un-integrated data making subsequent
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analysis of the data irresponsible from this perspective. Additionally, the pair-
wise differentially expressed genes were comprised of almost entirely different
genes (38.2%and 25.5%agreement), meaning the valuable treatment-dependent
fold change values have also been compromised. Lastly, the ML model was suc-
cessful at classifying the dataset of origin, thus confirming the results of the PCA
analysiswhere the inter-dataset variance and differentiating features have been
maintained but the important biological characteristics have been lost. In con-
text, these results are rational and expected as corrections have long been estab-
lished as appropriate protocols for improving cross platform analysis.251
ComBat integration with multiple covariates was outperformed by the pre-
treatment only integration andwas roughly on parwith the uncorrected integra-
tion methods. Correlation analysis revealed further reduced patient matched
similarity ~60%, again with the exception of dataset E2. This suggests there is
a systematic failure of these methods to alter the general expression profiles
of this dataset, however subsequent analysis fails to reveal a sufficiently viable
reason. Heatmap and PCA analysis of these methods complement each other
to emphasise the fact that the datasets are not significantly integrated on any of
the highlighted clinical or technical factors. Additionally, any overlapping of the
samples in the heatmaps can be seen more clearly in the PCA as non-integrative
dispersion of the data, which scaleswith the number of covariates. This is a clear
illustration of the fact that ComBat assumes uniform contributions of the covari-
ates, a feature that works against very heterogeneous data. The inability of Com-
Bat to sufficiently handle these non-uniform distributions is shown in the anal-
ysis of sub-distributions in these cohorts, which demonstrate clear and present
multi-modality. Subtyping concordance was on par with the uncorrected meth-
ods, even when starting subtype composition was taken into account, which
strongly indicates that the addition of covariates to integration is adding little
value to this analysis. The pairwise fold change values were maintained only
~32% of the time, meaning the intrinsic values of these samples is again lost
with these methods. Dataset E2 continues to be an outlier in this analysis, with
an average retention of 61.27% of the DE gene lists. Lastly, the unsupervised
machine learning methods had a range of performance in dataset classification.
Fundamentally, this result would indicate an improvement in integration per-
formance from Platform < Treatment time < Treatment type < Subtype, how-
ever with regards to the PCA and heatmap analysis this could equally be ex-
plained by the non-integrative dispersion and possible model over fitting. There
are very few examples of analysis like this and correspondingly it is very dif-
ficult to place the results outside of this thesis. Muller et al. have previously
shown that longitudinal integration is possible using precisely the methodolo-
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gies employed here, but the successful integration of this data is not replicated
in this study.252 This is possibly due to the nature of the data being substantially
different, this data is comprised of multiple time points from five different plat-
form’s, the Muller study was of a patient cohort with matched patient samples
after five years of follow up on the same platform.
GeneFu was heavily utilised for this section and its analysis. This library
provides easy to employ, reliable, means of classifying subtypes and predict-
ing prognostic risk. However, geneFu and its methods are only approximations
of the tests it seeks to emulate. They are in actuality models that estimate the
classifications that would be conferred on to BC samples tested with laboratory
conducted gene panels and IHC tests. This incurs a loss of accuracy inherently
as they are derived from expression matrices and not the true tissue samples.
geneFu primarily operates as a centroid mapping algorithm and this confers
a second approximation that must be considered. Fundamentally this method
works by comparing the transformed gene expression scores of pre-defined lists
of genes on a per sample basis to point values mapped to subtype annotated
centroids. Each sample is then compared to the centroid values and the classifi-
cation of least distance is chosen as the output. This means that a sample can be
massively dissimilar to every class, but will be assigned to the least distant one,
and also these values are affected by dataset composition through normalisation
and pre-processing, meaning the individual sample is affected by the composi-
tion of the whole cohort. These factors must all be considered fully when using
this library, and that is why these values were primarily used for comparative
analysis of the changed that occurred to integration instead of as an examination
of the composition of each cohort.
Of special interest with dataset E2 is that the samples from this cohort always
only cluster/align with samples from E2 despite also containing biological over-
lap with samples in E1. The same patient samples analysed under different con-
ditions still do not appear more similar after integration. This suggests that the
effects of batch are possibly insurmountable. This result stems from an error in
the construction of the backend data structure but is a serendipitous result as
it adds additional weight to the result that integration is not sufficient to over




Integration of sequentially matched neoadjuvantly treated datasets is a
formidable obstacle to large scale on-treatment breast cancer analysis. Under
the existing standards of data integration, post combination data was not
representative of the pre-integration data. This results strongly suggests that
a meta analysis of neoadjuvant therapies is a more appropriate method of
comparing different datasets in a non-destructive manner. At this time, the
standard methods for batch correction and dataset integration via quantile




5 | Meta-Analysis of Multiple
On-treatment Datasets Re-
veals Common Transcrip-




Analysis of small cohorts of neoadjuvantly treated breast cancer has yielded
some initially powerful results in the area of biomarker identification and risk
stratification of patients. However, these results are undercut by the limited sam-
ple size and possible lack of population representation of the underlying data. It
may be possible to identify more subtle signals in integrated data and make in-
ferences with significant statistical backing using the meta analysis of multiple
studies of this scarce data.
Methods
Five datasets of transcriptomic breast cancer data and matched annotation in-
formation were collected and combined to create a repository of independently
but homogeneously processed data. The crucial pairwise differences in gene ex-
pression were harvested to identify uniform patterns of change in gene expres-
sion common to all treatment types. Machine learning (ML) models including
Support vectorMachines and Neural Networks were trained to predict response




Analysis of the aggregate fold change values reveals that there is definite clus-
tering of the patients based on the factor of non-response regardless of the treat-
ment involved. Subsequent pathway analysis of these non-responsive samples
reveals a preponderance of genes associatedwith, and enrichment of, mTORand
PI3K pathways, suggesting a possible commonality in nonresponse and new tar-
gets and treatments for these patients. ML models were trained to attempt to
identify response status of BC patients cross treatment with significant accuracy
(89% Support Vector Machine (SVM), 92% Neural Network (NN)).
Conclusion
Examination of matched pre and on-treatment samples facilitates new kinds of
meta analysis from neoadjuvant data, yielding previously unseen insights into
BC treatment response vectors. While endocrine therapy and chemotherapy
have significantly different mechanisms of treatment and this can be seen in the
way patients respond to treatment. The vectors of non-response appear to have
overlap and are enriched for genes currently being targeted for new drug devel-
opment, mTOR and PI3K. Lastly, the ML methods presented are able to leverage
these values to train models for the accurate prediction of response across treat-
ment paradigms by targeting these vectors of non-response.
Overview
A generalized diagram of for this work, especially with regards to the gen-
eration of the most vital outcomes is presented in Fig. 5.1.1, on page 131. This
diagram highlights the critical difference presented in this chapter compared
with the study of the expression level integrated analysis performed in the pre-
vious results section. Results from the individual analysis of different data sets




Figure 5.1.1: Overall Study Design and work flow. The workflow for this
chapter is presented in this diagram. The datasets are seperat ely anal-
ysed for subtype, prognostic score and other molecular typings before the
output of these results are integated to form a meta-dataset of viable and
comparable results. Meta-analysis of these outputs is then then conducted
to attain pan-treatment, cross dataset results.
5.2 Background
There have been previous attempts to to use integrated expression data enmasse
to enhance the significance of research and provide more powerful answers to
questions posed about patient response prediction and risk stratification.253,254
Multiple algorithms have been developed for correcting the “batch” effect associ-
ated with disparately sourced data and aggregating it to facilitate new research,
these include Surrogate Variable Analysis (SVA),218 Bayesian Factor Regression
Modelling (BFRM),219 Factor Analysis (FA)220 and Array Generation Centering
(AGC).221 These methods all seek to shift the distributions of expression towards
one another and by so doing, integrate and normalize the data. These meth-
ods are all different implementations which seek to evaluate the contribution
of different features or variables that contribute to the shape of each different
distribution in the parent data. Then, upon integration center the data as much
as possible between the different data sources while maintaining the shape of
the distribution of the identified important features. ComBat222 has been estab-
lished as the standard method for batch correction and integration of microar-
ray data,223–225 but is, as of yet, untested in matched patient sequential samples.
However, due to the overwhelming evidence to suggest it’s applicability here, it
will be pursued over the alternatives.
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Recent successful attempts at leveraging the results of multiple translational
studies together have utilized various methods to escape these problems.
Jiang et al. constructed a network based approach that individually assessed
upstream involvement of gene expression to identify driver genes to describe
specific gene expression profiles.255 This is a popular approach, as there are
several example network analyses of transcriptomic data with associated
genomic quantitative and annotation data by other researchers from the last
few years. Primarily, these studies utilize microarray data from multiple
sources, but side step the problems of batch.256 Other teams have focused on
the integration of expression data with other types of data to perform intricate
multi-omic analysis.257,258 Tools to streamline the collection, creation, and
annotation of databases from publicly available repositories have even been
produced, however the tight integration of expression level data is uncommonly
attempted and more rarely successful.259
To circumvent the problems of batch andmultiple expression set alignments,
I have created a unique set of comparablematched pre and on-treatment expres-
sion level change values tomake summary analysis of the effects of neoadjuvant
therapy. Here, I examine the results of the scaled pairwise differences in gene
expression to gain new insight into the responses and changes in breast cancer
to treatment.
5.3 Methods and Materials
The five datasets used in this analysis were gathered either from the public do-
main, or through locally hosted andmaintained sources, details on each dataset
can be found in Table 4.1 for annotation and summary statistics of samples in-
cluding platform and treatment type. These were independently collected and
pre-processed to remove probes with no signal or variance and quality control
the sampleswith Limma,230 DESeq260 and edgeR.231 The datasetswere voomnor-
malized independently and attemptsweremade to integrate the expression data
using ComBat as described in Chapter 4. As these attempts were unsuccessful,
MetaMatchBreast (MMB) was constructed using R145 and the Bioconductor pack-
age XDE236 establishing an ExpressionSetList object type to build a frame work
of un-merged expression data with integrated annotation information. This pro-
vided an iterable list object for analysis and testing, with unified pathological
and clinical information for sub-setting of the data.
Additional factors included are all available clinical features and follow up,
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up as well as calculated subtypes. In addition, functionality for calculating
dataset specific differential expressed based on defined subclasses from within
the annotation has been written to allow for bespoke analysis of the bundled
data. Integration methodologies are also built in to allow for the combination
of any subset of the data with multiple different covariates to independent
analysis. MMB also contains high level exploratory and visualization functions
for survival analysis, statistical testing, comparative expression analysis and
appropriate plot out-puts for these functionalities. Critically for the longevity
of the work presented in this thesis MMB is infinitely extensible. The structure
of MMB is such that the expression set list can be appended with any new
expression matrix and the matching annotation information can be combined
with the expression-set pheno-data object. This functions as a means for con-
tinuing to incorporate and grow this aggregate resource as new data becomes
available.
The ability to extend the dataset to incorporate new and emerging neoadju-
vant trial data is pivotal to the long term value of this work. As has been stated
previously in the results chapters, this type of data is more rare and compar-
atively smaller due to the complications of multiple sampling. The ability to
aggregate this data for meta-analysis will hopefully allow for enhanced future
analysis of these samples to make more powered and profound results possible.
The full scope of this work was not completed by the conclusion of this thesis
work but has been carried on by myself and a new PhD student from my su-
pervisor. Ideally, this will ensure the continued legacy of the work and provide
stable maintained and updates for this work farther in to the future.
Fold change values of the pre and on-treatment samples’ gene expression val-
ues were used to perform the majority of the analysis as the original data could
not be directly compared. Differential analysis of the fold change values be-
tween treatment times of patients with known response (PCR vs. Non-PCR) was
performed for candidate gene analysis using Limma to perform the DE analy-
sis with a standard fdr of 0.5, this method uses Bayesian inferences about the
probability of the gene association to response class. Additional ranked prod-
uct analysis was performed using RankProd261 in R. Clustering of the patient-
matched fold change values was performed with T-distributed Stochastic Neigh-
bor Embedding (t-sne) to try to identify response associated expression profile
changes. Differentially expressed gene lists were then used independently of
each other, and secondly using the overlap of the gene lists, for GSEA262 analysis
and CAMERA263 pathway testing to better understand pan-treatment responses
to therapy. Over-represented genes in the GSEA and CAMERA analysis were col-
133
5 Integrative Analysis
lected and examined for correlated KEGG264 pathways. This was done by plot-
ting the representation of genes in their respective KEGG pathways in ascend-
ing order to identify an inflection point, an elbow, in the graph which signals
the genes of lesser pathway prominence to the genes of greater biological rele-
vance. The genes and pathways past this inflection point are selected for and
brought forward for additional analysis. Tests of significance between expres-
sion level for groups or genes defined by this analysis were performedwith stan-
dard Wilcoxon t-tests using a p value cutoff of 0.05 to indicate significance.
Python265 was used for the ML model building which was trained using
sklearn266 as the common api to access the SVM267 model, parameters, and for
hyperparameterization. Tensorflow268 and Keras269 were used for building,
compilation, and training of a sequential convolution neural network for the
prediction of response class from the pairwise fold change values. The SVM
model was trained with a radial kernel in order to better capture none linear
boundaries between response classes. The neural network was trained with
two dense layers with 64 neurons and a ten percent drop out layer to prevent
over fitting. RELU activation functions were used at each layer with a softmax
output and using a stochastic gradient descent loss function. The neural
network and SVM model were trained on fold change values for all samples
with known response in an 80:20 split of the data with a 10 fold cross validation
of randomly sampled data. Subsequent analysis was performed by randomly
removing one of the datasets, training on the remaining four and validating in
the fifth in order to test the impact of the model accuracy on a per dataset level.
Lastly, a pre-trained ResNet model270 was used inside a pytorch271 training loop
to classify heatmap images of the before and after treatment samples.
5.4 Results
5.4.1 General Changes in Gene Expression are Conserved Between
Treatments
Differentially expressed genes were identified as previously described215 and in
the methods with an fdr of 0.05 from the matched pre and on-treatment sam-
ples in the Chemotherapy cohorts. The genes lists defined by this method were
probed in the endocrine treated cohorts to view the similarity in expression level
change. This analysis shows similar patterns of expression in both cohorts, how-
ever with statistically significant differences (means expression level values of
the average gene expression per treatment cohort p < 0.05 Wilcoxon t-Test) in
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the amplitude of change, this indicated that the direction, but not magnitude of
change across the treatment types was the same. This means that genes that
become down-regulated post treatment in the Chemotherapy patients also see
a reduction in expression in the endocrine treated patients but to a greater ex-
tent. This indicates that the response to treatment is similar but possible path-
way involvement and specific methods of action are different between the two
treatment types. This result shows that many of the same changes occur in
Chemotherapy as in Endocrine therapy and separation of response or treatment
specific changes will need to be examined more subtly.
Following this analysis, rank product analysis between the response groups
of each treatment type was performed and the results can be found in Table 5.1.
This found 46 genes that were differentially expressed between the response
groups that overlapped in both treatment types. Subsequent analysis however
found no disease specific pathway enrichment from this gene list, indicating that
this is probably a statistical anomaly presenting false confidence in this over-






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4.2 Non-Response Vectors of Chemotherapy and Endocrine Show
Concordance On-treatment
Pre to on-treatment fold change values of matched patients cluster separately
on the basis of treatment and response when viewed as feature reduced
t-distributed Stochastic Neighbor Embedding (t-SNE) representations. t-SNE is
gaining popularity as a dimensionality reduction and visualization technique
for human genomics studies, it is potentially more sensitive for very high
dimensionality data, like is presented here, with regards to subpopulation
stratification than PCA.272 PCA and t-SNE are comparable methods in that they
are both methods of dimensionality reduction and make visualization of very
high dimensional space possible in two dimensions for regular plotting as
in the below example. They differ in that PCA is a deterministic model that
measures the variance of orthogonally derived vectors which are composed of
combinations of the data’s features and t-SNE is a stochastic (probability based)
model that measures the likelihood of samples being close together in space.
Responsive Chemotherapy and responsive Endocrine therapy patients clearly
cluster away from the non-responsive samples, which appear to have a more
similar lateral and vertical displacement, Figure 5.4.1, page 140. This is possibly
suggestive of differing pathways of response to different therapies but common
pathways of non-response. This possibly indicates that non-responsiveness can
be predicted using the pairwise differential gene scores.
To enumerate the differences between the response classes, I plotted the
D1/D2 contributions (these are the vectors that describe the lowest space
reductions, dimensions (D) that the data can be fit to, Dimension 1 and 2, or
when plotted commonly X and Y) for each sample and made statistical tests
(Wilcoxon T-test) between each group to see which were significantly distant,
Figure 5.4.2, page 141. In the first dimension, the non-responsive samples are
indistinguishable from each other but are significantly separated from the
responsive samples from either treatment paradigm. In the second dimension,
there is significant separation between all response-treatment classes. The
statistical differences presented in this analysis are highly suggestive that there
are systematic differences between the non-responders and the other classes
and between the response classes. I was unable to repeat this analysis for
different clinical factors as annotation is not uniformly complete for relevant
clinico-pathological factors (grade, receptor status, etc.) and would have been
impossible to compare the significance of results between different factors and








































Figure 5.4.1: t-SNE of BC Transcriptional Pairwise Values Shows Cluster-
ing of Patients by Categorical Response. t-SNE shows clear clustering of
groups by the joint grouping of response and treatment but with overlap
of the non-responsive endocrine and chemotherapy patients. t-SNE is a
probabalistic method of expressing similarity, hence this results suggests
that the groupings visible here are due to inherent similarity of the samples
in each cluster. The data in this model are the pairwise expression level





Examination of the separation of response classes | First t-SNE dimension
Examination of the separation of response classes | Second t-SNE dimension
Figure 5.4.2: Statistical Analysis of Intergroup Differences Show Signif-
icant Seperaration on Both Principal Components. Significance scores
(Wilxocon T-test) for the intergroup means differences are presented with
stars. AI is used to denote the endocrine treated cohorts for brevity in the
visualization. A) shows the intergroup differences in mean expression of
the eigenvetors that comprise the first dimension (X) of the t-SNE algorithm
for the different response/treatment pairs. B) shows the same comparison
for the second dimension (Y) of the t-SNE algorithm. The vertical scale
values are mean centered.
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5.4.3 Pathway Analysis Highlights Conserved Genes Indicative of
Non-response Pan-treatment
t-SNE representation shows there is a significant clustering of the non-
responsive patients pan-treatment using the pairwise fold change values of the
pre and on-treatment samples as input. In order to establish whether there was
a significant biological underpinning for the gene lists, pathway analysis were
performed and the results can be seen in Figure 5.4.3, page 143. This result is
suggestive of common expression profile changes in patients with no response
to treatment not present in either of the responsive classes. Combining the
overlap of prominently enriched genes from gene set enrichment score analysis
via GSEA and CAMERA filtered gene lists revealed significant enrichment of
the mTOR signalling and PI3K-AKT signalling KEGG pathways as well as Breast
cancer associated, p53 signalling, TNF, Insulin, ErbB and MAPK signalling path-
ways. In addition an elbow diagram was plotted to identify the most important
subset of genes which contribute most heavily to the pathway analysis results.
This type of diagram seeks to highlight an inflection point which shows a change
in the behaviour of the samples, which becomes apparent as an “elbow” bend
in the plotted data. Pathway analysis of this subset of genes was performed and
the results brought forward for further analysis to see if the reduced gene space
would offer a more concise view. Analysis of the surrounding literature of
non-responsive and TNBC breast cancer reveals mTOR and kinase inhibitors to
be of special interest to the treatment of these diseases. A further examination
of the gene lists was undertaken to examine the gene specific changes that
contribute to this result. There were significant differences in several of the
genes constituting the differential feature list used for the pathway analysis,
Figure 5.4.4, the two genes chosen for this diagram are MDM2 and RBL2, they
are representative of the behaviour of the selected genes, but were selected in
the subsample of two maintain visual clarity of the diagram. This supports the
pathway analysis and t-SNE diagrams that the pre- and on-treatment expression




Figure 5.4.3: KEGG Pathways Enriched in Non-responding Tumour Sam-
ples. A) This ”Elbow” graph is a dot plot showing the percentage of KEGG
pathways identified as being enriched in the non-responders compared to
the responders. This shows that a small portion of genes are present in
an large percentage the KEGG pathways. B) Shows the KEGG pathway
enrichment scores that the genes selected by the vertical line in A select for.
These are pathways enriched in the non-responders compared to the re-






























Relative expression changes in Responders and Non−responders
Figure 5.4.4: Differentially Expressed Genes Show Significant Differ-
ences Between Response ClassesMDM2 shows an increase in expression
level on-treatment in the non-responding patients, while a proliferation
associated marker RBL2 shows a decrease on treatment in the respon-
ders, but a steady level in the non-responders. These are two of the genes
that see significant differential expression between the overall responsive
classes and all labeled non-responders. There is no significant difference
in the fold change for these genes if the data is faceted on treatment type.
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5.4.4 Identification of Non-responsive Patients from Pairwise Delta
Expression Values
In order to determine if the aggregated differential gene lists from the pre- to
on-treatment matched patient expression levels changes could be used for the
accurate prediction of response, twomodels were trained to predict response in-
dependent of treatment. 823 Samples with available response status represent-
ing 365 patients were subset into an 80:20 training and test split and twomodels
were trained on the response classes, regardless of treatment paradigm, using
the differential gene lists to create a predictive model with ten fold cross vali-
dation. As the classes were well balanced, 385 non-responders, 438 responder
(skew = 1.137) accuracy could have been used as the test metric, but to ensure
fair testing the precision, recall, and F1 scores are reported in Table 5.2, page
145. F1 is a measure of accuracy that takes into account both the precision and
recall for a model, and is calculated as 𝐹1 = Precision×RecallPrecision+Recall , this metric was cho-
sen over AUC/ROC as it is less sensitive should a subset of validation data have
a class imbalance. SVM using a radial boosting function was trained to find the
boundary of the response class areas and had an F1 score of 0.91 in training and
0.89 in testing on our split data. In addition, a neural network was constructed
using Tensorflow and Keras with two dense layers and a 0.1 fractional dropout
layer to avoid over fitting, which resulted in a training accuracy of 0.97 and a
test validation of 0.92. Thesemodels were both highly accurate at detecting over-
all response from these pre- and on-treatment matched expression level values,
clearly indicating that the relative changes seen on-treatment are important for
stratifying risk and predicting patient response.
Model Precision Recall F1 SVM P.Responder P.Non-Responder
SVM 0.88 0.9 0.89 Responder 180 24




Table 5.2: Machine Learning Models Report High Accuracy for Predict-
ing Response From Matched Sequential Samples. This table presents
the confusion matrix that results from each ML classification technique,
SVM and NN. The columns of each matrix represent the ”Predicted” sta-
tus (P.Responder, P.Non-Responder), and the rows the ground truth for the
model to compare its performance to. SVM and NN’s were built and
trained on an 80/20 split to identify response. The precision, recall, and
F1 are listed in the table.
This analysis was also repeated by removing one of the five data sets to create
a 4:1 split of available training data. The models were then trained on samples
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from the four aggregate datasets and validated on the withheld samples. This
extra cross validation was performed on all five possible combinations of train-
ing/validation pairs and the results are tabulated in Table 5.3, page 146. The
performance of the SVM and NN models under these conditions ranged from
an F1 score of 0.88-0.93 in the NN and 0.85-0.91 in the SVM. The affect of this al-
ternative testing strategy on the classifier performance shows that these models
are affected by the training sample size as the lowest performance (0.85 F1 in
the SVM, 0.88 in the NN) in both models was when the largest data set was re-
moved from the training cohort (E1, 372 samples) and the highest performance
(0.91 F1 SVM, 0.93 F1 NN) was when the smallest data set (C1, 95 samples) was
removed. Comparable analysis of training on one treatment type and validating
in the other was not performed as this would have exposed new biases into the
trainingmodels. The chemo therapy cohorts were ofmarkedlyworse prognostic
grade (endocrine treated cohorts mean grade at diagnosis 2.11, chemotherapy,
2.6) as well as the sample imbalance between the two cohorts would have cre-
ated models of variable robustness.






Table 5.3: Cross Dataset Validation Accuracy Values Comparing Differ-
ent Subsets of Data. This table shows the balanced F1 accuracy scores for
the testing validation of the pre-trained NN and SVM models trained on
four datasets, then tested on the withheld samples. E1 is the largest dataset
and the affect on the accuracy is noticeable when it is removed from the
training cohort. Conversely, training on the combined data except C1, the
smallest dataset, shows a small improvement in accuracy in validation.
5.4.5 Breast Cancer Transformation and Classification
The possibility of transforming the tabular data to images as a means of prepro-
cessing was also investigated. The pairwise correlations of matching samples
pre- and on-treatment samples were calculated and plotted as heatmaps which
were saved and labelled as responder or non-responder. A ResNet model was
fine tuned on a randomly sampled 80:20 split and then validated on the hold out
data. This resulted in an F1 accuracy of 0.90 which is a marginal improvement
of 0.01 over the deep neural net work alone. Representative heatmap samples
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Figure 5.4.5: Breast Cancer Treatment Response Classification of Corre-
lation Heatmaps. Plots A, B, C and D are representative examples of the
correlation heatmaps that result from the pre- to on-treatment expression
value changes. By training on these files with associated known response
a deep convolutional neural network was trained to classify response in a
parallel method to the tabular classification approach.
5.5 Discussion
The results of this analysis reveal a few potentially important and suggestive
outcomes as to the net change experienced as part of normal neoadjuvant ther-
apy of breast cancer. Previous work has highlighted that there are important
genes differentially expressed in response to chemotherapy273,274 and endocrine
therapy275 and that it is clear that these lists are not identical. Common threads
are a decrease in the level of proliferation markers276,277 and apoptosis in both
paradigms. However, the initial analysis of the changes seen in chemotherapy
are mirrored, to a lesser extent in the endocrine cohorts suggesting some com-
monality in the overall expression profile of antimitotic therapy, regardless of
target.
Possibly of more clinical interest is the perceived overlap in the trajectory
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of gene expression for non-responsive patients in both treatment type cohorts.
While the pathways of response differ between endocrine treated and CT, the
pathways of non-response show greater similarity and unsupervised analysis
reveals them to appear to be the same sub-population. This is potentially of
great interest to novel drug discovery, as this could potentially lead to new tar-
geted therapies. This statement is emboldened by the results of the differential
gene expression analysis, pathway enrichment, and gene set scoring methods,
which show conserved similarity in the pathways between total response and
non-responsive patients. KEGG analysis showed significant enrichment of the
PI3K and mTOR pathways; two promising contemporary therapies to more re-
sistant tumours.278,278,279
Lastly, modelswere built using standard statisticalmachine learning andneu-
ral network approaches for the identification of response from the on-treatment
expression vectors with marked success in testing (SVM: 89%, NN: 92%). This is
highly concordant with the accuracy observed in previous studies of appliedML
to predicting risk and recurrence from clinical and pathological features (deci-
sion trees, CNN and SVM are 0.936, 0.947 and 0.957 accuracy respectively)280
and imaging data.281 This is further support for the work detailed in Chapter 2,
which began to enumerate the value of treatment samples for this precise pur-
pose. These results are of imminent interest to the body of work surrounding
this text in the area of biomarker identification and risk stratification.
5.6 Conclusion
Meta-analysis of multiple pre- and on-treatment neoadjuvantly treated datasets
has revealed several key insights into the value of sequential sampling and the
applicability of pan-treatment markers for response in primary breast cancer.
En masse some of the changes seen in one treatment are seen in the others and
the pairwise differences observed in different response classes can be utilized
to predict response from the pairwise fold change values captured by sequential
sampling. Patients that respond to chemotherapy and patients that respond to
endocrine therapy have different relative gene expression profiles, but the non-
responders to both therapies show strong overlap in relative expression from
the sequential samples. Lastly, supervised machine learning algorithms trained
on the sequential fold change values were highly accurate for the prediction of
response in both the neoadjuvant chemotherapy and endocrine settings.
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and Conclusion
An examination of The National Center for Biotechnology Information reveals
that there are over 505,000 papers returned for the query Breast Cancer, as of Oc-
tober 2019. The prospect of adding new and novel work to this body of literature
poses an enormous task and the contribution of this thesis to that corpus must
be considered fully. While there are clear and distinct areas of prominent re-
search, such as biomarker discovery, new targets for therapy, and identification
of new actionable subtypes, my own analysis of the 100,000most cited papers re-
veals many more distinct groupings in this domain, see Figure 6.0.1 on Page 150.
Finding my own niche in this extensive body of research helped to define the
parameters of my work and lead me to the results and output I have produced
during my PhD. In this thesis, I seek to fully explain the context of my research,
its impact, and what this work may lead to in the future.
6.1 Discussion
This thesis work is broken down into four discrete results chapters each com-
posed of modules of my work over the past four years but which in aggregate
represent a larger and more valuable message. Here I will discuss the inter-
play between the chapters and begin to introduce the conclusions which should
be drawn from this body of work. I will highlight the poignant results of each
area of my thesis, the setting and surrounding literature, and potential avenues
of further research. A fundamental problem in the treatment of breast can-
cer is the heterogeneity of the disease282. Breast cancer doesn’t represent one
disease but many, each with unique pathological and treatment options.283 In-
deed, even among a constituency of similar tumours, patient variation can still
occlude matched tumour characteristics. In this regard, pairwise matched sam-
ples taken during neoadjuvant therapy help to reduce the variance of the data
set, and allow for a remarkably granular view of patient risk on a personal level.
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Figure 6.0.1: UMAP reduced representation of breast cancer research.
100,000 breast cancer research papers were grouped by filtered content,
authorship and citations to reveal distinct areas of research.
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This is due to the fact that the inter-patient differences may be removed when
considering only the pairwise gene expression values from sequential samples
within each patient.284
In addition to capturing the response of each patient from the mid-chemo
time point of a sequentially sampled cohort, it was also able to forecast the sur-
vival of patients in both studies in a highly significant manner. This clearly
demonstrates that a marker generated on the delta values of gene expression
is able to capture response class specific changes to chemotherapy that are uni-
form among patients and cohorts at least partially due to the fact that the signal
to noise ratio present in the training samples is boosted by removing the inter-
patient variations. It should be noted that biomarker identification is a topic of
much scrutiny. Single novel biomarkers may be subject to noise and variation
and highly dependent on the subset of patients used to identify the signature.285
There is also evidence that random biomarkers may be predictive as many are
associated with proliferation, a positive indicator of response globally286 and
that realistic datasets for true identification of biomarkers would require mas-
sive sample sizes,287 the goal of chapter 4. An important take away is more the
value of the on-treatment samples and the extra information held in the pair-
wise gene expression change values. In addition, it is strongly suggested that
the on-treatment samples may be of increased prognostic value from a subtyp-
ing and stratification perspective, as the on-treatment samples had a demonstra-
bly differential expression profile and a greater ability to “correctly” reflect the
actual risk posed to each patient based on calculated metrics of prognostic risk
(MammaPrint, rorS). This is highly novel work, as there is a paucity of preceding
work in biomarker generation from on-treatment samples, the majority of the
accessible results have been included in thismanuscript already, primarily from
Sims et al.. Markers of proliferation have been previously studied for their abil-
ity to stratify patient risk, but thiswork is tangential, not identical to themethods
presented here. This does raise the question of what additional biomarkers can
be identified from these matched patient samples, especially when larger uni-
form datasets become available.
Matched patient sequential samples of primary breast cancer are not the only
additional samples taken in the routine clinical and pathological appraisal of BC.
Tumour positive nodes are also frequently examined as a categorical risk indi-
cator for future recurrences and metastasis. However, as I explore in chapter
three, the same pairwise relative expression differences can be utilized in this
new setting to improve the capture rate of patient recurrence. The gene expres-
sion level changes that facilitate the escape of the primary tumour from it’s tu-
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mour bed and to infiltrate beyond are over represented in the tumour profile of
the sampled lymphnode. This differential pattern of expression provides amore
accurate sampling of the patient specific risk posed by their metastatic disease
and can potentially be useful in improving the treatment of these especially high
risk patients. In this regard the additional sampling not for the purpose of ob-
serving the on-treatment gene expression changes, but to identify the tumour’s
evolution beyond the bounds of it’s original tumour bed is what provides the
new and requisite information for this analysis. Pairwise concordance of pri-
mary BC and metastatic disease has previously been examined for mutational
differences288,289 to understand the progression of disease and for identifying
new actionable targets290 and modern studies have identified gene expression
profiles between the two.291 However this is the first time that such a compar-
ison has been used to better estimate the risk posed by the primary diagnosis.
The data presented in this cohort is also the largest matched primary and lymph
node dataset currently available with follow up and on-treatment paired biop-
sies. The availability of contemporary datasets like the Lawler trial have greatly
boosted the validity of the claims made from this analysis as the same patterns
of expression and relative risk are clearly present in this parallel cohort.
From a high level the premise of more samples, better results seems intu-
itive. More powerful statistical analysis is possible, which means results can
be better supported and the impact of findings fundamentally of increased
integrity.292 However, it isn’t the static increase in dimensionality that pro-
vides the importance of these samples, partially as the patient number is not
inflated, but the relative changes that grant new insight and understanding
to breast cancer treatment and patient options. In the first instance this new
information is gained by observing temporal changes in differential expression
while minimizing the noise present in the comparison of the data. This has
been previously examined to some extent where time scale analysis of gene
expression reveals new pathway enrichment information from these fold
changes.293 These pairwise on-treatment difference have also been suggestive
of helping to identify the mechanistic drivers for aberrant molecular pathways
for patient and tumour characterization.294 In the latter, new value is added
by probing biopsies to see a facet of the disease that is not present in the
primary tumour body, but more pronounced in the metastatic reaches of the
disease. Patient matched and sequential samples are rare however, and no
unified resource or repository is available to freely probe on-treatment samples
for further biomarker identification or validation testing. The creation of
MetaMatchedBreast to improve the analytical prospects was inspired by this
precise lack of resources. This standalone R package wraps up expression sets,
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with further clinical information and considerable built-in tools for analysis
and biomarker comparison as well as cross study and treatment type response
and survivorship analysis. This will hopefully provide a useful functionality to
future researchers in this field of neoadjuvant breast cancer research.
In my fourth chapter I prepare two references to compare the performance
of quantile normalization with ComBat batch correction with additive covari-
ates of integration. First, pre-treatment samples only, second, using no integra-
tion methods and just retaining similar features. While integration of the pre-
treatment alone sample is supported by literary evidence as a viable means of
integration,216,226,240,241matched pre and on-treatment samples have never been
integrated as far as I am able to determine, hence the need to establish base lines
for performance. Integration of the underlying expression values was exhaus-
tively shown to be inadvisable frommy results, but this lead to the creation of a
new bioinformatics resource for the examination of these matched patient sam-
ples. This is a truly novel new tool for analysis as to date there are no available
such tools in the neoadjuvant or sequentially sampled space. Other existing tools
formeta analysis have focused exclusively on the aggregation and analysis of the
most available breast cancer data; pre-treatment only samples. MetaMatched-
Breast fills a niche not currently serviced by the existing tools for breast can-
cer meta-analysis.73,211,212 This leads to the distinct prospect of future improve-
ments in the understanding of the mechanistic and pathway related changed in
response to therapy,
MetaMatchedBreast refocuses instead on the most important features of this
data; the pairwise expression level changes. Here we avoid bringing together
the multiple distributions, and sub distributions of data present in each dataset.
Instead, by normalizing the values consistently and retaining the delta values
between each time point, the same-scale pre and on-treatment changes can be
compared across multiple studies. This facilitates the increased statistical sig-
nificance that this type of analysis has previously lacked, while emphasizing the
very features of this data thatmake themunique and additionally valuable. This
is possibly themost appropriateway of combining this type of data as it has been
suggested that integrative analysis falsely conveys confidence on results from
aggregated data.295 Analysis of this data as pairwise pre and on-treatment val-
ues immediately yielded results. Clustering analysis of patients with known re-
sponse highlighted that responsive chemotherapy and aromatase inhibitor ther-
apy have significantly different patterns of expression change. However, there
was dramatic overlap of the non-responsive patients from both groups. Upon
performing pathway analysis and enrichment scoring between the groups of
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responsive and non-responsive patients, genes present in the mTOR and PI3K
pathways were significantly over expressed in the non-responders. While not
definitive, this is at least suggestive of common escape pathways in BC that may
be utilized for future drug discovery. These pathways highlight the resolution
of known and important pathways in breast cancer, mTOR296–298 and PI3K299–301
that were over represented in the non-responsive samples and may represent
an exploitable future avenue for improving the outcome of these patients. This
work is similar in some regards to other network analysis of BC that has previ-
ously identified similar such pathways in non-responsive or resistant patients302.
However, the unique nature of this pairwise difference patient data may help to
elucidate further insights into the causes of non-response.
There are several other confounding factors which have varying degrees of
importance to the outcome of this thesis but which need to be considered fully
for subsequent work. Cell type heterogeneity was never explicitly examined in
the needle-biopsied samples. This means that there are fundamental assump-
tions in this work. Of primary concern is that the tumour samples provided by
the clinicians and examined by pathologists were ‘tumour’. As to my knowledge
no heterogeneity scoreswere calculated or estimated I can not saywith certainty
that this is the case, and that perhapswith a full cadre of these resultswouldhave
drawn some conclusions differently, or performed analysis in ways that would
be more tolerant of non-homogeneous sampling. This is especially important
when considering that in a recent review it was shown that in multiply sam-
pled breast cancer from the same patient there was remarkable intra-tumour
geographic heterogeneity303.
In a similar vein, in some contexts fresh frozen and FFPE samples were in-
cluded in the analysis. While all possible care was taken in the handling of these
results, and cross-platform-normalization was performed to unify these dataset
it should still be noted that FFPE samples show uniformly reduced differential
expression when compared with fresh frozen.304 This is important when com-
paring results as the relative expression of key genes related to breast cancer
risk assessment and analysis will be less pronounced in these cohorts, poten-
tially reducing the power of the entire study.
A major theme of this thesis is to determine whether the existing
diagnostic/pre-treatment methods like PAM50 work more effectively on
samples that have seen chemo/endocrine therapy. The assumption here is that
once tumour cells have been treated, even for as short a period as two weeks,
the tumour response will become manifest in the expression profile in a more
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pronounced way than pre-treatment and actual, categorical, risk of the patient
will be more accurately captured by these tests. While the results proposed in
this thesis indicate that this is indeed the case, the overall number of samples
in these studies is low and testing on greater cohort sizes would be preferable
to eliminate the chance of this being a statistical artefact. Alternatives to this
would include developing new tests, like the gene marker proposed in results
chapter one, designed for use exclusively on the treated samples, or simply
improving the diagnostic accuracy of the existing tests. There does exist a
serious concern as to the use of these methods. As they take expression matrix
values as the input these values can range due to the platform of analysis, the
means of normalization, non-homogeneous normalization methods and as it
turns out batch correction techniques.
A final assumption, one that was made out of necessity due to the limitations
of sample size and the different reporting of response between datasets is that
all responders look the same, and all non-responders look the same, from a gene
expression stand point. By defining this from the onsetwe aremaking the strong
assumption that they can be grouped, and neglecting to include partial response
as a category or allowing for the possibility that there are alternate escape path-
ways to response than than what is present in the majority. This assumption
was made due to the relatively small size of the data, and the fact that pathologi-
cal complete response was the only method for assigning response on mass that
was available across each study. This is an unfortunate product of circumstance,
but one that withmore time could be rectified by the inclusion of further studies.
In order to try and test for the possibility of sub groups of responders, multiple
iterative clustering approaches were performed in, but likely as a result of the
aforementioned limits on dataset size there was no significant sug-groupings of
samples within each response category.
A last piece for consideration is the crisis of reproducibility in academia and
how bioinformatics should be leading the charge towards better result replica-
tion, but why we aren’t. In an attempt to be as forthcoming and transparent
as possible I have hosted all of my scripts and publicly accessible data on a Git-
Lab page, ideally facilitating the easy sharing a reproduction of my results with
other researchers. However, outside of these containerised solutions it is worth
noting that at a systematic level the results of this thesis, and many others like
it, could invariably fail to work across data centers, across platforms, across dif-
ferent treatment types and pathologies. This is down to two factors, the massive
heterogeneity of disease meaning that biomarkers are usually developed for a
specific subset of disease, something this thesis sought to address, and the com-
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plete lack of a standard when it comes to the collection, storage, analysis and
processing of patient samples. Fundamentally, one of the most important rea-
sons biomarkers fail is down to this lack of standardization, essentially creating
microcosms of treatment/processing pairs in which solutions are viable, but not
outwardly extensible.
6.2 Conclusion
This thesis fundamentally set out to prove or disprove the following hypothe-
sis:
If patient-matched on-treatment or lymph node positive samples are in-
formative for the classification and characterization of breast cancer,
then they should facilitate improved differential and statistical analy-
sis of breast cancer.
In this regard this thesis has been successful in providing evidence for the
additional information available through the pairwise analysis of breast cancer
from the perspective of these samples. From my work in this thesis, I have
shown clearly that the on-treatment samples can be utilized for the creation
of novel and highly accurate biomarkers for the prediction of response to
chemotherapy and as a strong positive indicator of survival. In addition, these
samples, and other pairwise tissue sampling of metastatic lymph node tissue
are more informative for the use of existing risk scoring and profiling tests for
the prognostic stratification of patients. Lastly, that in aggregate, the pairwise
differences between the pre- and on-treatment samples can be a powerful tool
for pathway analysis to reveal new insights into the common mechanisms of
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Chemotherapy is among the most common effective treat-
ments for breast cancer, alongside radiotherapy, hormone
therapy, and targeted treatments. Neoadjuvant chemo-
therapy is given prior to surgery with the aim to reduce
the tumour burden and to provide early information on
the response to treatment [1]. Studies have shown patients
with tumours that have a pathological complete response
(pCR) following neoadjuvant chemotherapy are much less
likely to recur than those in women with residual disease
[2]. Neoadjuvant chemotherapy is now considered as the
standard of care in breast cancer and has seen a rise in re-
cent years with data from powered studies suggesting that
the pathological complete response achieved following
neoadjuvant chemotherapy might be a surrogate of good
prognosis [3]. A recent meta-analysis also showed signifi-
cant tumour response and an increase in the rate of
breast-conserving surgery following NACT with good
rates of long-term local recurrence (5.5% vs. 15.9% adju-
vant chemotherapy), however with an increase in the rate
of short-term local relapses (1.35 RR 0–4 years, 1.53 RR
5–9 years) [4].
Neoadjuvant treatment provides a “window of oppor-
tunity” (Fig. 1a), where sequential sampling of a tumour
enables observation of the changes that occur in re-
sponse to treatment to be measured and considered in
the context of response and outcome [5]. Neoadjuvant
therapy studies and pre-surgical treatments allow for a
unique in vivo analysis of tumour treatment response
[6], as well as the possibility of predicting the response
to treatment earlier in the treatment [5]. It has been sug-
gested that on-treatment biomarkers may be superior to
those measured before exposure to treatment [3, 7]. On-
treatment information has already been shown to be in-
formative for the accurate prediction of response to
endocrine therapy [8]. Here, it was found that patients
with elevated Ki67 levels (higher than 10%) at 2 or
4 weeks exhibited resistance to endocrine therapy and
were triaged to neoadjuvant chemotherapy [8]. We have
also demonstrated the potential of on-treatment bio-
markers by developing a four-gene signature which com-
bined pre-treatment expression levels or two biomarkers
(IL6ST and NGFRAP1) with patient-matched 2-week
on-treatment expression levels of two proliferation
Fig. 1 Unsupervised analysis cannot distinguish pre- and on-chemotherapy samples of breast tumours. a Schematic representation demonstrating
sequential sampling of breast tumours during treatment. b PCA analysis of pre- and on-treatment samples from the Edinburgh NEO and I-SPY studies
revealed no significant clustering of patients by time or response group. Red = non-responder, orange = partial responder, blue = complete responder
Bownes et al. Breast Cancer Research           (2019) 21:73 Page 2 of 12
159
markers (ASPM, MCM4) to accurately predict the re-
sponse to endocrine therapy in a blinded independent
validation set [7].
Gene expression-based studies of neoadjuvant chemo-
therapy treatment to date have largely been limited to
studying the association of pre-treatment samples with
pathological response [9, 10]. Patient-matched sequential
sampling gene expression studies have been previously
attempted; however, they have not evaluated the predict-
ive capacity or proposed new on-treatment predictive
biomarkers [11–13].
In this study, we present the largest sequentially sampled
patient-matched analysis of neoadjuvant chemotherapy-
treated breast cancer tumours to evaluate whether on-
treatment biomarkers can improve the accuracy of
predicting response before resection. Numbers of patients
with sequential breast tumour samples are limited, but we
compare and validate our results with the data from the I-
SPY 1 Trial.
Materials and methods
Patients, response criteria, and samples
The NEO study consists of 50 breast cancer patients
with sequentially sampled biopsies at four time points,
pre-treatment (PT, 34 samples), 2 weeks on treatment
(T2, 12 samples), mid-chemo (TM, 23 samples), and at
surgical resection (TS, 24 samples) with three clinically
defined response statuses: complete responders (pCR by
resection), good responders (tumour volume reduction,
but lack of pCR), and non-responders (progressive dis-
ease or small tumour volume changes on treatment). Pa-
tients were of mixed histological grade and HER2 status;
ages ranged from 29 to 76. Patients were primarily
treated with 3 cycles of FEC and docetaxel with Hercep-
tin where appropriate. Three patients received paclitaxel,
one patient received additional carboplatin, one patient
received Epi-cyclophosphamide and paclitaxel, and one
patient received docetaxel and cyclophosphamide. Eli-
gible patients were women with histologically confirmed
invasive breast tumours and with no evidence of distant
metastatic disease, no prior history of malignancy,
and fit enough to receive chemotherapy in the opin-
ion of the responsible clinician irrespective of age. All
cases were discussed at the breast MDM in Edin-
burgh Breast Unit at the Western General Hospital,
and consensus from this meeting was to be treated
with neoadjuvant chemotherapy.
Core needle (16-gauge) biopsies were taken from the
primary breast tumours before treatment (PT) and
between 10 and 14 days after the first dose (T2) of chemo-
therapy. A third sample was taken at the mid-
chemotherapy point day 20–21 (TM), and finally, a core
biopsy was taken from the excision specimen (TS) after it
has been removed prior to submission to pathology. Fixed
and frozen samples of normal and tumour tissue were col-
lected from all specimens.
Gene expression profiling
RNA extraction was performed via Ribo0-RNAseq, and
whole transcriptome sequencing was performed with
Life Sciences Ion AmpliSeq™ Transcriptome Human
Gene Expression Kit. This generated greater than 8M
reads per sample with an average of more than 90% valid
reads for 12,365 targeted genes. Most analyses were per-
formed in R (http://www.r-project.org) using packages
available through CRAN (http://cran.r-project.org/) and
Bioconductor (http://www.bioconductor.org/). Outside
of the R environment, the stand-alone application Mul-
tiple Experiment Viewer (http://mev.tm4.org/) was uti-
lised for pairwise ranked product feature selection, and
DAVID (https://david.ncifcrf.gov/) was used for pathway
identification. Additionally, the python package scikit-
learn [14] was used for unsupervised clustering analysis.
Ninety-seven samples were analysed over 13 AmpliSeq
chips, but no systematic batch effects were evident and
no batch correction was performed within the training
data. Gene expression data for the NEO study has been
made publicly available at the NCBI GEO data reposi-
tory under accession GSE122630.
The I-SPY 1 Trial is composed of patients with inva-
sive breast cancer > 3 cm, or at least one tumour-
positive axillary lymph node [11]. Patients were treated
with an anthracycline-based chemotherapy followed by
taxanes [11]. Samples were normalised and corrected for
background red/green signal; Bioconductor R packages
marray and limma [15] were used to this end. From the
original 221 patients, only 36 had matching pre- and on-
treatment samples, and 39 had matching biopsy and ex-
cision samples; pathological complete response was used
for response criteria. Pairwise gene expression was han-
dled with SAM and follow-up analysis with Ingenuity
Pathway Analysis from QIAGEN Bioinformatics. I-SPY 1
Trial data is hosted at NCBI GEO under accession
GSE32603 [11].
Statistical analysis methods
Principal component analysis (PCA) was performed on
unsupervised gene lists to reduce dimensionality and visu-
alise differences in response at all times and to identify
present differences between patient treatment statuses.
Local Fisher discriminant analysis (LFDA) [16] was used
at each time point to determine if the response groups
could be distinguished with treatment time with a semi-
supervised clustering approach, concurrently with class
advised K-means clustering. LFDA is a form of supervised
dimensionality reduction that maximises between-class
scattering and minimises within class scatter, and is a re-
fined version of normal Fisher discriminant analysis [16];
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this exploratory analysis was used in order to visualise
comparative differences in treatment time, not as a means
of feature selection. Pair-wise significance analysis of mi-
croarrays [17] using the siggenes package in R was used to
consider the consistency of differentially expressed genes
due to treatment in the sequential patient-matched
samples. Rank Product analysis was used to identify
differentially expressed genes between response clas-
ses at each time point. Successive levels of standard p
value (0.05, 0.01, 0.001), without correction for mul-
tiple testing, were used in order to determine the
number of differentially expressed genes, and at lower
p values which the time points had the most strongly
differentiating genes. Significance analysis of microar-
rays was also performed using varying false discovery
rates (1%, 5%, 10%) to try to identify common differ-
entially expressed genes between responders and non-
responders across both datasets at each time point.
Gene score enrichment analysis was used to validate
the time point selection by looking for the highest
number of enriched pathways. The gene list from the
most differential time point (TM) using the NEO
dataset was extracted and used in a random forest
model (10,000 trees, m-try as the square root of the
feature number) using pCR status as the class label
(clinician-identified pCR and non-pCR). The most de-
terministic genes for class prediction were fed into a
classification and regression tree in order to produce
a maximally reduced and repeatable model; this meth-
odology is further described by Turnbull et al. [7].
The CART decision tree was applied to the NEO
dataset for training and tested in the independent I-
SPY 1 dataset using the same cut-points determined
by mean-centring the datasets. This protocol was re-
peated using the gene list from the pre-treatment
only samples, using the same p values and tree con-
figurations for selection. Survival analysis was per-
formed at different time points using the log-rank test.
Intrinsic subtypes, Mammaprint, and risk or relapse
scores were estimated from the gene expression data using
the GeneFu R package [18].
Results
Gene expression differences between responding and
non-responding breast cancer tumours treated with
chemotherapy are subtle and time dependent
Unsupervised principal component analysis was first
used to assess whether sequential patient-matched sam-
ples from patients receiving chemotherapy (Fig. 1b)
would cluster by time point or response status. There
was no significant grouping of patients according to
sampling time: pre, early, or later after chemotherapy in
either the NEO or I-SPY 1 studies (Fig. 1b). There were
no significant differences between the two cohorts in
terms of age, grade hormone receptor, and HER2 status,
and the subset of patients with mid-chemo samples was
not significantly different from the whole NEO cohort
(Table 1). Patient-matched samples enable the pairwise
analysis to look for consistent changes in the gene ex-
pression during treatment. Pairwise significance analysis
of microarray analysis using a 10% false discovery rate
(FDR) identified a relatively small proportion of overlap-
ping upregulated (5%) and downregulated (4%) genes be-
tween the two studies. However, genes that were
increased or decreased in response to treatment in one
study were also clearly and consistently increased or de-
creased in the other study (Additional file 1: Figure
S1A), further suggesting it would be difficult to discrim-
inate responders from non-responders. Indeed, there
was no clustering by response status before or during
treatment (Additional file 1: Figure S1B). These results
likely reflect the considerable inter-patient differences
being substantially larger and more significant than the
subtler commonalities in gene expression of a particular
time point or response class of each tumour. More en-
couragingly, semi-supervised LFDA of each time point
Table 1 Summary of patient characteristics for the NEO study and I-SPY validation set
Characteristics NEO cohort (50) NEO cohort PT-TM pairs (23) p value I-SPY 1 PT-T2 pairs (36) p value
Median age at diagnosis 50.8 50.1 0.8 47
Tumour grade 0.52 0.58
1 0 (0%) 0 (0%) 1 (3%)
2 22 (44%) 12 (52%) 20 (55%)
3 28 (56%) 11 (48%) 15 (42%)
Hormone receptor status 0.24 0.66
Positive 23 (46%) 14 (61%) 24 (67%)
Negative 27 (54%) 9 (39%) 12 (33%)
HER2 status 0.87 0.64
Positive 10 (20%) 5 (22%) 6 (17%)
Negative 40 (80%) 18 (78%) 30 (83%)
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revealed significant separation on-treatment that was
not apparent in pre-treatment samples; this indicated
that there are meaningful differences between the clas-
ses, as early as 2 weeks on-treatment (Fig. 2a). Complete
responders and non-responsive patients were more
clearly separated than partially responding patients.
These results suggest that there is a potentially greater
predictive value looking at on-treatment than pre-
treatment biomarkers.
Responding and non-responding tumours are more
different upon exposure to chemotherapy
In an attempt to quantify the molecular differences be-
tween the response groups at each time point, rank prod-
uct analysis was performed at different standard p values
(0.05, 0.01, and 0.001). This approach was hampered by
different numbers of samples at each time point (with T2
having very few samples); however, the number of genes
differentially expressed at all p values tended to be greater
during rather than before treatment (Fig. 2b). Similar re-
sults were also seen using 1%, 5%, and 10% FDR (Fig. 2b).
The biggest differences between the response classes were
at TM (mid-chemo), which agrees with the LDFA results,
which showed the least amount of overlap of the response
classes at TM. Gene set enrichment analysis across the re-
sponse classes at each time point also demonstrated more
enriched pathways after 2 weeks of treatment (29), mid-
chemo (30), and resection (29), compared to pre-
treatment (18) (Additional file 2: Figure S2A). Next, we
sought to examine common differentially expressed genes
between responders and non-responders across the two
datasets. Far more genes were commonly significantly dif-
ferentially expressed (FDR = 10% between responders and
non-responders on-treatment in the NEO and I-SPY 1
datasets compared with pre-treatment. In accordance with
the LFDA results, more significantly differentially
expressed genes (1814) were observed between on-
treatment samples, with 6% (197), but only one was
common between NEO and I-SPY pre-treatment
(Additional file 2: Figure S2B and Additional file 4). Exam-
ination of the 468 most significantly differentially
expressed genes (p < 0.001) between responders and non-
responders in the NEO dataset at mid-chemo did not
clearly distinguish between response groups or time points
illustrated by the heatmap in Additional file 3: Figure S3,
further demonstrating that identifying biomarkers of re-
sponse to chemotherapy is very difficult.
We were also keen to evaluate whether the intrinsic
subtype assigned to tumours would alter upon treat-
ment. Looking at the NEO and I-SPY datasets, to-
gether we found that basal tumours were relatively
stable with only 2/19 (11%) tumours changing. More
tumours were classified as Luminal A or normal-like
on-treatment, which likely reflects a reduction in the
expression of proliferation genes during chemotherapy
(Fig. 2c).
AAGAB is a promising potential novel on-treatment
biomarker of response to chemotherapy
The mid-chemo gene list from the NEO dataset (1102
genes, unadjusted p value = 0.01) was fed to a random
forest model for further feature selection and classifica-
tion and regression tree (CART) model, which reported
AAGAB as the most predictive gene for response predic-
tion in the NEO training dataset with 100% accuracy for
pCR prediction on the mid-chemo samples (Fig. 3a).
Validation was conducted completely independently on
publicly available sequentially sampled chemotherapy
data from the I-SPY 1 Trial [10] and reported 76% ac-
curacy using AAGAB at the same expression level on
the scaled and centred expression data at the on-
treatment time point prior to resection (T2). For com-
parison, the pre-treatment only sample gene lists were
put through the same protocol in order to consider
whether highly predictive models could be generated be-
fore chemotherapy. IGF1R was the most predictive pre-
treatment marker with an accuracy of 74% and 63% in
the NEO and I-SPY datasets, respectively (Table 2).
AAGAB was the sixth most accurate predictor (65%,
57%); receiver operator curves show the relative specifi-
city and sensitivity of this marker pre- and on-treatment
(Fig. 3b). Gene expression levels of AAGAB were lower
in responders across all time points in the NEO cohort
but were most significantly different at mid-chemo. In
the I-SPY dataset, AAGAB was significantly lower before
treatment and at excision (Fig. 3c). We wondered
whether AAGAB was lower in responders due to a re-
duction in proliferation, but Pearson correlation analysis
(See figure on previous page.)
Fig. 2 Responders and non-responders are more distinct on than before treatment. a Supervised clustering using local Fisher discriminant
analysis (LFDA) indicates that as early as 2 weeks on treatment, there is a visible separation of the response classes that were unseen in the pre-
treatment samples in the NEO dataset. Red = non-responder, orange = partial responder, blue = complete responder. b Greater numbers of
genes are under and overexpressed between responders and non-responders on treatment. The three lines represent different statistical thresholds
(*p < 0.05, **p < 0.01, and ***p < 0.001 or FDR = 10%, FDR = 5%, and FDR = 1%, gene lists are in Additional file 4: Tables S2 and S3) in the NEO dataset. c
Sankey diagram illustrating the proportions of tumours that change or maintain PAM50 intrinsic subtype during chemotherapy treatment. Whilst basal
subtypes remain mostly stable, the composition of the cohort changes with treatment time, which may help to identify responsive or non-responsive
patients. PT = pre-treatment, T-ON = on-treatment
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with common proliferation-associated genes (TOP2A,
BUB1, MKI67, MCM2, FOXM1, and PCNA) demon-
strated no significant correlation to any of these genes
(Fig. 3d), suggesting that AAGAB is independent of pro-
liferation. Survival analysis demonstrated that response
status predicted by AAGAB level, at mid chemo in the
NEO study and at 2 weeks in the I-SPY 1, was signifi-
cantly associated with the outcome (NEO p = 0.048, I-
SPY 1 p = 0.0036) (Fig. 3e). Interestingly, the level of
AAGAB before treatment was not associated with the
outcome in either cohort (p = 0.71 and p = 0.2, Fig. 3e).
None of the other top 10 pre- or on-treatment markers
was significantly associated with the outcome in both
datasets (Table 2); only one gene (ARF5) was associated
with the outcome in the NEO dataset (p = 0.004). Taken
together, the single gene on-treatment biomarker
AAGAB appears to outperform novel pre-treatment
markers and established prognostic tests in predicting
pCR and long-term outcome to chemotherapy.
Comparison of pre- and on-treatment predictions of
response and outcome
We were also keen to assess whether estimations of estab-
lished prognostic signatures might be different upon treat-
ment and if on-treatment might be more accurate. All and
almost all responding patients were predicted to have poor
(See figure on previous page.)
Fig. 3 AAGAB is a promising on-treatment biomarker of chemotherapy response and outcome. a CART analysis identified AAGAB as a possible
biomarker from the Edinburgh NEO dataset and was 100% accurate at predicting pCR in the training data and 76% accurate in the I-SPY 1
validation set. b The ROC curves highlight the difference in on-treatment and pre-treatment accuracy and selectivity. c Strip charts showing the
level of AAGAB in responding and non-responding patients across time points. d AAGAB showed no significant (Pearson) correlation with
established markers of proliferation in the NEO dataset, indicating it does not seem to be a downstream proxy of their regulation. e Kaplan-Meier
plots demonstrate that on-treatment, but not pre-treatment, levels of AAGAB were significantly associated with the outcome in both
cohorts. p values are log-rank test
Table 2 Comparison of pre- and on-treatment biomarkers for predicting response and outcome. Evaluation of the performance of
the top 10 pre- and on-treatment genes identified for predicting pathological response in the NEO dataset
Response accuracy Response AUC Outcome (log-rank)
NEO I-SPY NEO I-SPY NEO I-SPY
On-treatment
AAGAB 100% 78% 1.00 0.63 0.048 0.0036
ZNF165 88% 54% 0.91 0.57 0.26 0.70
KRTCAP3 79% 52% 0.85 0.56 0.81 0.49
RFC2 79% 40% 0.85 0.35 0.51 0.44
C20orf151 70% NA 0.75 NA 0.36 NA
ARF5 70% 43% 0.75 0.36 0.0038 0.20
BSPRY 70% 48% 0.75 0.49 0.47 0.19
NGRN 58% NA 0.66 Na 0.53 Na
CHST7 29% 46% 0.21 0.52 0.65 0.40
SLC18B1 25% Na 0.18 NA 0.55 NA
Pre-treatment
IGF1R 74% 63% 0.76 0.69 0.36 0.11
CTNNB1 71% 49% 0.73 0.46 0.60 0.40
SLC20A2 71% 56% 0.72 0.57 0.063 0.56
HMGCL 68% 47% 0.67 0.45 0.10 0.97
ST6GALNAC5 68% 52% 0.69 0.53 0.6 0.28
AAGAB 65% 57% 0.65 0.58 0.71 0.20
C1orf51 62% NA 0.61 NA 0.12 NA
KRTCAP3 62% 54% 0.63 0.57 0.78 0.78
SETDB2 50% 49% 0.48 0.51 0.29 0.15
FADS2 29% 48% 0.27 0.5 0.14 0.73
NA not available, gene not represented in I-SPY dataset; AUC area under curve. Bold indicates significant p-values. Italics indicate training prediction percentages
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outcomes with the estimated Mammaprint [19], PAM50
[20], or rorS [21] signatures in pre-treatment samples of
the NEO cohort, whereas around half of the responding
patients were predicted as good outcome using on-
treatment data (Fig. 4a). Overall accuracy improved by 2–
8% using on- rather than pre-treatment data; however,
improvement in the predictive power of these tests was
not uniform between response classes. Good outcome
Fig. 4 On-treatment signatures more accurately predict pathological response and outcome than pre-treatment. a A greater proportion of
patients with pathological response are predicted as responders with estimations of molecular signatures on-treatment than pre-treatment.
Concordance between patients predicted as high and low risk across time is poor, but the positive predictive value of these tests increase with
treatment. For PAM50 subtypes, normal-like and Luminal A are considered good prognosis and basal/Luminal B/HER2-enriched are considered
poor outcome. Red = predicted poor outcome, blue = predicted good outcome. b Forrest plots to compare molecular signatures and AAGAB
before and on-treatment combining both datasets, except where indicated* due to individual sample data unavailable for I-SPY 1 patients
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predictions for responders to neoadjuvant chemotherapy
saw an aggregate increase in predictive power from 11 to
44.4%, whilst poor outcome predictions for non-
responders saw a moderate decrease in accuracy, 75 to
63%. None of the gene expression signatures either pre-
or on-treatment or established prognostic markers (NPI,
Grade, Her2 status) was significantly associated with the
outcome in contrast to the remarkable performance of
on-treatment measurement of AAGAB (Fig. 4b).
Discussion
Determining molecular differences between tumours to
select the most effective treatment is the defining feature
of precision oncology. Accurately predicting which pa-
tients will respond to treatment before exposure relies
on a highly specific target. In breast cancer, ER status is
a good indicator of response to endocrine treatment, but
resistance, both primary and acquired, is common.
Chemotherapy is an unselective treatment, relying on
cancer cells growing faster than normal cells. The results
presented here, along with others [7, 8], suggest on-
treatment biomarkers have improved value in predicting
whether tumours respond to treatment and are associ-
ated with the outcome. Changes in gene expression in
sequential patient-matched were fairly consistent in re-
sponse to chemotherapy across two independent data-
sets, regardless of the response status. Identifying
molecular markers between responding and non-
responding tumours was much more challenging. We
previously demonstrated that lobular and ductal breast
cancers respond to endocrine treatment in the same
way, despite clear histological and molecular distinctions
that are apparent and maintained on-treatment [22],
demonstrating that pre-treatment variations do not ne-
cessarily lead to differences in response. The results of
this study are somewhat exploratory, rather than defini-
tive, but further illustrate the considerable potential
value of on-treatment sampling.
There are no universally agreed-upon markers predict-
ive of response to chemotherapy, and the few that have
been investigated in the neoadjuvant setting typically
centre around established markers including ER, P53
HER2, and Ki-67 [23]; thus, the introduction of new
novel biomarkers can expand the currently available
clinical options for physicians. A study published over a
decade ago stated that the differences in gene expression
between responders and non-responders to neoadjuvant
chemotherapy must be rather subtle [12]. The results
presented here confirm this statement; however, our re-
sults suggest that on-treatment biomarkers may provide
important information for predicting response.
As cancer is inherently a proliferative disease, measur-
ing the change in markers of proliferation on-treatment
is logical and genes like ki-67 have been demonstrated
previously to be potentially a new clinical tool for dis-
ease prognosis and prediction [24, 25]. It is therefore all
the more interesting that the potentially novel biomarker
identified in this study, AAGAB is not tightly correlated
with known markers of proliferation. AAGAB has pri-
marily been studied for its role in punctate palmoplantar
keratoderma [26] and the role of adaptin in the clathrin-
independent endocytosis of epidermal growth factors.
The level of AAGAB was found to be prognostic of re-
sponse (p < 0.001) in renal cancers (favourably) and in
thyroid cancers (unfavourably) from the TCGA study,
and expression is elevated in breast cancer, relative to
the normal breast (p < 0.001). However, the exact role of
AAGAB in breast cancer is currently unclear and poten-
tially warrants further investigation. Clearly, further val-
idation of the role of AAGAB in breast cancer is
warranted and will be performed as new neoadjuvant
chemotherapy datasets become available. This study
supports the use and identification of genes or markers
from on-treatment biopsies as a tool for improving pa-
tient response classification. We propose that the use of
on-treatment samples offers valuable insight into the dy-
namic changes correlated with response, and submit our
findings as support for continued neoadjuvant sampling,
and novel biomarker generation.
Conclusion
We have identified AAGAB as a novel on-treatment bio-
marker for accurate prediction of pCR and outcome in
patients treated with neoadjuvant chemotherapy. A
semi-supervised analysis and evaluation of estimations
of established molecular signatures also highlight the po-
tential value of on-treatment biomarkers. Combining
on-treatment biomarkers with known clinical prognostic
factors could further improve the accuracy of response
predictions and deserve further study. On-treatment ex-
pression changes in the neoadjuvant setting may offer
greater possibilities for the identification and creation of
more future novel biomarkers.
Additional files
Additional file 1: Figure S1. A, Pairwise significant analysis of
microarrays (FDR = 10%) demonstrating that whilst only a relatively small
proportion of genes are significantly up- or downregulated in response
to chemotherapy in both datasets, overall changes in patient-matched
sequential samples response to treatment are highly consistent. Red =
upregulated, blue = downregulated on- relative to pre-treatment. Gene
lists are in Additional file 4: Table S1. B, Unsupervised principal compo-
nent analysis cannot distinguish responding from non-responding breast
tumours receiving chemotherapy, before or on-treatment. (JPG 126 kb)
Additional file 2: Figure S2. A, Gene set enrichment analysis (GSEA)
results showing greater numbers of enriched pathways between
responders and non-responders on-treatment compared to pre-
treatment in the NEO dataset. B, Venn diagrams indicating that there
were many more overlapping significantly differentially expressed genes
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between responders and non-responders across the two studies on-
treatment compared to pre-treatment. Gene lists are for FDR = 10% (see
Additional file 4: Table S3). (JPG 72 kb)
Additional file 3: Figure S3. Heatmap of the 468 most significantly
differentially expressed genes (p < 0.001) between responders and non-
responders in the NEO dataset at mid-chemo, demonstrating rather poor
separation between the response groups and time points. Gene list is in
Additional file 4: Table S2. (JPG 91 kb)
Additional file 4: Table S1. Gene lists of pairwise analysis of pre- and
on-treatment sequential patient-matched samples from NEO and I-SPY
datasets using Significance analysis of microarrays with FDR = 10%.
Table S2. Gene lists distinguishing between responders and non-
responders at different time points across the NEO and ISPY datasets
using rank product analysis with p < 0.05, p < 0.01, and p < 0.001. Pre-
treatment (TP), 2 weeks (T2), mid-chemo (TM), and surgery (TS). Table S3.
Gene lists distinguishing between responders and non-responders at
different time points across the NEO and I-SPY datasets using significance
analysis of microarrays with FDR = 10%, FDR = 5%, and FDR = 1%.
Pre-treatment (TP), 2 weeks (T2), mid-chemo (TM), and surgery (TS).
(XLSX 1184 kb)
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